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Introduction 
For obvious reasons, 2009 has 
been a very busy year for those 
involved in the surveillance 
of infectious disease. Credit 
is due to everyone in public 
health departments around the 
country and within HPSC for 
managing to analyse and report 
on trends and developments in 
2008 which make up this report, 
despite the considerable workload caused by the 
influenza pandemic.  
In 2008 we saw a marked resurgence in mumps cases 
predominantly affecting those aged between 15 
and 24 years. Complications included inflammation 
of the testes, deafness, pancreatitis, meningitis, 
mastitis and encephalitis.  Fifty seven outbreaks of 
mumps were reported in 2008, mainly in educational 
settings. Efforts to control the outbreak by promoting 
vaccine uptake in third level institutions were largely 
unsuccessful and lead to a decision in 2009 to target 
older children in secondary schools with an MMR 
campaign.  Thankfully, this approach has resulted in a 
decline in cases but a more complete  MMR catch up 
in primary and secondary schools is required to prevent 
further outbreaks of mumps and the other two diseases 
covered by MMR – measles and rubella.
Invasive Streptococcus pneumoniae infection 
caused three deaths amongst children in 2008. The 
introduction of the pneumococcal conjugate vaccine 
to the childhood programme in September 2008 was 
very welcome especially as an increasing proportion 
of cases of this disease in Ireland have been shown to 
be resistant to penicillin. Routine hepatitis B vaccine 
was introduced at the same time.  It will be many years 
before the effects of the hep B vaccine in childhood 
will impact on the hepatitis B figures and therefore it is 
essential that those in high risk groups continue to be 
targeted for this vaccine.   
The absence of a formal streptococcal reference 
laboratory highlights the need  for improved funding of 
reference facilities in Ireland. It will be important over 
the coming years that any reductions in funding for 
health services do not negatively impact on our capacity 
to detect and monitor infectious disease threats.  
The 2008/2009 influenza season was one of the most 
intense in the past 10 years. H3N2 predominated 
and was associated with an increase in mortality 
in the early part of 2009. Efforts over the past 
number of years to strengthen influenza surveillance 
continued in the 2008/2009 season as part of the 
pandemic preparedness process. The emergence of 
a new pandemic strain in April 2009 emphasised the 
importance of influenza surveillance and the recently 
developed capacity to monitor this infection on a year 
round basis.  
The on-going rise in cases of Verotoxigenic E. coli 
continues to give cause for concern. Fifteen cases 
of VTEC-associated haemolytic uraemic syndrome 
occurred, 50% of which were associated with non-O157 
VTEC. Person to person transmission was suspected 
to have played a role in 21 VTEC outbreaks in 2008, 
including three crèche associated outbreaks. This 
highlights the importance of implementing hygiene 
precautions early when dealing with diarrhoeal illness 
and the importance of seeking laboratory confirmation 
of outbreaks of infectious intestinal disease. Drinking 
untreated water from private wells also remains an 
important risk factor for VTEC infection in Ireland. 
In 2008 a significant outbreak of salmonellosis              
(S. Agona) occurred resulting in the identification of 
11 Irish cases and 152 cases in the UK and five other 
European countries. Epidemiological investigations 
identified contaminated meat products produced in an 
Irish food plant as the source of the outbreak, which was 
eventually halted following the closure of the implicated 
section of the plant and the recall of the implicated 
products. 
Cases of leptospirosis continue to increase in 2008 and 
Ireland has one of the highest rates in Europe. The 
disease occurs mainly in adult males, through exposure 
to farm animals and rodent infested environments in 
watersports.  
Bloodborne infections continue to occur at a high 
rate in Ireland.  New hepatitis C cases continue to 
occur unabated, mainly through injecting drug use.  
New HIV cases have increased and the incidence is 
higher in Ireland than the average for Western Europe. 
Heterosexual transmission accounted for 56% of cases 
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where the route of transmission was known. Sexually 
transmitted infections showed a 20% increase in 2007, 
the latest year for which data are available.   There is a 
continuing problem with syphilis especially in the men 
who have sex with men (MSM) community, many of 
whom report oral sex as the main risk factor. 
It is good to see that national immunisation rates 
continue to improve.  However, in 2008 national uptake 
at 24 months for diphtheria, tetanus and pertussis, and 
other childhood vaccines, were 2-3% below the target 
uptake of 95%.  MMR uptake was 6% below the target 
uptake.  
It is also positive to see that antibiotic consumption in 
outpatients decreased during 2008 for the first time 
since the year 2000. The overall antibiotic consumption 
rate remains mid to high in comparison with other 
EU countries. The proportion of MRSA of all invasive           
S. aureus infections decreased in 2008 to 33.7%, down 
from 38.5 % in 2007. This is the second successive 
year in which a decrease has been observed and this 
downward trend is highly significant and very welcome.   
Antimicrobial resistance continues, however, to be a 
major problem in other pathogens and highlights the 
ongoing commitment required to reduce the burden in 
Ireland. 
Once again, I’d like to thank the Scientific Advisory 
Committee, along with the HPSC sub committees for 
all their hard work. Special thanks also to all the staff 
at HPSC whose commitment and professionalism is 
reflected throughout this report and whose tireless 
efforts in the midst of an influenza pandemic have made 
this report possible.
Dr Darina O’Flanagan
Director
Health Protection Surveillance Centre
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In 2008, 22 cases of invasive Haemophilus influenzae 
disease were notified in Ireland (0.5/100,000 total 
population).  This a marked reduction compared to the 
previous years when 31 and 38 cases were notified in 
2007 and 2006, respectively (Figure 1). 
The main change in 2008, when compared to 2007, 
is the continuing, albeit slower, decline in the overall 
number of cases due to non-capsular and type b strains 
(Figure 1). No other noteworthy change in the number 
of cases due to other serotypes has been observed in 
recent years.
Non-capsular strains accounted for the majority of 
the invasive H. influenzae cases notified in 2008 (50%, 
n=11/22).  The remaining cases were due to H. influenza 
type b (n=5, 22.7%), type f (n=3), and three isolates that 
were not typed. The cases ranged in age from three 
weeks to 88 years. The incidence rates were highest in 
infants <1 year (8.2/100,000) and those aged 65+ years 
(1.7/100,000) (Table 1).
Cases occurring in children <10 years of age (n=9) and 
elderly adults >=65 years (n=8) accounted for 77% of 
the invasive H. influenzae notifications in 2008 (Table 1)
The clinical manifestations of invasive H. influenzae 
disease in the nine children <10 years of age in 2008 
were two cases of meningitis  and one case each of  
meningitis/septicaemia, epiglottitis, pneumonia and 
septic arthritis along with three cases where the clinical 
diagnosis was not reported. A breakdown by clinical 
diagnosis for all age groups by year between 2004 and 
2008 is presented in Table 2.
Two invasive H. influenzae related deaths were reported 
in 2008, both of which occurred in adults over 65 
years of age. One was associated with a type b strain 
and was the primary cause of death (the patient was 
unvaccinated). The second death was associated with a 
non-capsular H. influenzae strain. 
 
H. influenzae type b (Hib) accounted for 23% of the 
invasive H. influenzae notifications in 2008, with five 
cases being notified (0.12/100,000 total population).  
Three of the five Hib cases (60%) occurred in children 
<=4 years of age, with two cases occurring in infants <1 
year and one in the 1-4 years age group. Of these three 
cases, two were unvaccinated and one had received 
one dose of the Hib vaccine. Similarly, in 2007, three 
of the seven Hib cases notified (42.9%) occurred in 
1.1 Haemophilus influenzae (invasive) 
Number of cases,  2008: 22
Number of cases,  2007: 31
Number of cases,  2006: 38
Crude incidence rate, 2008: 0.5/100,000
Summary
2004 2005 2006
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Figure 1. Annual number of invasive Haemophilus influenzae cases 
notified in Ireland, 2004-2008
Year
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children <=4 years of age. In 2006, when 14 cases in 
total were notified, the number of Hib cases in children 
<=4 years of age was five (35.7%). The introduction of 
a Hib booster catch-up campaign for children under 
four years of age in November 2005 and a routine 
Hib booster dose at 12 months in September 2006 is 
continuing to reduce the incidence of Hib disease in 
young children in 2008.
In 2008, no true Hib vaccine failures were reported, thus 
highlighting the positive impact the Hib booster catch 
up campaign has had in Ireland.  In contrast, in 2007, 
two true Hib vaccine failures occurred in children aged 
14 years or less, one of whom died from septicaemia. 
Both children received three doses of Hib vaccine when 
they were less than one year of age.  Of note was the 
fact that one of the two true vaccine failures in 2007 
occurred in a slightly older child, aged 10-14 years, 
who would not have been targeted by the catch-up 
programme.  
In 2008, one apparent Hib vaccine failure occurred (in a 
child under one year of age), compared to none in 2007 
and three in 2006. Apparent failures are defined as 
cases in children who are incompletely vaccinated. 
Since September 2008, the, Hib booster dose has been 
administered at 13 months of age as part of the routine 
childhood immunisation schedule in addition to the 
three doses at 2, 4 and 6 months of age. Vaccination is 
routinely recommended for those at increased risk of 
Hib disease.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 8th July 2009.  
These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
               
Table 1. Number and incidence rates of invasive Haemophilus influenzae cases by serotype plus number of Hib vaccine failures 
by age group, 2008
 Type b Type e Type f Non-capsular
Not 
Typed
Total ASIR of Hib
ASIR of all H. 
influenzae
TVFs
<1 2 0 2 1 0 5 3.3 8.2 0
1-4 1 0 1 0 0 2 0.4 0.8 0
5-9 0 0 0 1 1 2 0.0 0.7 0
10-19 0 0 0 0 0 0 0.0 0.0 0
20-34 0 0 0 1 0 1 0.0 0.1 0
35-54 1 0 0 1 0 2 0.1 0.2 0
55-64 0 0 0 1 1 2 0.0 0.5 0
65+ 1 0 0 6 1 8 0.2 1.7 0
All Ages 5 0 3 11 3 22 0.1 0.5 0
CIR 0.12 0.00 0.07 0.26 0.07 0.52 - - -
CIR, crude incidence rate per 100,000 total population
ASIR, age specific incidence rate per 100,000
TVFs, true Hib vaccine failures
Table 2. Number of invasive Haemophilus influenzae cases by 
clinical diagnosis, 2004- 2008
Clinical 
Diagnosis
2004 2005 2006 2007 2008
2004-
2008
% of 
Total
Septicaemia 8 14 13 6 3 44 27.0%
Meningitis 3 9 3 2 2 19 11.7%
Septicaemia/
Meningitis
1 0 1 0 1 3 1.8%
Pneumonia 5 0 3 6 3 17 10.4%
Epiglottitis 1 3 3 1 1 9 5.5%
Cellulitis 1 1 2 1 1 6 3.7%
Septic 
arthritis
0 1 0 0 1 2 1.2%
Osteomyelitis 1 0 0 0 0 1 0.6%
Unknown 18 6 13 15 10 62 38.0%
Total 38 34 38 31 22 163 100%
Table 3. Incidence rates of invasive Haemophilus influenzae by 
HSE area, 2004-2008
HSE Area 2004 2005 2006 2007 2008
E 1.1 1.0 0.9 0.8 0.5
M 0.5 0.5 0.2 0.5 0.3
MW 0.8 0.3 0.8 0.6 0.8
NE 0.2 1.1 0.2 0.0 0.0
NW 0.4 0.0 2.0 0.4 0.0
SE 1.3 0.5 1.0 1.3 0.8
S 3.0 0.8 3.4 0.8 1.7
W 0.5 1.4 0.7 1.4 0.5
Ireland 0.9 0.8 0.9 0.7 0.5
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In 2008, there were 55 measles cases (1.3/100,000) 
notified in Ireland.  This is similar to 2007 when 53 cases 
were notified.
Forty-two cases (76%) in 2008 were classified as possible 
while 13 (24%) were classified as confirmed, giving 
a crude confirmed incidence rate of 0.3 per 100,000 
population.  Ten of the confirmed cases were laboratory 
confirmed while three were epidemiologically linked to 
a laboratory confirmed case.  In 2007, 20 (38%) of the 
53 measles cases notified were classified as confirmed.
In 2008, measles cases ranged in age from three months 
to 41 years.  The largest number of cases (n=27) and 
the highest age specific incidence rate (22.3/100,000) 
were in the age group one to two years (figures 1 and 
2).  Of the 55 measles cases 30 (55%) were female and 
25 (45%) were male.
Laboratory results were provided for 22 (40%) cases in 
2008.  Ten cases were laboratory positive for measles.  
Twelve cases were laboratory negative for measles, 
however, for six of these the oral fluid specimens were 
not taken at the optimal time following disease onset 
or the date of specimen collection in relation to disease 
onset was unknown (the optimal time for collecting oral 
fluid specimens for measles IgM testing is greater than 
seven days to two months following disease onset).  All 
cases that were laboratory negative for measles were 
classified as possible cases.
Measles vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.
Vaccination data were reported for 46 (84%) measles 
cases in 2008.  Thirty-one cases (n=31/46, 67%) were 
unvaccinated; seven (n=7/31, 23%) of these were less 
than 12 months of age.
Thirteen cases (n=13/46, 28%) had one dose of MMR 
vaccine; twelve (92%) of these were less than six years 
of age.  Only two (15%) of these 13 cases were classified 
as confirmed.  
1.2 Measles 
Summary
Number of cases, 2008: 55
Number of confirmed cases, 2008 :13
Crude incidence rate, 2008: 1.3/100,000
Crude confirmed incidence rate, 2008: 0.3/100,000
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Figure 1.   Number of notified measles cases in 2008 by 
age group and case classification
Confirmed Possible
Figure 2. The age specific incidence rates (per 100,000) of 
notified measles cases in 2008 by case classification
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Two cases (n=2/46, 4%) were reported as having 
received two doses of MMR.  Only one of these cases 
was classified as a confirmed case; this case was 
reported to have an underlying illness.
Seven cases were hospitalised representing 17 percent 
(n=7/42) of all cases with known hospitalisation status.  
The seven cases ranged in age from nine months to 11 
years with four cases classified as confirmed and three 
classified as possible.  One case was hospitalised for 
one day, one was hospitalised for three days while the 
number of days hospitalised was not reported for the 
remainder.  Of the seven hospitalised cases, three were 
unvaccinated and three were reported to have one 
dose of MMR.  The remaining hospitalised case had 
two doses of MMR; this case was reported to have an 
underlying illness.  
Information on measles associated complications was 
reported for 32 cases.  One case, aged 11 months, was 
reported to have pneumonia while one case, aged 17 
months, had otitis media.  The remaining 30 cases had 
no complications.
Four cases were reported as being infected outside 
Ireland.  The country of infection for two confirmed 
cases was reported as India and the countries of 
infection for two possible cases were reported as Poland 
(n=1) and the United Kingdom (n=1).
Two localised measles outbreaks were notified during 
2008, with a total of six cases attributed to these 
outbreaks.  Both outbreaks were in private houses.  
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 11th August 2009.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR. 
EU data are available at www.euvac.net and WHO 
European data are available at http://data.euro.who.int/
CISID/.
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In 2008, 168 cases (4.0/100,000) cases of invasive 
meningococcal disease (IMD) were notified in Ireland. 
This was a notable decrease from the previous two 
years when 179 cases (4.2/100,000) and 209 cases 
(4.9/100,000), were notified in 2006 and 2005, 
respectively (figure 1). When compared with rates 
reported in 1999 and 2000, incidence rates have 
substantially declined in recent years (figure 1).
Based on the meningococcal disease case definition, 
157 of the 168 cases (93.5%) notified in 2008 were 
classified as definite, none as presumed and 11 (6.5%) 
as possible. The vast majority of the cases (93.5%; 
n=157/168) were laboratory confirmed. Most cases were 
confirmed by PCR alone (53.5%, 84/157). Confirmation 
of the remaining 73 cases was by culture only (n=11), 
by PCR and/or culture (n=66). None were confirmed by 
serology or microscopy exclusively.  
In 2008, male cases (n=100) exceeded female cases 
(n=68), resulting in a male to female ratio of 1.22:1.0.  
Cases ranged in age from two weeks to 91 years ( 
median age of two years). The incidence of IMD was 
highest in infants and young children. Age specific 
incidence rate (ASIR) was highest among infants <1 year 
of age (68.8/100,000), followed by children in the 1-4 
year age group (24/100,000), and the 15-19 year age 
group (5.9/100,000) (table 1).  
In 2008 the overall incidence of IMD in Ireland was 
highest in the HSE-NE area (6.1/100,000) followed by 
the HSE-SE area (5.9/100,000) (table 2).
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2008 and 
accounted for 149 (89%) of the 168 notifications (figure 
1). Since 2003 serogroup B has accounted for 80% or 
more of annual IMD notifications (figure 1).  
IMD due to serogroup C has remained at very low 
levels over the last six years with no more than five 
1.3 Meningococcal Disease 
Summary
Number of cases,  2008: 168
Number of cases,  2007: 179
Number of cases,  2006: 209
Crude incidence rate,  2008: 4.0/100,000
N
um
be
r o
f c
as
es
Figure 1. Number of invasive meningococcal disease (IMD) 
notifications in Ireland by serogroup, 1999-2008
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cases occurring annually. In 2008, four (0.09/100,000) 
serogroup C cases arose (figure 1).  All four cases 
occurred in adults (age range 17-46 years), one of whom 
was vaccinated and another who died.  One MenC 
vaccine failure also occurred in 2007, 2006 and again in 
2005, while no failures arising in either 2004 or 2003.
These recent low incidence rates highlight the huge 
impact the introduction of the MenC conjugate vaccine 
in October 2000 has had in almost eliminating IMD due 
to serogroup C (figure 1). Prior to the introduction of 
this vaccine, the serogroup C incidence rate in 1999 was 
3.7 per 100,000 total population.  
There were eight IMD related notified deaths in 2008 
(case fatality ratio of 4.8%) compared to an average of 
six deaths between 2005 and 2007.  The case fatality 
ratio (CFR) was highest amongst cases 25+ years of age 
(17.6%) as a result of three deaths from 17 cases (table 
1). The next highest CFR occurred in children aged 5-9 
years (8.3%) and adults aged 20-24 years or more (7.7%) 
(table 1).
Six of the eight deaths in 2008 were due to serogroup 
B disease (age range 15 months to 64 years) and 
one death each was caused by serogroup C (in an 
unvaccinated adult aged >25 years) and by serogroup 
W135 (in a child aged between 5-9 years). 
In marked contrast to the 11 deaths reported  in 2000 
due to serogroup C disease (out of a total of 139 cases), 
only one  such death (an adult aged > 25 years) was 
reported in 2008 (out of a total of four cases). This 
was the first death from this disease since 2004. One 
death from serogroup C disease occurred in 2003 and 
in 2004, both in adults over 55 year of age. In 2001 
three deaths from serogroup C disease were reported, 
one in a child <15 years of age and two in adults aged 
between 20 and 64 years. Since 2001, the decline in the 
annual number of serogroup C deaths has been quite 
significant, especially in those aged under 25 years of 
age with no deaths being reported during this period of 
time. (table 3). 
Despite a reduction in the overall incidence in recent 
years, IMD continues to be treated as a serious public 
health concern due to its associated severity, high 
mortality rate and serious adverse sequelae. 
Table 1. Number of cases, deaths, age-group specific incidence rates 
and case fatality ratios of IMD in Ireland, 2008
Age Group No. Cases ASIR No. 
Deaths
CFR (%)
<1 42 68.8 0 0%
1-4 58 24.0 3 5.2%
5-9 12 4.2 1 8.3%
10-14 9 3.3 0 0%
15-19 17 5.9 0 0%
20-24 13 3.8 1 7.7%
25+ 17 0.6 3 17.6%
All ages 168 4.0 8 4.8%
ASIR, age specific incidence rate per 100,000 population
CFR, case fatality ratio
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Effective vaccination is necessary for the complete 
prevention and control of IMD. Although effective 
vaccines are available against serogroups A, C, W135 
and Y forms of the disease, a suitable vaccine against 
serogroup B disease, the most common form of IMD 
in Ireland, is not yet available.  Until such time that an 
effective MenB vaccine, suitable for use in infants, is 
on the market, IMD will remain a significant cause of 
morbidity and mortality in children and young adults in 
Ireland.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 16th July 2009. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
     
Table 2. Number of cases and age specific incidence rates per 100,000 population of IMD by HSE area, 2008
HSE area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
E 23.4 12.1 2.1 3.4 6.1 4.3 0.9 2.7
M 132.1 31.7 0.0 0.0 11.4 5.5 0.0 5.2
MW 19.6 44.8 0.0 4.2 3.9 0.0 0.0 3.3
NE 110.1 27.6 6.7 11.1 3.7 7.1 0.8 6.1
NW 59.4 21.9 0.0 0.0 5.8 0.0 0.7 3.0
SE 133.5 33.3 12.2 0.0 6.2 3.1 0.7 5.9
S 104.9 35.4 9.6 2.5 7.1 2.1 0.7 5.3
W 69.5 13.2 0.0 3.7 3.4 6.2 0.0 2.7
Ireland 68.8 24.0 4.2 3.3 5.9 3.8 0.6 4.0
Table 3. Number of cases, deaths and case fatality ratios by year of meningococcal serogroups B and C disease in Ireland, 1999-2008
Meningococcal B Meningococcal C
Year No. Cases No. Deaths CFR% No. Cases No. Deaths CFR%
1999 292 12 4.1% 135 5 3.7%
2000 258 13 5.0% 139 11 7.9%
2001 245 8 3.3% 35 3 8.6%
2002 199 8 4.0% 14 0 0%
2003 206 11 5.3% 5 1 20%
2004 163 7 4.3% 5 1 20%
2005 169 5 3.0% 5 0 0%
2006 168 5 3.0% 4 0 0%
2007 157 6 3.8% 2 0 0%
2008 149 6 4.0% 4 1 25%
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Mumps notifications had declined in 2007 (n=142) 
following a national mumps outbreak that began at the 
end of 2004, however, mumps notifications increased 
again in 2008 with 1,385 cases (32.7/100,000) notified 
(figure 1).  In contrast, in the six years prior to 2004 
there were on average 43 mumps cases notified each 
year (figure 1).   Sixty percent of cases in 2008 were 
notified between late September and the end of 
December.
In 2008, of the 1,385 mumps cases notified 51% 
(n=705) were classified as confirmed, 17% (n=231) were 
classified as probable and 32% (n=446) were classified 
as possible (three cases had no case classification 
specified).
In 2008, cases ranged in age from two months to 
73 years; with a mean age of 22 years and a median 
age of 20 years (age was unknown for 17 cases).  The 
largest number of cases and the highest age specific 
incidence rates were in those aged 15-19 years and 20-
24 years (figures 2 and 3).  Of the 1,385 mumps cases, 
57% (n=785) were male and 43% (n=596) were female 
(gender was unreported for four cases).
Of the 865 mumps cases where vaccination data were 
reported 27% (n=234/865) were unvaccinated, 34% 
(n=296/865) had one dose of the measles-mumps-
rubella vaccine (MMR) and 39% (n=335/865) were 
reported to have received two doses of MMR.  The 
vaccination date was reported for 61% (n=182/296) 
of cases reported to have received one dose of 
MMR.  Both vaccination dates were reported for 35% 
(n=116/335) of cases vaccinated with two doses of 
MMR.  One third (n=111/335) of the cases reported 
to have received two doses of MMR were laboratory 
confirmed.  
1.4 Mumps 
Summary
Number of cases, 2008: 1,385
Number of cases, 2007: 142
Crude incidence rate, 2008: 32.7/100,000
Figure 1. Number of mumps notifications by year and year of introduction of the measles-mumps-rubella (MMR) vaccine in Ireland
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2008 data collated by HPSC
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Of the 895 cases where hospitalisation data were 
reported seven percent (n=65/895) were hospitalised.  
The number of days hospitalised was reported for 62% 
of these (n=40/65) hospitalised cases.  The number of 
days the cases were hospitalised ranged from one to 18 
with a median of four days and a mean of five days.  
Reported complications of mumps included orchitis 
(14%, n=74/523), deafness (1%, n=9/892), pancreatitis 
(0.9%, n=8/886), meningitis (0.8%, n=7/905), mastitis 
(0.6%, n=5/893) and encephalitis (0.3%, n=3/903).
University/college was reported as the setting in which 
the case had most likely acquired mumps for 54% of 
cases where this information was provided (n=338/629) 
and primary or secondary school was reported for 12% 
(n=74/629) of cases.
Fifty-seven outbreaks of mumps were notified during 
2008 with 580 associated cases of illness.  The majority 
of these cases were associated with outbreaks in 
educational settings.  The outbreak locations included 
18 universities/colleges (with 388 ill), 17 private houses 
(with 49 ill), seven schools (with 37 ill), six community 
outbreaks (with 33 ill), two summer schools (with 14 
ill), one crèche (with three ill), one third level college/
community  (with 41 ill), one training centre (with 
three ill), one workplace (with three ill), an outbreak 
associated with a business/commercial centre (with 
three ill), an outbreak associated with social contacts 
(with two ill) and an outbreak associated with a sports 
team (with four ill).  As some of these outbreaks 
continued into 2009 the final number of cases 
associated with these outbreaks may change.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 14th August 2009.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.  
EU data are available at www.euvac.net.
Figure 2.   Number of notified mumps cases in 2008 by age group 
and case classification. 
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Figure 3. The age specific incidence rates (per 100,000) of notified 
mumps cases in 2008 (age is unknown for 17 cases).
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Figure 3. The age specific incidence rates (per 100,000) of notified 
mumps cases in 2008 (age is unknown for 17 cases).
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Apart from Neisseria meningitidis, which is considered 
the most common cause of bacterial meningitis in 
Ireland, other forms of the disease do occur, including 
those caused by non-notifiable organisms, details of 
which are presented below. For information on invasive 
meningococcal disease (Neisseria meningitidis), see 
a separate chapter within this report. The figures 
presented in this chapter are based on data extracted 
from the Computerised Infectious Disease Reporting 
(CIDR) system on 6th and 7th July 2009.  
Haemophilus influenzae
In 2008, three cases of meningitis due to H. influenzae 
were notified, all of whom were under one year of age. 
Two of the cases were attributable to a type f infection 
and the third was caused by a type b disease. The latter 
patient had been incompletely vaccinated. No deaths 
were reported. See a separate chapter on invasive H. 
influenzae disease for further details.
Leptospira species
One case of leptospirosis meningitis was notified 
in 2008 in an adolescent male following a leisure-
related river water contact. The causative organism 
was identified as a Leptospira interrogans serovar 
icterohaemorrhagiae. See a separate chapter on non-IID 
zoonotic diseases for further details.
Listeria species
Two cases of listeriosis meningitis were notified in 
males in 2008, one of whom was over 65 years of age. 
No deaths were reported. See a separate chapter on 
listeriosis disease for further details.
Streptococcus pneumoniae
In 2008, 32 cases of pneumococcal meningitis were 
notified, compared to 35 in 2007 and 24 in 2006.  
Cases in 2008 ranged in age from one week to 85 
years.  There were five pneumococcal meningitis 
related reported deaths, all but one were adults.  See a 
separate chapter on invasive pneumococcal disease for 
further details.
Streptococcus pyogenes (Streptococcus group A 
infection (invasive) (iGAS))
There were two reported cases of iGAS causing 
meningitis in 2008, both of whom recovered. In 
contrast, there were no cases in 2007, but there was one 
each in 2006 and 2005. See a separate chapter on iGAS 
infection for further details.
1.5 Other forms of Bacterial Meningitis
Summary
Bacterial meningitis, Not Otherwise Specified
Number of cases,  2008: 40
Number of cases,  2007: 33
Number of cases,  2006: 46
Crude incidence rate,  2008: 0.94/100,000
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Mycobacterium species
In 2008, five tuberculosis meningitis cases were notified 
(provisional).  Cases ranged in age from 10-73 years. 
One tuberculosis meningitis death was also reported. 
See a separate chapter on tuberculosis for further 
details.
Bacterial meningitis (not otherwise specified)
In total 40 cases of meningitis under this disease 
category were notified in 2008, among which two 
patients died. The causative pathogens were identified 
in 23 of these. No causative pathogen was identified for 
17 of the 40 (42.5%) notifications in 2008, a decrease 
compared to 2007 (66.7%; n=22/33) and 2006 (78.2%; 
n=36/46). 
Among the bacterial meningitis (not otherwise specified) 
cases notified in 2008 were 11 cases of Escherichia coli 
meningitis, all but one was one month old or less, with 
no deaths reported. Six cases of Group B streptococci 
meningitis were also notified in 2008 with all but one 
being under five months of age and with no deaths 
reported. In addition, three cases of meningitis caused 
by Staphylococcus aureus were reported in 2008, one of 
which died. Other meningitis notifications include one 
each caused by the following pathogens: Citrobacter 
koseri in a one month infant, Enterococcus species in an 
adult and Serratia liquefaciens in a 3-month old infant, 
all of whom recovered.
Table 1. Annual notifications of bacterial meningitis other than meningococcal disease, 2006-2008
Notified under Causative organism 2006 2007 2008
2006-
2008
Haemophilus influenzae disease (invasive) Haemophilus influenzae 4 2 3 9
Leptospirosis Leptospira species 1 1 1 3
Listerosis Listeria species 1 1 2 4
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae 24 35 32 91
Streptococcus Group A infection (invasive) Streptococcus Group A (S. pyogenes) 1 0 2 3
Tuberculosis* Mycobacterium species 7 7 5 19
 Citrobacter koseri 0 0 1 1
 Coagulase Negative Staphylococci 1 0 0 1
 Escherichia coli 3 0 11 14
 Enterococcus species 0 0 1 1
Bacterial meningitis, NOS Gemella species 0 1 0 1
(not otherwise specified) Klebsiella pneumoniae 1 0 0 1
 Proteus mirabilis 0 1 0 1
 Serratia liquefaciens 0 0 1 1
 Staphylococcus aureus 1 0 3 4
 Streptococcus Group B (S. agalactiae ) 4 9 6 19
 Unknown 36 22 17 75
 Total Bacterial Meningitis, NOS 46 33 40 119
Total**  84 79 85 248
Notes
* Tuberculosis meningitis figures for 2007 and 2008 are provisional
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One hundred and four cases (2.5/100,000) of pertussis 
were notified in 2008 compared to 77 cases in 2007.  
Of the 104 cases in 2008 71 (68%) were classified 
as confirmed, two (2%) as probable and 31 (30%) as 
possible.
In 2008, the majority of cases (n=54, 52%) and the 
highest age-specific incidence rate (88.4/100,000) were 
in children aged less than one year with 48 percent 
(n=50) of all cases aged less than six months (figures 1 
and 2). Sixty-five cases (63%) were female, 36 were male 
(35%) while gender was not reported for three cases 
(3%).
In Ireland it is recommended that children be vaccinated 
with an acellular pertussis-containing vaccine at two, 
four and six months of age and a booster dose at four 
to five years of age.  Since 2008 a booster with low dose 
acellular pertussis vaccine is recommended at 11-14 
years of age.
The vaccine provides protection in over 80% of children 
who are fully vaccinated.  However, protection declines 
over time, with little or no protection 10-12 years 
after primary immunisation, if no booster doses are 
administered.  
In 2008, the vaccination status was reported for 60 
(58%) pertussis cases.  Thirty-three (n=33/60, 55%) cases 
were unvaccinated; these cases ranged in age from one 
month to 16 years with two thirds (n=22) aged less than 
six months.  Nine unvaccinated cases (n=9/33, 27%) 
were less than two months of age and were therefore 
not eligible for pertussis vaccine in the Irish schedule.  
Eighteen (n=18/60, 30%) cases were reported as 
incompletely vaccinated, but this included nine cases 
(n=9/18, 50%) who were less than six months of age and 
were therefore not eligible for three doses of pertussis 
vaccine in the Irish schedule.  Nine (n=9/60, 15%) cases 
were reported as completely vaccinated, with one of the 
nine cases reported/known to have received a booster 
dose.  The case vaccinated with the booster dose was 
aged 13 years.
 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 11th August 2009.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
EU data are available at www.euvac.net. 
1.6 Pertussis
Summary
Number of cases, 2008: 104
Number of cases, 2007: 77
Crude incidence rate, 2008: 2.5/100,000
Confirmed Probable Possible
Figure 1. Number of notified pertussis cases in 2008 by age group 
and case classification. “Mo” in graph indicates months i.e. 0-5 months 
and 6-11 months, the remaining age groups are in years.
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Figure 2. The age specific incidence rates (per 100,000) of notified 
pertussis cases in 2008 by case classification.
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In 2008, 40 cases (1.0/100,000) of rubella were notified 
in Ireland compared to 19 cases in 2007.
Two of the cases in 2008 were classified as confirmed 
giving a crude confirmed incidence rate of 0.05 per 
100,000 total population.  Both confirmed cases were 
in the age group 25-34 years (figure 1).  Thirty seven 
cases in 2008 were classified as possible; over two thirds 
of these were less than three years of age (figure 1).  
One case, in the age group 1-2 years, was classified as 
probable (figure 1).  The age specific incidence rates by 
case classification are shown in figure 2.
Of the 40 rubella cases 26 (65%) were male and 14 
(35%) were female.  Of the two confirmed cases one 
was male and one was female.
Rubella vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.   
Vaccination status was reported for 31 (78%) of the 
rubella cases in 2008.  Fourteen cases (n=14/31, 45%) 
were unvaccinated and three cases (n=3/31, 10%) were 
reported as incompletely vaccinated.  Fourteen cases 
(n=14/31, 45%) were reported as completely vaccinated 
for their age, only three (n=3/14, 21%) of these were 
reported to have two doses of MMR.  All 31 cases 
where vaccination status was reported were classified as 
possible cases.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 30th July 2009.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
WHO European data are available at http://data.euro.
who.int/CISID/.
1.7 Rubella
Summary
Number of cases, 2008: 40
Number of confirmed cases, 2008: 2
Crude incidence rate, 2008:1.0/100,000
Crude confirmed incidence rate, 2008: 0.05/100,000
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Figure 1.   Number of notified rubella cases in 2008 by age group and 
case classification. 
Figure 2. The age specific incidence rates (per 100,000 population) of notified 
rubella cases in 2008 by case classification.
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Figure 1.   Number of notified rubella cases in 2008 by age group and 
case classification. 
Figure 2. The age specific incidence rates (per 100,000 population) of notified 
rubella cases in 2008 by case class fication.
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Streptococcus pneumoniae (invasive)
Invasive infections due to Streptococcus pneumoniae 
are notifiable in Ireland since January 2004 and data 
on these notifications are collated in the Computerised 
Infectious Disease Reporting (CIDR) system.  For the 
purposes of this report the term invasive pneumococcal 
disease (IPD) will be used to describe these infections. 
In 2008, 465 cases of IPD (11/100,000) were notified 
in Ireland, increasing from 361 cases (8.5/100,000) in 
2007 (figure 1), representing a 29% increase.  There has 
been a steady increase in IPD notifications each year 
since 2004.  However, this increase is considered to 
be a reflection of improved reporting of IPD cases by 
laboratories in particular, through the infectious disease 
notification system, with the result that the notification 
figures now more closely reflect the IPD figures as 
reported through the European Antimicrobial Resistance 
Surveillance System (EARSS) (figure 1). 
In 2008, 405 (87.1%) IPD cases notified were classified 
as confirmed, 59 (12.7%) as probable and 1 as possible 
(0.2%).  Of the 161 (34.6%) cases that has a clinical 
diagnosis reported, 49.1% (n=79) had a clinical 
diagnosis of meningitis and/or septicaemia, 48.4% 
(n=78) had pneumonia and other diagnoses accounted 
for the remainder (2.5%); muscoskeletal infection (n=2), 
abscess (n=1) and soft tissue (n=1).
More cases occurred in males (57%; n=265) than in 
females (43%; n=200).  Cases ranged in age from 1 
week to 93 years with a median age of 59 years.  The 
elderly i.e. those aged 65 years and older accounted for 
the greatest proportion of case (42%, n=195), followed 
by children <5 years of age (15.7%, n=73) (figure 2).  
Similar to 2007, in 2008 the incidence of IPD was high 
in the very young and very old and was relatively low 
in the age groups in between (figure 2).  In children, 
the incidence was highest in infants <1 year of age 
(50.8/100,000), followed by the 1 year old children 
(34.7/100,000).  In the age groups thereafter the 
incidence declined and did not exceed 14 cases per 
100,000 in those aged 2-64 years.  
In the elderly the incidence increased considerably, 
almost doubling between each of these age groups, 
from 28.9 cases per 100,000 in the 65-74 year olds, to 
48.3 cases per 100,000 in the 75-84 year olds to the 
highest incidence rate of all of 89.5 cases per 100, 000 
in those aged 85 years and older (figure 2). 
Outcome was reported for only 25% (n=115) of the 
notifications in 2008 and therefore the figures presented 
in this section will underestimate the mortality due to 
IPD in Ireland.  Based on the data available, 17 deaths 
associated with IPD infection were reported in 2008. 
Three deaths occurred in children (all < 5 years of age) 
and the remainder (n=14) were in adults, age range 
28-90 years.  The clinical presentation for 16 of the 
17 deaths was reported; 13 had meningitis and/or 
septicaemia and three had pneumonia.  
The IPD notification figures presented in this report 
are based on data extracted from the Computerised 
Infectious Disease Reporting (CIDR) system on 11th 
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of cases in 2008: 465
Number of cases in 2007: 361
Number of deaths in 2008 17
Number of deaths in 2007: 18
Crude incidence rate, 2008: 11/100,000
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Figure 1.  Annual number of invasive pneumococcal disease cases 
reported through the infectious disease surveillance system and 
the EARSS, 2004-2008
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September 2009.  These figures may differ slightly from 
those previously published due to ongoing updating of 
notification data on CIDR.  EARSS data were obtained 
from the Whonet database at HPSC.
A collaborative pilot-project was established in April 
2007 between RCSI Beaumont Hospital, The Children’s 
University Hospital, Temple Street and HPSC to offer 
a typing service to Irish Microbiology laboratories for 
all isolates of Streptococcus pneumoniae submitted.  
Amongst the isolates typed to date, this includes 379 
isolates (excluding duplicates etc.) with a specimen 
date in 2008.  Based on the results from these 379 
isolates, 32 different serotypes were identified.  The 
most common serotypes in circulation were 14, 4, 9V, 
7F, 8, 23F and 6B accounting for over half (52.5%) of the 
isolates typed (figure 3).  The seven serotypes contained 
in PCV7 occurred in the 12 top most prevalent 
serotypes associated with IPD in Ireland in 2008. Sixty 
nine percent of isolates from children aged <2 years had 
serotypes covered by PCV7.  
One objective of this project was to establish the 
serotype distribution of IPD isolates in circulation in 
Ireland prior to the introduction of the pneumococcal 
conjugate 7-valent vaccine (PCV7, Prevenar) to the 
childhood immunisation schedule, which took place in 
September 2008. This objective has been achieved.  
The current focus of the project is to continue offering a 
typing service in order to effectively monitor the impact 
of introducing PCV7, to investigate vaccine failures 
and to inform future public health policy regarding 
immunisation schedules and the value of introducing 
expanded valency vaccines following their licensing.  
The pilot typing project continues throughout 2009.  
However, permanent funding of this project is critical 
to ensure the above very important health protection 
objectives can be delivered on.
Figure 2. Number and age specific incidence rates (ASIR) of invasive pneumococcal disease notifications by age group, 2008
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Figure 3.  Serotype distribution of invasive Streptococcus pneumoniae isolates in Ireland, 2008 (n=379)
*Bars highlighted in red indicate serotype is covered by PCV7 vaccine
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Two cases of tetanus were notified in 2008.  The cases 
were in the age groups 20-24 years and 65+ years and 
both were male.  Risk factors for infection were reported 
for both cases; one case had wound injuries from a road 
traffic accident and one had a wound injury from a fall 
outdoors.  The immunisation status of the case aged 
≥65 years was unknown while the case aged 20-24 years 
had no history of tetanus immunisation. Both cases were 
given a tetanus vaccine at the time of injury; only one of 
the cases was given tetanus immunoglobulin G (TIG) at 
the time of injury.  
Summary of data since 1981:
Twelve cases of tetanus were reported since tetanus 
became notifiable in November 1981.  The cases ranged 
in age from 15 to 84 years with a  mean age of 53 years 
and a median age of 61 years (age was unknown for two 
cases).  The number of tetanus cases notified by age 
group is shown in figure 1.  Two deaths were reported in 
cases aged >60 years.  
Of the 12 tetanus cases seven (58%) were male, three 
(25%) were female while gender was unreported for 
two (17%).
The following wound injuries (n=8) were reported 
among the 12  notified cases: wound injuries from a 
road traffic accident (n=1), wound from a fall outdoors 
(n=1), wound associated with a dog bite (n=1), wound 
from a kitchen knife (n=1), gardening associated leg 
wound (n=1), leg scratches in an avid gardener (n=1), 
hand wound associated with a clean piece of wood 
(n=1) and a farming associated hand wound (n=1).  
Vaccination data were reported for five of the 12 cases, 
three of whom were either unvaccinated or vaccination 
status at the time of injury was unknown.  All three cases 
received a tetanus vaccine at the time of injury. One 
case, in the age group 15-19 years, was reported to 
have received three doses of tetanus vaccine as a child 
and a booster at four years and again at five-six years of 
age.  One case was reported to have received a single 
tetanus vaccine around 40 years prior to infection and at 
the time of injury.
Tetanus vaccine provides protection in 90-95% of 
children who are fully vaccinated.   However, as 
protection declines over time up to 50% of 20-year-olds 
and up to 70% of 70-year-olds may be unprotected 
if they have not received boosters.  The childhood 
immunisation schedule in Ireland recommends children 
receive a dose of tetanus toxid-containing vaccine at 
two, four and six months of age and booster doses at 
four-five years and 11-14 years of age. 
Persons aged 10 years or over (who are unimmunised 
or partly immunised) are recommended three doses 
of tetanus toxoid with intervals of at least one month 
between doses.  A booster dose of tetanus toxoid 
should be given five years after the primary course and 
again 10 years later.  For more detailed information 
on tetanus immunisations please see the document 
Immunisation Guidelines for Ireland available at www.
immunisation.ie.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 18th August 2009.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
1.9 Tetanus
Summary
Number of cases, 2008:  2
Number of cases, 2007:  1
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Figure 1. Tetanus cases notified (n=12) from 1982 to 2008 by age group
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02
Influenza
HPSC is working in collaboration with the NVRL, the 
ICGP and the Departments of Public Health on the 
influenza sentinel surveillance project. Fifty-four general 
practices (located in all HSE-Areas) were recruited to 
report electronically, on a weekly basis, the number of 
patients who consulted with influenza-like illness (ILI). 
Sentinel GPs were requested to send a combined nasal 
and throat swab on at least one ILI patient per week to 
the NVRL. Other indicators of influenza activity include a 
network of sentinel hospitals reporting admission levels, 
sentinel schools reporting absenteeism and enhanced 
surveillance of hospitalised influenza cases in 0-14 year 
olds.  
Influenza activity in Ireland was high during the 
2008/2009-influenza season, peaking during week 2 
2009 at 120.6 per 100,000 population (figure 1). During 
the peak of activity, the majority of ILI cases reported 
were in the 15-64 year age group. A baseline threshold 
of 17.8 ILI GP consultations per 100,000 population 
was also used for the first time in Ireland during the 
2008/2009 season.
The NVRL tested 353 sentinel specimens for influenza 
virus during the 2008/2009 season. Two hundred 
and one (56.9%) sentinel specimens were positive for 
influenza: 147 influenza A (129 A H3 and 18 A H1N1) 
and 54 influenza B. 
Influenza A (H3) was the predominant subtype detected 
during 2008/2009. Influenza A (H3), accounted for 
87.8% of subtyped positive sentinel specimens. The 
majority of positive influenza sentinel cases were in the 
15-64 year age group (84.3%). 
The NVRL tested 2,756 non-sentinel respiratory 
specimens during the 2008/2009 season, 73 (2.6%) of 
which were positive: 59 influenza A and 14 influenza B. 
2.1 Influenza
Summary
2008/2009 Influenza Season
Peak influenza-like illness rate: 120.6/100,000
% of influenza positive sentinel specimens: 56.9
Dominant circulating (sub)type: A (H3) 
European data available at: www.euroflu.org
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Figure 1: GP ILI consultation rate per 100,000 population and the number of positive influenza specimens detected by the NVRL by week and season, 
2006/2007 to 2008/2009
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The NVRL completed genetic characterisation for two 
influenza A(H3) and five influenza B viruses during 
2008/2009. Both A(H3) viruses were characterised as A/
Brisbane/10/2007-like virus.  All five influenza B viruses 
were characterised as B/Malaysia/2506/2004-like (B/
Victoria/2/87 lineage).
The NVRL conducted nucleotide sequencing on 10 
influenza A(H1) specimens taken by sentinel GPs in 
Ireland during 2008/2009, nine (90%) of which were 
resistant to oseltamivir and one was sensitive.  
Of the 201 positive influenza virus detections from 
sentinel specimens, 171 (85.1%) were unvaccinated, 
10 (5.0%) were vaccinated and vaccination status was 
unknown in 20 (10.0%) cases. Of the 10 vaccinated 
cases, influenza A (H1) was detected in one case, 
influenza A(H3) in 7 cases and influenza B in two cases.  
Overall, influenza activity was most intense in HSE-E, 
-NE and -SE during the 2008/2009 season. Seven 
influenza/ILI outbreaks were reported to HPSC during 
the 2008/2009 season. Influenza A was detected in four 
outbreaks, influenza B in one and the remaining two 
outbreaks were suspected influenza/ILI.  
Hospital respiratory admissions (as a proportion of 
total hospital admissions) in sentinel hospitals peaked 
during week 52 2008 (figure 2), two weeks prior to the 
peak in sentinel GP ILI consultation rates. Absenteeism 
in several sentinel schools was also at elevated levels 
during peaks in ILI consultation rates. 
A total of 434 influenza notifications were reported on 
CIDR during the 2008/2009 influenza season. Of the 
434 notifications, 116 were patients aged between 0 to 
14 years, 37 of whom were hospitalised. Enhanced data 
were completed for all 37 cases. Twenty-four enhanced 
cases were positive for influenza A, 10 were positive 
for influenza B and influenza type was not reported for 
three cases. Symptoms included fever (30/37), cough 
(30/37), gastrointestinal manifestations (14/37) and 
sore throat (12/37). Complications included bronchitis, 
croup, primary viral pneumonia, secondary bacterial 
pneumonia, bone marrow dysfunction and other 
respiratory complications. The mean number of days 
hospitalised was 3 (ranging from 0-10). Three cases were 
in an at-risk category for influenza vaccine. No cases 
were vaccinated. Twenty-seven cases recovered, one 
died, outcome was unknown for five and outcome was 
not reported in four cases.
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Figure 2: Respiratory admissions as a percentage of total hospital admissions in ten sentinel 
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Four influenza associated deaths were registered 
with the General Register Office (GRO) during the 
2008/2009-influenza season. Influenza was the 
secondary cause of death and not the primary cause 
in all four cases. One death was in the 15-64 year age 
group and three deaths were in those aged 65 years 
and older. 
On 25th April 2009, a public health emergency of 
international concern was declared by the World Health 
Organization (WHO) due to an outbreak of pandemic 
(H1N1) infection in Mexico and the USA. WHO has 
described this virus as a new strain of influenza A(H1N1) 
not previously detected in humans and containing a mix 
of swine, human and avian influenza virus genes. On 
11th June 2009, WHO raised the pandemic alert level 
from phase five to phase six, declaring the outbreak a 
pandemic.
For the forthcoming season, existing surveillance 
systems have been strengthened and a number 
of additional measures have been put in place in 
Ireland to improve surveillance of ILI/influenza and 
pandemic influenza (H1N1) 2009. The number of 
sentinel general practices has been increased to 62.  In 
addition, virological surveillance in sentinel practices 
has been expanded so that each practitioner takes at 
least 5 swabs per week from ILI patients. The NVRL 
will continue monitoring oseltamivir resistance. Non 
sentinel influenza virology data will also be included 
from Cork University Hospital and University College 
Hospital in Galway.  Surveillance of hospitalised cases 
and outbreaks of pandemic (H1N1) 2009 will continue 
and intensive care unit (ICU) surveillance of pandemic 
(H1N1) is currently being implemented.  Mortality 
surveillance monitoring excess all cause deaths 
and pneumonia and influenza deaths has also been 
augmented and is now undertaken in a more timely 
manner. Data from these surveillance systems will 
assist in guiding the management and control of the 
pandemic 
Further information on influenza is available at
 www.hpsc.ie 
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In 2008, 11 cases of legionnaires’ disease were notified 
in Ireland, a rate of 2.6/million population. This was a 
slight drop in the rate recorded in the previous two 
years but the numbers are small (Table 1). One death 
was recorded in 2008. Five  cases were notified from 
HSE East, two each from HSE Midlands and HSE South, 
and one each from HSE North East and HSE West. 
The majority of cases (54.5%) were male. The median age 
was 62 years, with a range from 47 to 82 years.
There were ten confirmed cases and one probable case. 
The organism involved was Legionella pneumophila 
serogroup 1 in nine cases while the Legionella species 
was unknown in two cases. Urinary antigen testing was 
the method of diagnosis in eight cases and serology in 
three cases. 
Of the 11 cases, three were travel-associated, one was 
nosocomial and seven were community-associated. 
Countries of travel included Spain (1),  Turkey (1), and 
Bulgaria (1). A case of legionnaires’ disease is defined 
as travel-associated if the patient spent one or more 
nights away from home in accommodation used for 
commercial purposes (hotels, holiday apartments) in the 
10 days before onset of illness. Travel-associated cases 
may involve travel within Ireland or abroad.
Pontiac fever
In 2008, there was one laboratory-confirmed case of 
pontiac fever. There were 36 suspect pontiac fever cases 
associated with a workplace outbreak of legionellosis.  
Outbreak
In 2008, there was an outbreak of legionnellosis 
involving two cases of legionnaires’ disease and 36 
suspect cases of pontiac fever. Pontiac fever is a self-
limiting flu-like illness. The incubation period is 24-48 
hours and patients recover spontaneously.
All the suspect pontiac fever cases were diagnosed on 
clinical grounds and were also epidemiologically linked 
to the two confirmed cases of legionnaires’ disease. 
None had positive serology. The majority of cases 
(63.9%) were female. The median age was 35.5 years, 
with a range from 20 to 58 years.
2.2 Legionellosis
Summary
Number of cases in 2008: 11
Crude incidence rate: 2.6/1,000,000
Number of deaths in 2008: 1
Table 1. Number of legionnaires’ disease cases per million population notified in Ireland, 2000-2008
Age group 
(years)
2000 2001 2002 2003 2004 2005 2006 2007 2008
<30 1 0 0 1 0 0 0 1 0
30-39 2 1 2 0 0 2 0 4 0
40-49 1 1 3 0 1 4 8 4 2
50-59 1 0 0 1 1 1 2 2 3
60-69 2 1 1 2 1 1 1 3 4
70+ 2 0 0 3 1 1 2 2 2
Total 9 3 6 7 4 9 13 16 11
CIR 2.3 0.8 1.5 1.8 0.9 2.1 3.1 3.8 2.6
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Notifications
Sixty-eight cases of invasive Group A streptococcal 
(iGAS) disease were notified in 2008.  This corresponds 
to 1.60 iGAS cases per 100,000 population (95% 
confidence interval, 1.25 to 2.03 per 100,000) and 
represents an increase when compared to 2007 when 
the iGAS rate was 1.34 per 100,000 population (95% CI, 
1.02 to 1.74 per 100,000).  
Of the 68 cases:
•  66 were confirmed - defined as patients with group 
A Streptococcus (GAS), or Streptococcus pyogenes, 
isolated from a sterile site 
•  one was probable - defined as a clinically compatible 
case and meeting the probable laboratory criteria 
for streptococcal toxic shock syndrome (STSS), i.e., 
isolated from a non-sterile site such as the throat or 
vagina 
•  one was not specified (in an 18 month old male with 
no clinical details provided)
Patient demographics
Of the 68 cases, 36 (53%) were males and 32 (47%) were 
females, with ages ranging from 10 months to 89 years. 
The age and sex specific rates of iGAS cases are shown 
in Figure 1. Children aged up to 9 years and adults aged 
over 55 years were most affected.
Geographic spread and seasonal variation
Table 1 outlines the numbers and crude incidence rates 
(CIRs) of iGAS disease by HSE area from 2004 to 2008. 
Of note, the highest number of cases in 2008 occurred 
in the HSE-E (n=31) while the highest CIRs were in the 
HSE-NE (2.5 per 100,000 population) and the HSE-W 
(2.4 per 100,000 population). 
Although the numbers of iGAS notified to date have 
been low and it is not possible to discern distinct 
seasonal variations, the majority of notifications to 
date have been made during the first half of the year 
(data not shown). In 2008, the majority of cases (n=36) 
occurred in the first four months of the year.
Enhanced surveillance data
Enhanced data fields were entered for 48 (71%) of the 
68 cases reported in 2008, compared with 70% (40 of 57 
cases) in 2007. Of the 48 cases for which enhanced data 
were available, there was a wide variation in the fields 
completed. Thirteen laboratories were identified as the 
source for 39 cases. 
Isolate details
GAS was isolated from a sterile site from 39 of 48 cases 
for which enhanced data were available, primarily from 
blood cultures (33 isolates, or 85%) but also abscesses 
(3), deep tissue (2) and joint (1). 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Number of cases, 2008: 68
Crude incidence rate, 2008: 1.60 per 100,000 
population
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Figure 1. Age and sex specific rates of iGAS disease in 2008
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No serological typing data, based on the detection of 
M and T-proteins, were available. This is predominantly 
due to the absence of a streptococcal reference 
laboratory in this country and thus laboratories are 
required to send their isolates to reference facilities 
abroad.
Clinical details
As in 2007 and previous years, bacteraemia (35 cases, 
including cases where bacteraemia was not specifically 
stated but GAS was isolated from blood) and cellulitis 
(17) were the most common clinical presentations, 
followed by pneumonia (6), septic arthritis (6), 
streptococcal toxic shock syndrome (STSS) (7; 2 of which 
were implied based on the clinical presentation given), 
necrotising fasciitis (4), puerperal sepsis (3), meningitis 
(2) and myositis (2). Note that cases could have more 
than one clinical presentation.  Table 2 outlines the 
clinical syndromes associated with the 35 cases for 
which data on clinical presentation were provided: 
Risk factors
Risk factors associated with iGAS disease included the 
following: 
•  age over 65 years (18)
•  skin and wound lesions (11)
•  diabetes (5)
•  steroid use (4)
•  malignancy (3)
•  non-steroidal anti-inflammatory drugs (NSAID) (3) 
•  intravenous drug use (IVDU) (2)
•  varicella infection (2)
•  alcoholism (1)
Note that cases could have one or more associated 
risk factors. No risk factors were identified for 38 cases. 
Among the seven cases with STSS, age over 65 years 
was identified as a risk factor in four cases, NSAID use 
in two and steroid use diabetes, malignancy and skin 
lesions in one each. No risk factors were identified for 
two STSS cases. 
Clinical management
Surgical intervention was required for nine patients 
(compared to two in 2007), ranging in age from 26 to 
76 years, with clinical presentations that included one or 
more of the following:
•  necrotising fasciitis (3) +/- myositis
•  cellulitis (4)
•  septic arthritis (2)
Admission to the intensive care unit was required for 
seven patients (compared to five in 2007), ranging in 
age from 5 to 77 years, with clinical presentations that 
included one or more of the following:
•  bacteraemia and STSS (3) [one with pneumonia]
•  bacteraemia and necrotising fasciitis (1) 
•  STSS and necrotising fasciitis (1)
•  bacteraemia and pneumonia (1)
Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area, 2004-2008HSE Area 2004 2005 2006 2007 2008
 n CIR  n CIR n  CIR   n   CIR    n   CIR    
HSE-E 25 1.7 19 1.3 37 2.5 28 1.9 31 2.1
HSE-M 0 0.0 1 0.4 2 0.8 0 0.0 0 0.0
HSE-MW 1 0.3 3 0.8 2 0.6 2 0.6 1 0.3
HSE-NE 1 0.3 3 0.8 5 1.3 3 0.8 10 2.5
HSE-NW 0 0.0 3 1.3 1 0.4 3 1.3 3 1.3
HSE-SE 7 1.5 1 0.2 4 0.9 10 2.2 8 1.7
HSE-S 1 0.2 1 0.2 3 0.5 4 0.6 5 0.8
HSE-W 0 0.0 18 4.3 7 1.7 7 1.7 10 2.4
IRELAND 35 0.8 49 1.2 61 1.4 57 1.3 68 1.6
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Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE area, 2004-2008.
Length of ICU stay was provided for four cases: 2, 3, 7 
and 10 days. Surgical intervention was required for the 
two patients with necrotising fasciitis.
Other epidemiological information
One case (puerperal sepsis in a 31 year old female) was 
reported as having been hospital-acquired compared 
to none in 2007. As in 2007, no outbreaks of iGAS were 
notified in 2008.
Outcome
Outcome at 7-days following GAS isolation was 
reported for 27 cases: 
•  26 were still alive (including the probable case)
•  one patient died (age 84 years, with diabetes, steroid 
and NSAID use and presenting with STSS)
In addition to the above:
•  three cases (ages 16, 46 and 52 years) were reported 
to have died but it was not stated if these deaths 
were directly attributable to iGAS
•  four cases were still ill at the time of reporting to 
CIDR and their final outcome was not ascertained
Of the seven STSS cases, one patient died resulting in 
a case fatality rate (CFR) of 14%, while four were still ill 
or recovering and one was recovered. No final outcome 
was provided for one patient, but was alive after 7 days.
The case fatality rate (CFR) for outcome from iGAS 
disease reported at 7-days in 2008 was 4%, a decrease 
from 19% (five deaths) in 2007. 
Antimicrobial susceptibility
Antimicrobial susceptibility data were reported on 38 
iGAS isolates (37 from blood and one from a joint fluid) 
by ten laboratories in 2008. All isolates were susceptible 
to penicillin (n=37), clindamycin (n=5) and vancomycin 
(n=31).  Resistance to erythromycin was reported in 
three of 30 (10%) isolates and to tetracycline in one of 
12 (8%) isolates.
Conclusion
In 2008, there were 11 more cases of iGAS reported 
in Ireland than in the previous year, an increase of 
almost 20%. This could be a genuine increase in the 
incidence of iGAS or could represent better reporting 
bacteraemia, cellulitis, myositis and necrotising fasciitis (1)•	
bacteraemia, cellulitis, pneumonia and STSS (1)•	
bacteraemia, meningitis, septic arthritis and STSS (1)•	
bacteraemia, cellulitis and meningitis (1)•	
bacteraemia, pneumonia and STSS (1)•	
bacteraemia, cellulitis and STSS (1)•	
bacteraemia, myositis and necrotising fasciitis (1)•	
bacteraemia and pneumonia (1)•	
bacteraemia and cellulitis (7)•	
bacteraemia and septic arthritis (2)•	
bacteraemia and STSS (1)•	
cellulitis and necrotising fasciitis (1)•	
necrotising fasciitis and STSS (1)•	
pneumonia and STSS (1)•	
bacteraemia without a focus (5)•	
cellulitis (3)•	
puerperal sepsis (3)•	
septic arthritis (3)•	
Table 2. Clinical syndromes of 35 patients with iGAS disease in 2008
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of this disease, which only became notifiable in Ireland 
as of 2004. The number of cases notified in Ireland still 
remains low compared to other Northern European 
countries and the US. Data reported to the Strep-Euro 
Program for 2003 and 2004 showed that the highest 
rates of iGAS disease were in Northern Europe with 
age-standardised rates of 3.31 and 3.10 per 100,000 
population in the UK and Sweden, respectively. The 
estimated rate of iGAS disease in the US in 2008 
[provisional data from CDC’s Active Bacterial Core 
Surveillance (ABCS) Program] was 3.8 per 100,000 
population while the mortality rate was 0.5. Certain 
serotypes of GAS are known to be more virulent than 
others, e.g. serotypes M1 and M3, but in the absence of 
a streptococcal reference laboratory in this country, no 
serological typing data are available to investigate such 
a link between Irish isolates and severity of disease. 
While enhanced data were available for 71% of cases, 
improved completion of the enhanced questionnaire 
for all cases will further augment our understanding of 
iGAS disease in Ireland.  
HPSC thanks the microbiology laboratories for their 
contribution to date and encourages those that do 
not, to complete enhanced data forms and to submit 
antimicrobial susceptibility data on all iGAS cases along 
with their EARSS quarterly returns.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 22nd August 
2009. 
Further information on iGAS disease in Ireland including 
national guidelines is available at: http://www.ndsc.ie/
hpsc/A-Z/Other/GroupAStreptococcalDiseaseGAS/ 
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TIn 2007, 480 cases of tuberculosis (TB) were notified 
in Ireland, corresponding to a crude notification rate 
of 11.3 per 100,000 population. This is slightly higher 
than the rates reported between 2000 and 2006, which 
ranged from 9.7 to 11.0 per 100,000 population, but is 
lower than the crude incidence rates reported between 
1991 and 1999, which ranged from 11.5/100,000 to 
18.2/100,000. A summary of the epidemiology of TB 
in Ireland during 2007 is shown in table 1. Number of 
cases and crude incidence rates from 1991 to 2008 with 
three-year moving averages are also shown in figure 1.
The highest crude incidence rate was reported in HSE 
South at 16.4 per 100,000 population. The next highest 
rates were reported in HSE East (14.6) and HSE West 
(10.6). Rates reported in HSE Northeast (6.1), Southeast 
(6.3) and Midlands (6.4) were significantly lower than the 
national incidence rate. Differences in age-standardised 
TB incidence rates were also found between HSE areas 
with HSE South having the highest rate (16.4/100,000) in 
2007 followed by HSE East (13.3) and HSE West (10.4). 
The remaining HSE areas had rates ranging from 6.2 to 
8.2/100,000. 
The highest age-specific rate in 2007 occurred among 
those aged 25-34 years old (17.9/100,000) followed 
by those aged 65 years and over (16.9/100,000). The 
rate among males (14.0/100,000) was higher than that 
among females (8.7/100,000) and rates among males 
were higher than females for all age groups except 
in the 0-14 year age group where the rate was the 
same (4.7/100,000). The highest rate among males 
(26.1/100,000) was in the group aged 65 years and 
older while the highest rate in females (16.6/100,000) 
was in the 25-34 year age group. The male to female 
ratio (1.6:1) reported in 2007 was consistent with the 
rate reported in previous years. 
During 2007, 40.0% (192 cases) of TB cases were born 
outside Ireland. This is higher than reported between 
2.4 Tuberculosis, 2007
Summary
Number of cases in 2007: 480
Number of culture confirmed cases: 315
Crude incidence rate in 2007: 11.3/100,000
Number of TB deaths in 2007: 7
Number of cases in 2008*: 470 
Crude incidence rate in 2008*: 11.1/100,000
Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2008* and 3-year moving 
averages, 1992-2007
* Provisional data which may change significantly following validation
-37-HPSC Annual Report 2008 2. Respiratory and Direct Contact Diseases
2003 and 2006 when the proportion of foreign born 
cases ranged from 21% to 34.6%.. The crude rate in the 
indigenous population was 8.0/100,000 while the crude 
rate in the foreign-born population was 31.3/100,000. 
There was a notable difference in age between those 
born in Ireland and those born outside Ireland, with a 
median age of 44 years and 31 years respectively. In 
2007, among countries in the EU and Western Europe 
who reported data to the EuroTB network, 21% of 
notifications were in foreign-born patients.
Pulmonary TB was reported in 349 (72.7%) cases and 
131 (27.3%) had exclusively extrapulmonary disease. Of 
the extrapulmonary cases reported in 2007, there were 
six cases of TB meningitis corresponding to a rate of 
0.14/100,000 population (1.4/million population). 
Of the 480 cases reported in 2007, 65.6% (315 cases) 
were culture confirmed. Species identification showed 
M.tuberculosis in 96.8% (305 cases), M.bovis in 1.9% (6 
cases) and M.Africanum in 0.6% (2 cases) of the culture 
confirmed cases (two culture confirmed cases with 
unknown organism). Of the 349 cases with a pulmonary 
component, 246 (70.5%) were culture confirmed, and 
153 (43.9%) were smear positive.  
The proportion of drug resistant TB cases notified in 
2007 was 5.0% (24 cases). The proportion of MDR-TB 
cases was 1.5% (7 cases). Mono-resistance to isoniazid 
was recorded in 12 cases, to rifampicin in three cases 
and to pyrazinamide in two cases. Twelve of the 24 
(50.0%) drug resistant cases, including five (71.4%) of 
the MDR-TB cases, were born outside Ireland.
In 2007, information on treatment outcome was 
provided for 86.0% (413) of cases. Of the 413 cases, 
332 (69.2%) completed treatment, 40 (8.4%) died, 18 
(3.8%) were lost to follow up, 17 were still on treatment 
(3.5%) and 6 (1.3%) had treatment interrupted.  Seven 
of the 40 deaths were attributable to TB. It is of critical 
importance to TB control in Ireland that surveillance of 
TB and reporting of outcome data be maintained at a 
high level especially with the global threat of resistant 
strains. 
The Global Plan to Stop TB 2006-2015 was launched in 
January 2006 and aims to reduce the global prevalence 
of, and deaths due to TB by 50% in 2015 relative to 
1990.  In addition it proposes to eliminate TB as a 
public health problem (<1 case per million population) 
by 2050. This strategy calls on countries to strengthen 
health systems for TB treatment and control and to 
address MDR-TB, TB/HIV and other challenges e.g. 
high risk groups and areas where TB rates are high. 
Table 1: Summary of the epidemiology of TB in Ireland, 2007
Parameter 2007
Total number of cases 480
Crude notification rate per 100,000 11.3
Cases in indigenous population** 283 (59%)
Cases in foreign-born persons** 192 (40%)
Culture positive cases 315 (65.6%)
Pulmonary cases 349 (72.7%)
Smear positive pulmonary cases 153 (31.9%)
Multi-drug resistant cases 7 (1.5%)
Mono-resistant to isoniazid 19 (4.0%)
Deaths attributable to TB 7 (1.5%)
Outcomes reported in cases 413 (86.0%)
TB meningitis cases 6 (1.4 per million)
**Country of birth not reported for 5 cases
-38-HPSC Annual Report 2008 2. Respiratory and Direct Contact Diseases
The importance of good surveillance data cannot be 
underestimated in this context as they will help guide 
where resources should be directed in order to ensure 
the effective prevention and control of TB in Ireland and 
in order to reach the elimination target by 2050.
Provisional 2008 data
There were 470 cases of TB provisionally notified in 
2008, corresponding to a crude rate of 11.1 per 100,000 
population. It is important to note that these data are 
provisional and may change significantly following 
validation. 
Of the 470 cases provisionally notified in 2008, 
Pulmonary TB was diagnosed in 297 cases (63.2%), •	
extrapulmonary TB in 123 cases (26.2%) and 
pulmonary and extrapulmonary TB in 32 cases (6.8%).
Of the 329 cases with a pulmonary disease •	
component, 148 (45.0%) were culture positive and 
159 (48.3%) were smear positive.
There were five cases of TB meningitis provisionally •	
notified corresponding to a rate of 0.12/100,000 
population (1.2/million population).
There were 265 (56.4%) cases born in Ireland and 186 •	
(39.6%) were foreign-born. Country of birth was not 
reported for 19 cases.
There were 288 cases (61.3%) notified in males, 182 •	
cases (38.7%) in females and the median age of cases 
was 39 years (range 1 to 93 years).
Resistance was reported in 10 cases, three were •	
mono-resistant to isoniazid and three were MDR-TB. 
Six of the 10 resistant cases, including one of the 
MDR-TB cases, were born outside Ireland.
More detailed surveillance reports can be found  
at www.hpsc.ie/hpsc/A-Z/VaccinePreventable/
TuberculosisTB/
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Campylobacter became a notifiable disease in Ireland 
in 2004 under the Infectious Diseases regulations. 
Prior to this, data on laboratory-confirmed cases of 
Campylobacter infection in humans were collected 
nationally as part of the EU Zoonoses Regulations. It is 
an acute zoonotic bacterial disease and characterised by 
diarrhoea, abdominal pain, malaise, fever, nausea and 
vomiting. Symptoms generally last for only a few days. 
Undercooked meat especially poultry is often associated 
with illness as is unpasteurised milk and untreated 
water. Findings of the first national case control study 
conducted in Ireland investigating risk factors for 
sporadic Campylobacter infections show that consuming 
chicken, lettuce and eating takeaways were important 
risk factors for contracting the disease in Ireland. 
Contact with sheep, peptic ulcer, hiatus hernia, lower 
bowel problems were also independently associated 
with infection. However mains water supply showed 
protective effect from contracting the illness1. 
Campylobacteriosis is the commonest bacterial cause 
of gastroenteritis in Ireland and Europe. Despite 
there being 133 less notifications than in 2007 this 
dominant trend continued in 2008 with 1758 cases of 
Campylobacter notified. Of the cases notified 99.8% 
were laboratory confirmed. 
The national crude incidence rate (CIR) was 
41.4/100,000. The most recent community summary 
report published by the European Food Safety Authority 
(EFSA) in January 2009 calculates a European CIR of 
45.2/100,000 for 20072. 
The CIR varied regionally ranging from 34.0/100,000 in 
the Northeast, to 60.0 /100,000 in the Midlands (Figure 
1). Over the past three years a consistent increase in 
rates has been observed in the Mid and Midwest areas 
of the country. Conversely the East and the Northwest 
have both incurred year on year consistent decrease 
rates per 100,000. 
Campylobcateriosis is seen in all age groups with 
the highest burden of illness experienced in the 0-4 
age group. This group had the highest age specific 
incidence rate (ASIR) of 141.9/100,000 in 2008 (figure 
2). The second highest ASIR observed was in the 20-
24 age group (43.8/100,000). The least affected age 
group were the 10-14 year olds (ASIR of 21.2/100,000). 
This preponderance in younger children is a well known 
characteristic of the disease and is also observed at 
European level. The EFSA community summary report 
for 2007 calculates the ASIR of the 0-4 age group at 
120.0/100,000. Table 1 presents both ASIR and CIR by 
region for 2008.
Campylobacter has a well documented seasonal 
distribution with a peak in early summer. During 2008 
the occurrence of Campylobacter did not conform to 
this usual trend. July experienced the highest rate of 
occurrence during the summer months (n=204) but 
in October there was late second peak (n=230).  The 
reason for this is not known. The number of cases 
remained elevated for the remaining months with 128 
cases notified in December (figure 3).
3.1 Campylobacter 
Summary
Number of cases 2008: 1758
Number of cases 2007: 1891
Crude Incidence Rate: 41.4/100,000
Table 1: ASIR and CIR of Campylobacter by Region, 2008 
HSE-Region
Age Standardised 
Incidence Rate 
(95% CI)
Crude Incidence Rate 
(95% CI)
East 36.8 [33.8 - 40.0] 37.7 [34.6 - 40.8]
Midlands 58.8 [49.4 - 68.3] 60.0 [50.4 - 69.6]
Midwest 48.8 [41.6 - 56.1] 48.8 [41.6 - 56.0]
Northeast 32.7 [27.2 - 38.3] 34.0 [28.3 - 39.8]
Northwest 40.9 [32.8 - 49.1] 41.3 [33.2 - 49.5]
Southeast   38.8 [33.1 - 44.5] 39.1 [33.4 - 44.8]
South 44.0 [38.7 - 49.2] 43.2 [38.0 - 48.3]
West 45.8 [39.2 - 52.4] 44.7 [38.2 - 51.1]
National 41.3 [39.3 - 43.2] 41.4 [39.5 - 43.4]
 
Figure 1: National CIR of Campylobacter by Region, 2007 and 2008.
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Overall there was a slighltly elevated rate of male cases 
reported in 2008. This is evident when the ASIRs are 
examined by age-sex adjusted rates. The porportion 
varies between age groups, most notably in the 10-14 
age group where the occurrence in male cases is almost 
three times greater than in their female counterparts. 
There is currently no national referencing facility for 
routine typing of Campylobacter isolates. As a result 
information on species type is very poor. In 2008 67.5% 
of Campylobacter cases identified were not further 
speciated. Of those that were typed C. jejuni accounted 
for 88.1% (n=503) of cases, C. coli (n=67) for 11.7% and 
C. lari for 0.2% (n=1). 
Information on country of origin was recorded in 16.9% 
of all cases. This is a slight improvement on the rate 
of information provided in 2007 (14% of all cases). Of 
cases where country of origin was specified, indigenous 
cases accounted for 94.3%. There were 17 foreign travel 
cases associated with 16 different countries (two cases 
identified the UK in travel history).
During 2008 there were seven family outbreaks of 
Campylobacter notified on CIDR with 14 associated 
cases of illness. These were all small clusters of illness 
with no more than two people ill in any outbreak. Mode 
of transmission was described in five of the outbreaks 
with person to person spread being the most common 
route (n=3). Foodborne and animal route contact was 
suggested for the remaining two outbreaks however 
no further details were available to substantiate these 
hypothesised routes.
References:
1.  Danis K et al., Risk factors for sporadic Campylobacter infection: an 
all-Ireland case-control study. Euro-Surveillance. 2009 Feb 19;14(7). 
pii: 19123
2.  Community Summary Report – Trends and Sources of Zoonoses 
and Zoonotic Agents in the European Union in 2007; Published by 
the European Food Safety Authority and the European Centre for 
Disease Control, January 2009
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Figure 3: Camplobacter Notifacations in Ireland by Month, 2004-2008
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Figure 2: National ASIR of Campylobacter by Age Group, 1999 – 2008
Table 2: ASIR of Campylobacteriosis by Age Group and Sex, 2008
Age Group
Rate per 100,000 - 
Females
Rate per 100,000 
-  Males
0-4 58.9 81.7
05-09 21.5 19.1
10-14 5.5 15.7
15-19 12.4 13.8
20-24 23.7 20.2
25-34 22.8 19.7
35-44 16.7 15.1
45-54 11.5 14.2
55-64 12.5 13
65+ 18 19
Total 19.7 21.4
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In 2008, 416 cases of cryptosporidiosis were notified 
in Ireland, a crude incidence rate of 9.8 per 100,000 
population (Table 1). This was a 32% decrease on the 
number of cases notified in 2007, being similar to the 
reported incidence rates of 2004 and 2006. In the two 
years for which data are available for the incidence of 
cryptosporidiosis across European Member States (2005 
and 2006), Ireland has had the highest incidence in both 
years. On average in these two years, the European 
Union had incidence rates of 2.8 and 2.2 per 100,000 
population, respectively.
The crude incidence (CIR) and age standardised 
incidence (ASIR) rates by HSE area for 2008 are reported 
in table 1. As before, there was a strong urban-rural 
divide, with the HSE-E having a much lower incidence 
rate than other HSE areas, and there was a peak in the 
reported number of cases in spring (Figure 1).
Typically, the highest reported incidence rates are in 
children under 5 years, and this year, the trend was 
similar, with almost 90 notifications per 100,000 children 
under the age of five. Overall, there were more males 
(n=239) than females (n=176) reported, particularly in 
younger age groups. 
A crude indicator of disease severity can be obtained 
from reviewing rates of hospitalisation among cases. 
This information is available for cases reported in 
HSE-areas whose data was recorded live on CIDR 
during 2008. Using data from these 6 HSE-areas (258 
notifications), 39% of cases were reported as hospital 
inpatients, 3% as hospital outpatients, 52% as GP 
patients, 1% as other, and this information was unknown 
or not specified for 5% of cases.
3.2 Cryptosporidiosis
Summary
Number of cases, 2008: 416
Number of cases, 2007: 609
Crude incidence rate, 2008: 9.8/100,000
Table 1. Number of notified cases, crude incidence rate and age-
standardised incidence rate cryptosporidiosis by HSE area, 2008, and 
annual number of cryptosporidiosis notifications and crude incidence 
rate, Ireland 2004-2007
HSE area Number of 
notifications
CIR (95% CI)* ASIR (95% CI)*
E 12 0.8 (0.4-1.3) 0.8 (0.4-1.3)
M 32 12.7 (8.3-17.1) 11.6 (7.6-15.7)
MW 70 19.4 (14.9-23.9) 19.6 (15.0-24.2)
NE 33 8.4 (5.5-11.2) 7.4 (4.8-10.0)
NW 41 17.3 (12.0-22.6) 17.0 (11.8-22.2)
SE 66 14.3 (10.9-17.8) 14.1 (10.7-17.5)
S 74 11.9 (9.2-14.6) 12.2 (9.5-15.0)
W 88 21.2 (16.8-25.7) 21.9 (17.3-26.5)
Total 
2008
416 9.8 (8.9-10.8) -
Total 
2007
609 14.4 (13.2-15.5) -
Total 
2006
367 8.7 (7.8-9.5) -
Total 
2005
570 13.4 (12.3-14.5) -
Total 
2004
431 10.2 (9.2-11.1) -
*Rates calculations based on CSO census 2006, and may differ from 
rate published previously based on 2002 census
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In 2008, around 35% of positive human Cryptosporidium 
specimens were referred for speciation to the UK 
Cryptosporidium Reference Unit in Swansea by a small 
number of hospital laboratories. The results of these 
studies provide evidence of the relative importance of 
different Cryptosporidium species here. 
In 2008, information was available on species for 145 
cases, largely from the HSE-SE, HSE-NW and HSE-W 
areas. There were 118 C. parvum, 22 C. hominis, two 
corvine, one felis, one rabbit, and one non-typeable 
infection reported, with the species not known/not 
reported for the remaining 271 cases. The seasonal 
distribution by species is presented in Figure 2. C. 
parvum was the most common species reported, 
in particular during the spring peak in incidence. In 
the United Kingdom, cases due to C. parvum have 
historically been more common in spring with those due 
to C. hominis more common in autumn months. 
Eight outbreaks of cryptosporidiosis were reported in 
2008: four general outbreaks and four family outbreaks 
(Table 2). All were small outbreaks, and between 
them accounted for 29 cases. Two small outbreaks 
occurred in crèches and were believed to be due to 
person-to-person spread, as was one of the family 
outbreaks. Water was suspected to have played a role 
in transmission for three of the family outbreaks. One 
of the two small general community outbreaks were 
reported as being due to person-to-person spread and 
animal contact, while the transmission route was not 
specified for the second community outbreak.
 
Table 2. Cryptosporidiosis outbreaks Ireland 2008
Month HSE-area Transmission route Type Location No. ill
Jan SE Person-to-person General Crèche and household 3
Jan W Waterborne Family Private house 3
Feb NE Person-to-person General Crèche 5
Mar MW Not Specified General Community outbreak 3
Mar S P-P and WB Family Private house 2
Apr SE P-P and Animal General Community outbreak 7
Jul SE WB and Animal Family Private house 2
Sep NW Person-to-person Family Private house 4
P-P denoted person-to-person; WB denoted waterborne
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Figure 2: Seasonal distribution cryptosporidiosis by species, Ireland 2008
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In 2008, 226 confirmed and probable cases of VTEC 
were notified to HPSC, a crude incidence rate (CIR) of 
5.3 per 100,000 (table 1). This is the highest number 
of cases reported since data collection on VTEC cases 
began in 1999. If only confirmed VTEC cases are 
considered, the 213 confirmed cases (CIR=5.0 [4.4-5.0]) 
notified this year represent an 85% increase on the 
number of confirmed cases notified in 2007. Figure 1 
shows the number of confirmed and probable VTEC 
O157 and non-O157 VTEC reported in Ireland since 
1999.
Two additional (HUS) cases were reported as suspected 
VTEC cases. These cases are not notifiable but were 
reported voluntarily by clinicians. 
In 2007, the last year for which data is available on an 
EU-wide basis, the highest CIRs for confirmed VTEC 
cases were reported by Sweden and Denmark, both of 
whom reported CIRs of 2.9/100,0002. These were the 
only Member States reported to have higher rates of 
VTEC infection than Ireland in 2007. Given the large 
increase in incidence here in 2008, it is likely that Ireland 
will have one of the highest incidence rates in Europe 
again in 2008.  
The highest crude incidence rate for VTEC overall this 
year was reported in the HSE-M, where the rate was 
more than three times the national crude rate. As in 
previous years, the HSE-E reported the lowest overall 
crude incidence rate (Table 2), about half of the national 
rate this year.
The HSE-E, however, reported the highest numbers of 
non-O157 VTEC infections (table 2), in part because of a 
large VTEC O26 outbreak which occurred during quarter 
2. Historically, the HSE-NW has also reported relatively 
high numbers of VTEC O26, and this year almost two-
thirds of their VTEC cases were serogroup O26. While 
it is possible that there is a true geographical difference 
in risk for different serogroups, it is more likely that 
regional variation in the serogroup-specific incidence to 
some extent reflects regional differences in laboratory 
diagnostic practice for non-O157 infections.
Typically, VTEC cases are most commonly associated 
with late summer; overall this year, 43% of cases were 
reported in quarter 3, although this varied by HSE-area 
with the HSE-M reporting their highest incidence in 
3.3 Verotoxigenic E. coli 
Summary
Number of cases, 2008: 226
Number of cases, 2007: 167
Crude incidence rate: 5.3/100,000
Table 1. Number and crude incidence rates confirmed and probable 
VTEC, Ireland 2004-2008
Year Confirmed 
cases 
Probable 
cases 
Total 
VTEC 
CIR VTECa 
(95% CI) 
2004 61 0 61 1.4 (1.1-1.8)
2005 125 0 125 3.0 (2.4-3.5)
2006 153 5 158 3.7 (3.2-4.3)
2007 115 52 167 3.9 (3.3-4.5)
2008 b 213 13 226 5.3 (4.6-6.0)
a Data from the 2006 census were used to calculate rates 
b Confirmed cases include VTEC O157 (n=162), VTEC O26 (n=35), with 
16 additional cases of other serogroups. Three of the VTEC O157 cases 
were co-infected with VTEC O26 strains. Five probable cases were 
reported on the basis of being epidemiologically-linked to known cases, 
and eight probable cases were reported on the basis of detection of 
verotoxin genes without isolation of the implicated strain (six VTEC O26 
and two Ungroupable VTEC).
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quarter 1 and the HSE-E reporting their highest number 
of cases in quarter 2 (Table 2).
The reported disease incidence was highest among 
young children (median age =6 years), which is 
consistent with previous years, although there were 
more cases reported this year among females (n=135) 
than among males (n=91) at all age groups. 
155 notified cases were reported as symptomatic, 71% 
of the cases for whom this information was available 
(n=217). Reported symptoms included bloody diarrhoea 
in 74 cases, and HUS in fifteen cases (6.9%). This is an 
increase on the number of VTEC-associated HUS cases 
reported compared to last year (n=5), but is similar to 
the number of HUS cases reported in 2006 and 2007 
(n=17 each year). 
HUS cases this year ranged in age from less than 1 
year to 67 years (median age 3 years), with non-O157 
VTEC infections contributing up to half of these. This 
was the highest reported annual number of HUS cases 
associated with non-O157 VTEC since the surveillance 
system in Ireland was extended to include all VTEC 
strains in 2003. For the additional two HUS cases 
reported as suspected VTEC cases, one was young child 
and one was an adult. 
216 human VTEC isolates were referred to the HSE PHL 
Dublin Mid Leinster, Cherry Orchard Hospital from 213 
confirmed VTEC cases (table 3). In addition, laboratory 
findings are included in Table 3 from eight probable 
VTEC cases identified on the basis of detection of 
verotoxin genes in the absence of obtaining an isolate.  
As in previous years, PT32 was the commonest phage 
type reported (n=75), accounting for 46% of the 
confirmed VTEC O157 reported. Other common phage 
types in 2008 were PT21/28 (n=19), PT8 (n=16) and 
PT14 (n=16) –Table 3. 
Two sorbitol-fermenting VTEC O157 were reported, 
both of which were PT RDNC.
The verotoxin profiles of VTEC O157 strains were similar 
to those reported historically for human VTEC isolates 
in Ireland (Table 3). Eighty-three per cent of VTEC O157 
strains carried the genes for VT2 only while 17% carried 
the genes for both VT1 and VT2. In contrast, 21.7% of 
non-O157 VTEC isolates carried the genes for VT1 only, 
20% for VT2 only, and 58.3% VT1 and VT2. 
Forty-two VTEC outbreaks were reported in 2008, which 
included 145 of the 213 confirmed cases notified. Nine 
outbreaks were described as general outbreaks and 33 
as family outbreaks. Twenty-nine outbreaks were due 
to VTEC O157, seven due to VTEC O26, and six were 
caused by a mixture of VTEC strains. The suspected 
modes of transmission reported are listed in table 4. 
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Figure 1. Annual number of confirmed and probable VTEC cases by serogroup, Ireland 1999-2008
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Person-to-person spread is an important mode of VTEC 
transmission in households, child-care facilities and 
institutions, and was suspected to have played a role 
in 21 VTEC outbreaks in 2008 (Table 4). These included 
three outbreaks associated with crèches. For two 
additional crèche outbreaks, the transmission route was 
reported as unknown.
The second most common transmission route reported 
for outbreaks in 2008 was waterborne, with drinking 
water believed to have contributed to eight outbreaks 
(Table 4). For two family outbreaks, examination of 
water from the private wells of the affected households 
confirmed the presence of the same VTEC strain in the 
water as was identified in some or all of the associated 
patients. For two further outbreaks, although the 
VTEC strains identified in the household wells were 
not identical to the strains detected in the associated 
cases, the detection of VTEC in their drinking water 
was strongly suggestive that their private wells were 
responsible for their infections. For three of the 
remaining four waterborne outbreaks, evidence was 
circumstantial in that E. coli and/or coliforms were 
detected in the private wells of the affected households.
In addition for two sporadic VTEC cases, environmental 
investigations identified VTEC of the same type in 
private well samples as was found in the associated 
patients. And finally, a water sample from the private 
well of a suspected VTEC case was found to contain 
Table 2. Number of confirmed and probable VTEC cases by quarter and HSE area, and crude incidence rate by HSE area, Ireland 2008
Quarter E M MW NE NW SE S W Total
Q1 0 21 4 4 2 0 0 2 33
Q2 20 4 2 5 4 2 12 4 53
Q3 16 8 12 8 9 14 21 10 98
Q4 5 8 10 0 1 6 5 7 42
VTEC O157 15 35 21 13 6 22 36 14 162
VTEC O26 16 5 3 4 10 0 2 3 43
Other VTEC 9 0 4 0 0 0 0 5 18
Mixed infection 1 1 0 0 0 0 0 1 3
Total 41 41 28 17 16 22 38 23 226
CIR VTEC*
(95% CI)
2.7 (1.9-
3.6)
16.3 (11.3-
21.3)
7.8 (4.9-
10.6)
4.3 (2.3-
6.4)
6.6 (3.4-
10.0)
4.8 (2.8-
6.8)
6.1 (4.2-
8.1)
5.6 (3.3-
7.8)
5.3 (4.6-
6.0)
*Rates calculated using CSO census 2006 
Table 3. Verotoxin and phage typing results for VTEC referred to the PHL HSE Dublin Mid Leinster, Cherry Orchard Hospital in 2008
Serogroup PT VT1 only VT2 only VT1 & VT2 VT not reported Total
O157 2 2 2
4 1 1
8 16 16
14 16 16
31 11 11
32 70 5 75
34 1 1
38 1 1
51 5 5
72 1 1
21/28 19 19
RDNC 4 4
Untypable 1 1
N/K 2 7 9
O26 - 10 8 26 44
O ungroupable - 1 2 6 2 11
O103 - 1 1 2
O113 - 1 1
O153 - 1 1
O75 - 1 1
O76 - 1 1
O8 - 1 1
Total - 13 146 63 2 224
Note that for five probable cases reported on the basis of epidemiological linkage, isolates were not available for typing. Includes all strains 
isolated from single and mixed confirmed VTEC infections, and in addition contains information on laboratory findings from 8 probable cases 
identified on the basis of detection of vt genes in the absence of obtaining an isolate.
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VTEC O145, suggesting that VTEC in their drinking 
water may have been the source of their infection, 
although no VTEC isolate was obtained from the 
individual. In total, these known waterborne incidents 
gave rise to 35 cases (31 confirmed, three probable and 
one suspected), six of whom developed HUS. 
Over the last number of years, considerable evidence 
has been accumulating demonstrating that drinking 
untreated water from private wells is a strong risk 
factor for VTEC in Ireland.1,3,4. VTEC case numbers were 
particularly high during August 2008; in the HSE-S, this 
rise in incidence was reported to be linked to drinking 
water from contaminated private wells following 
exceptional rainfall.5 It appears that VTEC activity in 
Ireland may have been influenced by the particularly 
high levels of rainfall that occurred last summer.5,6 
Drinking water from untreated private water supplies 
remains a very important risk factor for VTEC infection 
in Ireland. 
Of particular concern is the number of VTEC cases 
reported among small children from urban backgrounds 
after visiting friends/relatives in rural areas either with 
an untreated water supply or close to grazing animals. 
Cases such as these were reported from Irish urban 
areas, and among visitors from the United Kingdom and 
the United States. This underlines the ongoing risk to 
immunologically naïve young children from untreated 
drinking water and the faeces of grazing animals. 
Moreover in Ireland, VTEC cases of all ages are more 
likely to report having exposure to a private well than 
would be expected based on private well ownership 
data published by the CSO.  During periods of heavy 
rainfall, those with private wells may need to consider 
boiling their water or taking other appropriate measures 
particularly if vulnerable groups such as children, the 
elderly or immunocompromised persons use the well 
water, or in the event of a change in the character of 
the well water e.g. colour/taste/odour.  
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1.  Garvey, P. et al. 2009. Epidemiology of verotoxigenic E. coli in 
Ireland, 2007. Epi-Insight: 10(3): 1-3
2.  EFSA. 2008. The Community Summary Report on Trends and 
Sources of Zoonoses, Zoonotic Agents, Antimicrobial resistance 
and Foodborne outbreaks in the European Union in 2007. 
Accessible online at http://www.efsa.europa.eu/EFSA/efsa_
locale-1178620753812_1178671312912.htm 
3.  Garvey P et al. 2006. Epidemiology of Verotoxigenic E. coli in 
Ireland, 2005. Epi-Insight 2006; 7(9):2-3.
4.  Garvey, P. et al. 2005. Epidemiology of Verotoxigenic E. coli in 
Ireland, 2004. Epi-Insight 6(12):2-3 
5.  O’Sullivan et al. 2008. Increase in VTEC cases in the south of 
Ireland: link to private wells? Eurosurveillance 13(39) http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=18991 
6.  HPSC. 2008. Press release. Householders must properly maintain 
private water supplies following increase in contamination – HPSC. 
http://www.hpsc.ie/hpsc/PressReleases/2008PressReleases/
MainBody,3127,en.html 
 
Table 4. VTEC outbreaks in Ireland 2008 by suspected mode of transmission
Suspected mode of transmission Number of outbreaks Number confirmed cases Number ill
Animal contact 1 3 1
Environmental/fomite 1 14 10
Foodborne 2 4 3
Foodborne/waterborne 1 3 3
Person-to-person 16 52 41
Person-to-person & waterborne 5 18 21
Waterborne 2 9 8
Other 2 9 3
Unknown/Not specified 12 33 28
Total 42 145 118
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Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from 
person to person via the faecal-oral route and is 
associated with poor hygiene and sanitation. Common 
source outbreaks due to contaminated food or water 
may also occur.
The incidence of hepatitis A in Ireland has been low in 
recent years and remained low in 2008, with 42 cases 
notified. This corresponds to a crude notification rate 
of 1/100,000 population and represents a 31% increase 
compared to 2007, when 32 cases were notified (figure 
1). Case classification was reported for all cases. Forty 
one cases were laboratory confirmed and one was 
classified as probable.
Forty three percent of cases were male (n=18) and 57% 
were female (n=24). All age groups were affected  
(figure 2).  
Thirteen cases were linked to travel outside of Ireland, 
three cases were contacts of cases infected outside of 
Ireland and a further seven cases had travelled outside 
of Ireland within the incubation period of the disease 
but could also have been infected in Ireland. 
Of the remaining cases, eleven were infected in Ireland 
(five associated with family outbreaks) and information 
on country of infection was not available for eight. 
Four hepatitis A outbreaks were reported in 2008. 
Two were associated with travel. The first involved two 
young adults, one of whom was infected in South Africa, 
and the second involved two children, one of whom 
had travelled to Pakistan. The other two outbreaks were 
family or extended-family outbreaks. One involved three 
children and the second involved one adult and one 
child.
There was a fatality in one person notified as an acute 
hepatitis A case.
3.4 Hepatitis A
Summary
Number of cases, 2008: 42
Crude notification rate, 2008: 1/100,000 population
Number of cases, 2007: 32
Figure 1. Number of hepatitis A notifications, 1998-2008
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis A, 2008
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The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 7th August 2009. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
Figure 1. Number of hepatitis A notifications, 1998-2008
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis A, 2008
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Rotavirus is the the commonest cause of paediatric 
gastrointestinal infection and causes sporadic, 
seasonal, often severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and 
watery diarrhoea. Transmission is usually person-to-
person, mainly via the faecal-oral route. Children 
less than two years of age are most susceptible to 
infection, although cases are often seen in elderly and 
immunocompromised adults – particularly in institutional 
settings. Symptoms usually last for only a few days but 
in severe cases hospitalisation may be required due to 
dehydration. In developed countries, mortality due to 
rotavirus is low; however, the morbidity and economic 
costs associated with infection are significant.
 
Given the universal distribution of Rotavirus, the 
numbers of notifications will always represent an 
underestimate of the true incidence and are likely to 
be more reflective of habits of presentation to medical 
practitioners and of styles of investigation, notification 
and testing.
Since 2004 Rotavirus, although not specifically listed, 
has been a notifiable disease in Ireland under the Acute 
Infectious Gastroenteritis (AIG) disease category. Prior 
to 2004, only gastroenteritis cases in children under 
two years of age were notifiable. In April 2008 the case 
definition of AIG was amended specifying definitions for 
both Rotavirus and newly notifiable Clostridium difficile 
associated disease. On the 4th May 2008 these amended 
definitions formally replaced the outdated AIG case 
classification.   
 In 2008 there were 4204 cases of AIG notified in 
Ireland. This represents a 67% increase on the number 
of AIG notifications made in 2007. This increase is solely 
attributable to the addition of C. difficile associated 
disease to the AIG category. Rotavirus notification 
numbers remained similar to the previous year with 
2342 rotavirus cases notified in 2008 (representing a 
0.7% increase on 2007).  
Updated Rotavirus Definition:
A case of rotavirus infection is a patient with acute onset 
of vomiting followed by watery diarrhoea with fever, 
which typically lasts between three and eight days, AND 
one of the following laboratory criteria for diagnosis:
Detection of rotavirus by antigen assay•	
Detection of rotavirus-specific RNA•	
Detection of rotavirus by electron microscopy •	
Isolation of rotavirus•	
The national crude incidence rate (CIR) reached 55.2 
per 100,000 population (table 1). There was significant 
variation in CIR nationally with the Midland region 
incurring the highest rate of 125.2 cases per 100,000. 
The West region had the second highest rate of 85.2 
per 100,000. This was similar to the previous year.  The 
lowest rate of occurrence was observed in the East with 
a CIR of 34.9 per 100,000.  
Rotaviral infection has a well documented seasonal 
pattern in Ireland with peaks in cases occurring each 
year in early spring. Analysis of the data by week of 
notification from 2004 to 2008 is shown in Figure 2.  
(There is a ‘false’ second peak seen in 2005 during week 
33, 2005 which is attributable to bulk uploading of 
3.5 Rotavirus
Summary
Number of cases 2008: 2342
Number of cases 2007: 2326
Number of cases 2006: 2112
Crude incidence rate:  55.2/100,000
Table 1. Number of cases, CIR of rotavirus infections in Ireland by HSE 
area, 2008 and total number with crude incidence rate for 2004-2008. 
HSE 
Area
No. of 
cases
*CIR incl. 95% C.I. *ASIR incl. 95% C.I.
E 524 34.9 [31.9 - 37.9] 35.7 [32.6 - 38.7]
M 315 125.2 [111.4 - 139.0] 113.0 [100.5 - 125.5]
MW 86 23.8 [18.8 - 28.9] 24.3 [19.1 - 29.4]
NE 165 41.9 [35.5 - 48.3] 36.7 [31.1 - 42.3]
NW 198 83.5 [71.9 - 95.1] 82.2 [70.8 - 93.6]
SE 327 71.0 [63.3 - 78.6] 69.0 [61.6 - 76.4]
S 374 60.2 [54.1 - 66.3] 62.6 [56.3 -68.9]
W 353 85.2 [76.3 - 94.1] 88.1 [79.0 - 97.3]
Total 
2008
2342 55.2 [53.0 - 57.5] 54.9 [52.7 - 57.2]
Total 
2007
2326 54.9 [52.6 - 57.1]
Total 
2006
2112 50.0 [48.0 - 52.0]
Total 
2005
2251 53.1 [50.9 – 55.3]
Total 
2004
1600 37.8 [35.9 – 39.6]
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notifications for the HSE-W region). A change observed 
in this seasonal pattern in 2007 was not as apparent in 
2008. 
Rotavirus is the most common cause of acute 
gastroenteritis in children worldwide with children 
generally affected in the first 2-3 years of life. In 2008 
87.4% (n=2047) of cases were aged two or under. Data 
from 2004 to 2008 show that the peak incidence of 
clinical disease occurred in the 6-24 month age group.   
There has been a continuous increase in the number of 
cases affecting this age group over recent years. Figure 
1 presents the number of cases of rotavirus in children 
less than two years of age by year, 2001 to 2008.
In 2008 males accounted for 1,213 cases (51.8%); 
females 1,114 (47.6%) and 15 (0.6%) cases where sex 
was not known.  This represented a ratio of males: 
females of 1.1:1.  This was similar to previous years.
There were eight outbreaks of rotavirus notified via 
CIDR during 2008 (table 2). These outbreaks accounted 
for 97 cases of illness. Four of the seven outbreaks 
occurred in crèches, two were private family outbreaks, 
the location of one was unknown and the final outbreak 
occurred in a long stay community hospital.
The largest outbreaks of rotavirus occurred in April 
in a community hospital/long stay unit. There were 
45 persons ill with 40 cases aged 65+ (ages of the 
remaining cases were unknown). Person to person 
transmission was suspected. The second largest rotaviral 
occurred again in April in a crèche with 28 cases of 
illness.  The majority of cases were under 
four years of age (75%). 
Table 2: Rotavirus Outbreaks Notified on CIDR, 2008.
Date Location Numbers ill
Mode of 
transmission
Feb Crèche 4 Airborne
April Crèche 28 Person-to-person
April Crèche 8 Person-to-person
April Crèche 6 Person-to-person
April
Comm. Hosp
/Long-stay 
unit
45 Person-to-person
April
Private house
2
Person-to –person
and airborne
May
Unknown
2
Person-to –person
and airborne
October
Private house
2
Person-to –person
and airborne
Figure 2: Seasonal distribution of rotavirus events by week, 2004-2008 (CIDR)
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Salmonellosis presents clinically as an acute 
enterocolitis, with sudden onset of headache, 
abdominal pain, diarrhoea, nausea and occasionally 
vomiting. Fever is almost always present. Dehydration, 
especially amongst vulnerable populations such as 
infants, the immunocompromised and the elderly, may 
be severe. S. Typhi and S. Paratyphi can cause enteric 
fever, a severe systemic life threatening condition, but 
this is very rare in Ireland and is almost invariably travel-
associated.
There were 449 cases of salmonellosis species in 2008. 
Of these 448 were laboratory confirmed and there was 
one case classified as probable that was not laboratory 
confirmed. In addition to the cases of salmonellosis, 
there were five cases of S. Typhi and eight cases of S. 
Paratyphi notified on CIDR. The national salmonella 
reference laboratory (NSRL) based in Galway has been 
providing reference testing nationally since 2000. In 
2008 the NSRL analysed 447 human specimens.
The national crude incidence rate (CIR) of salmonellosis 
in 2008 was 10.8/100,000 (table 1). This is similar to 
the CIR calculated for 2007. CIR’s varied regionally. 
The Midlands region experienced the highest CIR of 
17.5/100,000 (an increase of 8.4 /100,000 on the 2007 
CIR).  The Northwest region had the lowest incidence 
of 8.0/100,000. Of note the Northeast experienced 
an increase in CIR of 7.8/100,000 while the South 
experienced a decrease in CIR of 12.2/100,000. In 2007 
HSE-S notified a large salmonella outbreak which would 
account for the difference in annual CIR’s. CIR’s for all 
other regions remained similar to their previous annual 
CIR’s.
The male to female ratio for the year was 1.00:0.98.  
In terms of age distribution 26% of cases occurred in 
children under five. This is likely to be a reflection of 
clinicians seeking clinical samples in children under five. 
This is reflected in the age specific incidence (ASIR). 
The 0-4 age group has the highest ASIR nationally 
(46.0/100,000) and in all regions with the exception 
3.6 Salmonella 
Summary
Number of confirmed cases 2008 (CIDR): 449
Number of probable cases 2008 (CIDR): 1
Crude incidence rate: 10.6/100,000
Figure 1: Seasonal Distribution of Salmonella Notifications by History of Foreign Travel, CIDR 2008
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of the northwest. In this region the ASIR of the 20-24 
age group was 31.2/100,000, compared to an ASIR of 
23.5/100,000 in the 0-4 age group. 
The seasonality of salmonellosis notifications in Ireland 
is shown in figure 1. It can be seen that the highest 
number of notifications occurred in the summer months 
(mid June to the start of October). These are expected 
seasonal increases that correlate with peak holiday 
periods and an increase of people travelling abroad.
Serotyping analysis is conducted at the NSRL. Review 
of information provided by the NSRL show serotyping 
was conducted on 435 isolates identifying 63 serotypes 
in 2008. Table 2 presents the most dominant serotypes 
recorded for the year. In 2008 S. Typhimurium (n=139) 
was the dominant serotype, followed by S. Enteritidis 
(n=122), S. Agona (n=13, please see outbreaks 
paragraph) and S. Virchow (n=10). There are 20 CIDR 
events which could not be definitively linked to a 
serotype result and are not present on the CIDR system. 
The 415 events which were updated with serotyping 
information are presented by age group in figure 2.
The NSRL conducted phage typing analysis on all S. 
Typhimurium and S. Enteritidis isolates. Of the 139 S. 
Typhimurium isolates phage types were assigned to 138 
specimens. DT104 (20%), DT104b (20%) and DT193 
(13%) were the commonest phage types observed. 
All 122 S. Enteritidis isolated were typed. PT1 (19%), 
PT21 (18%), PT4 (18%) and PT8 (12%) were the 
dominant types.
Two hundred and fifty of the 447 human isolates 
analysed by the NSRL were fully sensitive to all 
antibiotics tested. The remaining 197 isolates exhibited 
some degree of antibiotic resistance. The commonest 
resistance pattern seen was of type Ampicillin, 
Chloramphenicol, Streptomycin, Sulphonamide and 
Tetracyclin (ACSSuT) (n=54). All isolates with this pattern 
were S. Typhimurium. 
Twenty-nine S. Enteritidis isolates exhibited some 
degree of antibiotic resistance, which was mostly mild 
(79% were resistant to only one type of antibiotic 
tested). There was one S. Enteritidis isolate that was 
resistant to eight antibiotics tested. This case had a 
travel history to the Maldives and was PT1. 
Please refer to the NSRLs Annual Report 2008 for more 
detailed analysis of results1.
Travel history was provided on CIDR in 53% of cases in 
2008. Future improvement in this data will be reflected 
in these analysis.  
Using information provided via CIDR it is known that 
25% of salmonellosis cases were indigenous to Ireland, 
28% of cases had a recent history of travel and in 47% 
of cases the travel history was either unknown or not 
specified. 
Figure 1 also illustrates the number of cases where a 
comprehensive answer to recent travel was entered on 
CIDR (base on event date). As expected the number of 
cases associated with foreign travel increases during the 
summer months. Where travel history was documented, 
people with a recent history of travel to Spain 
(n=21) had the greatest occurrence of salmonellosis. 
Portugal (n=11), Thailand (n=10) and Turkey (n=10) 
were countries with high rates of recent travel and 
subsequent development of salmonellosis (table 3).  
These results are likely to reflect the popularity of these 
countries as travel destinations.
When serotyping data are analysed by history of foreign 
travel, the most common serotype among indigenous 
cases was S. Typhimurium (table 4). The 2008 annual 
report published by the National Reference Laboratory 
Salmonella – Food, Feed and Animal Health, which 
is part of the Central Veterinary Research Laboratory 
(CVRL), show that of the 1251 Salmonella isolates 
received resulting from checks on food business 
operators, S. Kentucky (n=476) and S.Typhimurium 
(n=229) were the prevalent strains. S. Kentucky was 
Table 2: Serotyping Information, NSRL2008. 
Serotype No. of Isolates
S. Typhimurium 139
S. Enteritidis 122
S. Agona 13
S. Virchow 10
S. Java 7
S. Worthington 7
S. Panama 7
S. Bredeney 6
S. Newport 6
S. Hadar 6
S. Kentucky 6
Other 87
Table 1: Number of cases and CIR of human salmonellosis in Ireland, 
2008 (CIDR) 
HSE Area
No Cases 
(2008)
CIR incl. 95% CI 2008
HSE - E 149 9.9 [8.3-11.5]
HSE - M 44 17.5 [12.3-22.6]
HSE - MW 35 9.7 [6.5-12.9]
HSE - NE 60 15.2 [11.4-19.1]
HSE - NW 19 8 [4.4-11.6]
HSE - SE 43 9.3 [6.5-12.1]
HSE - S 55 8.9 [6.5-11.2]
HSE - W 44 10.6 [7.5-13.8]
Total 449 10.6 [9.6-11.6]
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Table 3: Travel Associated Salmonellosis by Country, CIDR 2008 
Country of Infection
% of  Travel Associated Salmonella 
Cases
Spain 16.5% (n=21)
Portugal 8.7% (n=11)
Thailand 7.9% (n=10)
Turkey 7.9% (n=10)
Egypt 6.6% (n=8)
Greece 5.5% (n=7)
Italy 4.7% (n=6)
United states 3.9% (n=5)
Barbados 3.9% (n=5)
Tunisia 3.1% (n=4)
Other 31.5% (n=40)
found in 263 environmental poultry samples.   
S. Typhimurium was found in 139 porcine and 46 bovine 
raw meat samples/carcass swabs. These findings may 
account for the high indigenous rates of S.Typhimurium 
human isolates during 2008. Please refer to the CVRLs 
annual report for more detailed analysis2.
Like 2007, the number of S. Typhi and S. Paratyphi’s 
diagnosed in Ireland in 2008 remains elevated when 
compared to previous years. In 2008 there were five 
reported cases of S. Typhi, seven cases of Paratyphi A 
and one case of S. Paratyphi B. Three of the S. Typhi had 
known recent travel history to India, one had a recent 
travel history to Nigeria, and in the final case the travel 
history of the patient was unknown. In the S. Paratyphi 
A cases three had recent travel history to India, one 
case had travel history to Indonesia, one case had travel 
history to Pakistan and in the remaining two cases the 
travel history was not specified. Finally, the case of  
S. Paratyphi B had recent travel to South America
There were 22 outbreaks of Salmonella during the 
year resulting in 79 persons ill and an associated 
hospitalisation rate of 25%. This is an increase of 120% 
on the number of salmonellosis outbreaks reported in 
the previous year. Three of these outbreaks were travel 
related. Associated countries included Egypt, Barbados 
and Greece. Ten outbreaks were family outbreaks in 
private houses and the remaining 12 outbreaks occurred 
in a variety of locations. The general outbreaks, included 
the  three travel related outbreaks (all foodborne), three 
were community based (all foodborne), four occurred 
in hospitals (n=3 person to person transmission, n=1 
foodborne), one in a residential institution (person to 
person transmission) and one was unknown. Foodborne 
general outbreaks accounted for 53 persons ill.
In two of these general, foodborne, travel related 
outbreaks specialists at the HPSC liaised with 
international agencies and aided them with their 
investigations. As the three general community 
outbreaks occurred across several HSE areas, the HPSC 
acted as the co-ordinating body for the associated 
investigations. 
The most significant outbreak during 2008 was that 
of serotype of S. Agona. In July 2008 the National 
Surveillance Reference Laboratory (NSRL) alerted the 
Table 4: Median Age, and, Percent of S. Enteritidis, S. Typhimurium 
and All other Salmonella Serotypes by History of Foreign Travel 
Status, CIDR 2008. 
History of 
Foreign 
Travel 
(n=127)
Indigenous
(n=113)
Not 
known
(n=208)
Median Age (All serotypes) 27 22 25
% S. Enteritidis 41.31% 18.58% 22.12%
% S. Typhimurium 19.69% 39.82% 33.17%
% Other 37.01% 41.59% 44.71%
Figure 2: Salmonella Serotypes Reported on CIDR by Age Group, 2008
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HPSC of a cluster of five  S. Agona cases.  Following 
contact with UK colleagues, a much larger cluster 
involving the UK was identified.  Epidemiological 
investigations were conducted and alerts sent using 
the Food and Waterborne Diseases (FWD) network, the 
European Union’s Early Warning and Response System 
(EWRS), and the European Unions’ Rapid Alert System 
for Food and Feed (RASFF). These ultimately resulted 
in the identification of 11 Irish cases and 152 cases 
throughout England, Scotland, Wales and five other 
European countries. The outbreak strain was associated 
with two deaths. Epidemiological investigations, 
supported by microbiological evidence, identified meat 
product produced at an Irish food plant as the source 
of the outbreak. The company voluntarily temporarily 
closed the implicated section of the plant and recalled 
affected product.
In April four cases of S. Typhimurium (PTU320) were 
linked to a larger outbreak in the UK. Epidemiological 
information provided by public health departments and 
the HPSC contributed to a case control study conducted 
by the Health Protection Agency (HPA) in the UK. This 
study identified pre-packed egg sandwiches as the most 
likely source of the outbreak.
References:
1.  National Salmonella Reference Laboratory of Ireland, Annual Report 
for 2008.
2.  National Reference Laboratory Salmonella (Food, Feed and Animal 
Health), Annual Report 2008.
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Listeriosis 
Thirteen cases of human listeriosis were notified in 2008 
compared to 21 in 2007 and 7 in 2006. 
There were two pregnancy-related cases and two 
neonatal cases reported. 
There were also nine adult cases, five of which were 
reported as elderly (>65 years) and three of which were 
reported as suffering from an underlying illness that 
predisposed them to listeriosis. No information was 
available on the ninth case. There were 5 males, four 
females, and ages ranged from 24 to 94 years of age. 
One of the neonatal cases died as a result of their 
infection, while one pregnancy resulted in a miscarriage. 
There were no deaths among the adult cases. 
Since 2007, the National Salmonella Reference 
Laboratory has offered a national service for typing 
of Listeria strains. In 2008, ten human isolates were 
received for typing at NSRL (77%). The serotype 
distribution of these strains is outlined in the table 
below.
Listeriosis remains a hazard for the elderly, persons with 
underlying illness, and other vulnerable groups such as 
pregnant women and neonates.  
3.7  Less common gastrointestinal 
 infections
Serotype 1/2 Serotype 4b Not referred for 
serotyping
Total
Adult or juvenile 3 3 3 9
Pregnancy-related 1 1 0 2
Neonatal 0 2 0 2
Total 4 6 3 13
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Listeriosis notifications by case type and serotype, Ireland 2008.
Typing data provided courtesy of Professor Martin Cormican and staff at the NSRL.
Giardiasis
In 2008, there were 71 cases of giardiasis notified, a 
slight increase on the number notified in 2007 (n=62) 
and in 2006 (n=64).
Cases ranged in age from 1-86 years (mean age=34 
years, median age=33 years), with more males (n=39) 
affected than females (n=32).
Eight cases were reported associated with foreign 
travel: the countries of infection reported were India 
(n=3), Mexico (n=1), Nepal (n=1), Russian federation 
(n=1), Tunisia (n=1) and Turkey (n=1). Five cases were 
reported as being acquired in Ireland, and for the 
remaining 58 cases, country of infection was unknown or 
not specified.
In 2008, there were three small family outbreaks 
reported with six persons ill in total. Two outbreaks were 
related to foreign travel. 
Yersiniosis
In 2008, there were three cases of yersiniosis, compared 
to six in 2007 and one in 2006. 
All three cases were in the age group 45-64 years; two 
were female. 
One case was reported as Y. enterocolitica and two as 
Yersinia species.
Foodborne Intoxication
Notifications of foodborne intoxications in Ireland are 
uncommon. In 2008, there was one case of Clostridium 
perfringens (type A) food-borne disease, one case 
of staphylococcal food poisoning and one case of 
foodborne botulism notified. 
Six notifications of botulism notified in 2008 were wound 
botulism.1
1 Barry et al. 2009. Botulism in Injecting Drug Users, Dublin, Ireland, 
2008. http://www.hpsc.ie/hpsc/EPI-Insight/Volume102009/
File,3376,en.pdf
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Table 1: Number of notifications shigellosis by species and country of infection, Ireland 2008
Ireland Africa Asia Other Not known/ not 
reported
Total
S. boydii 1 0 3 0 2 6
S. flexneri 3 5 5 1 8 22
S. sonnei 9 4 2 2 16 33
Species not specified/not known 1 0 0 1 0 2
Probable cases 12 0 0 0 1 13
Total 26 9 10 4 27 76
0
100
200
300
400
500
600
700
800
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Year
N
um
b
er
 o
f 
ca
se
s
Figure: Annual number of notifications shigellosis, Ireland 1991-2008
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Figure: Annual number of notifications shigellosis, Ireland 1991-2008
Summary
Number of cases 2008: 76
Number of cases 2007: 43
Crude incidence rate: 1.8/100,000
In the last decade, the number of cases of shigellosis 
in Ireland has been low in comparison to the number 
of cases notified in the early 1990s (Figure). Shigellosis, 
however, remains a common cause of gastrointestinal 
illness in developing countries, and many cases notified 
in Ireland are now identified as being travel-associated.  
Mor over, risks also remain from food, with at least four 
general outbreaks having been reported in Scandanavia 
in 2009 associated with imported fresh produce.1-5  The 
foods implicated included sugar peas and baby corn 
eaten raw. 
Seventy-six cases of shigellosis were notified in 
Ireland in 2008, 63 of which were confirmed cases 
and 13 were probable cases reported on the basis of 
being epidemiologically-linked to one outbreak. This 
compares to 43 cases in 2007 and 54 in 2006 (Figure). 
The increase in numbers was primarily due to the 
occurrence of two indigenous general outbreaks in 
2008.
Cases ranges in age from one to 61 years (mean 
age=26 years, median age=27 years), with more 
females (n=47) than males (n=27) notified; for two cases 
sex was not reported. 
Information on travel history is very valuable when 
reviewing surveillance data for possible indigenous 
clusters, and data on country of infection in the national 
dataset is improving being available this year for almost 
two-thirds (49/76) of notifications. In 2008, twenty-three 
cases (30%) were reported associated with foreign 
travel (Table 1). The countries of infection reported 
were India (n=5), Egypt (n=3), Pakistan (n=2), Mexico 
(n=2), and there was one case associated with travel 
to each of Afghanistan, China, Ghana, Jordan, Liberia, 
Madagascar, Morocco, Namibia, Nigeria, Spain and 
Venezuela. Twenty-six cases were reported as being 
acquired in Ireland. 
Among confirmed cases, Shigella sonnei was the most 
common species reported (n=33). There were also 
22 S. flexneri, six S. boydii, and two confirmed cases 
3.8 Shigellosis
-59-HPSC Annual Report 2008 3. Infectious Intestinal Diseases
for which the species was not reported. The species 
distribution of cases by country of infection is reported 
in Table 1. 
More detailed typing of Shigella isolates can provide 
useful information on the relatedness of strains which 
can be used by public health personnel to outrule/
provide evidence for links between cases during 
investigations of case clusters. The National Salmonella 
Reference Laboratory (NSRL) in University College 
Hospital, Galway can provide laboratory services 
for speciation, serotyping, antimicrobial resistance 
profiling, and where appropriate, Pulsed Field Gel 
Electrophoresis (PFGE) of Shigella isolates.
In 2008, 43 human Shigella isolates were referred to the 
NSRL, almost 70% of all confirmed cases. The species/
serotype distribution of these cases is reported in 
Table 2.
There were four shigellosis outbreaks notified in 2008, 
details of which are provided in Table 3. Importantly, 
this included two general outbreaks. During 
investigation of the community outbreak of shigellosis 
in the HSE-MW, molecular typing (PFGE) of isolates was 
used at NSRL to compare the relatedness of strains and 
confirmed the likelihood that most of the cases were 
epidemiologically-linked.6
Shigella has been designated by the European 
Centre for Disease Control as one of six priority 
gastroenteric pathogens at European level (along 
with Campylobacter, Salmonella, VTEC, Listeria and 
Yersinia). The continuing potential for foodborne 
outbreaks means that surveillance for shigellosis 
remains important, both for the identification of 
indigenous outbreaks, and for the identification of 
cases/clusters that could be part of larger international 
outbreaks associated with internationally-distributed 
foodstuffs. The continued referral of Shigella isolates to 
NSRL by primary hospital laboratories has the potential 
to play a key role in this work, and is much appreciated. 
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Table 2: Species/serotypes of isolates referred to NSRL in 2008 (Data 
courtesy of Prof. Martin Cormican and staff at NSRL)
Strain Number of isolates
Shigella boydii 4
Shigella boydii 19 1
Shigella flexneri 1b 2
Shigella flexneri 2a 7
Shigella flexneri 2b 1
Shigella flexneri 3a 3
Shigella flexneri 3b 1
Shigella flexneri 4 2
Shigella sonnei 22
Total 43
Table 3: Shigellosis outbreaks, Ireland 2008
Month HSE-
area
Transmission 
Route
Location Type Number 
ill
Feb MW Person-
person
Community General 8
May E Not specified Travel-
related
Family 2
May E Person-
person /
Foodborne
Private 
house
Family 2
June M Person-
person
Creche General 24
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Toxoplasmosis
During 2008, 49 cases of toxoplasmosis were notified 
compared to 49 in 2007 and 44 in 2006.  
Two cases were reported as congenital cases, one of 
whom died. 
The remaining 47 cases ranged in age from 3 years to 
75 years (median, 30 years).  Of the 47cases, 34 were 
female and 15 were male. The high number of cases 
reported among women of child-bearing age may 
reflect enhanced testing during pregnancy (see Table). 
      
Brucellosis
During 2008, only three cases of brucellosis were 
notified compared to 28 in 2007 and 29 notifications in 
2006. 
All three cases were males in their forties and fifties. The 
age and sex distribution for brucellosis in recent years in 
Ireland suggests that occupational exposure is likely to 
be the main transmission route for this disease. 
The case definition permits inclusion of acute and 
chronic cases. In 2008, two cases were reported as 
chronic cases; acute/chronic status was not reported for 
the third case.  
 
4.1 Other Non-IID Zoonotic Diseases
Table: Toxoplasmosis notifications by age and sex, Ireland 2008
Age group Male Female Total
<1 yr 0 2 2
1-4 yrs 0 1 1
5-14 yrs 1 1 2
15-24 yrs 7 7 14
25-44 yrs 4 18 22
45-64 yrs 3 4 7
65+ yrs 0 1 1
Total 15 34 49
Table: Brucellosis notifications by age and sex, Ireland 2008
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 0 0 0
25-44 yrs 1 0 1
45-64 yrs 2 0 2
65+ yrs 0 0 0
Total 3 0 3
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Q Fever
Thirteen cases of Q fever were notified during 2008 
compared to 17 in 2007 and 12 in 2006. 
Nine cases occurred in males and four in females. The 
cases ranged in age from two to 96 years (mean age, 50 
years; median age, 48 years). 
Ten cases were classified as confirmed and three as 
probable.
The disease is commonly acquired through occupational 
exposure to infected sheep and other small ruminants, 
e.g. by farmers, veterinarians, and abattoir workers. 
Over the last three years, the south of the Netherlands 
has been experiencing large community outbreaks 
of Q fever during the summer months. Some clusters 
have been linked with Q fever outbreaks on goat farms. 
Further investigations and control measures are ongoing 
including the introduction of mandatory vaccination of 
small ruminants in the region. 1
1.  Schwimmer et al, B. 2009. Sustained intensive transmission of Q 
fever in the South of the Netherlands, 2009.   
http://www.eurosurveillance.org/images/dynamic/EE/V14N19/
art19210.pdf
 
Echinococcosis
In 2008, there were two notifications of echinococcosis, 
one male and one female. Both were adults. These are 
the first cases of echinococcosis notified in Ireland since 
the disease became notifiable in 2004. 
Because of the long incubation period for this disease, 
it is possible that infection occurred many years ago. As 
no enhanced information is collected on cases of this 
disease in Ireland, it is not possible to conjecture if their 
infections were acquired in Ireland or abroad.
Table: Q fever notifications by age and sex, Ireland 2008
Age group Male Female Total
<5 yr 1 0 1
5-14 yrs 0 0 0
15-24 yrs 0 1 1
25-44 yrs 2 1 3
45-64 yrs 4 2 6
65+ yrs 2 0 2
Total 9 4 13
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In 2008, 82 cases of malaria were notified (Figure). This 
is an increase of 15% on the number reported in 2007, 
and equates to a crude annual incidence rate of 1.9 per 
100,000 (95% C.I. 1.5-2.4). 
Cases ranged in age from 0 to 56 years (mean 28 yrs, 
median 32 years), and male cases (n=48) were more 
common than female cases (n=34). Paediatric cases 
accounted for 16 cases (almost 20%), with an additional 
70% of cases between the ages of 20 and 50. 
Malaria, in particular that caused by P falciparum, can 
cause severe illness, and this year 49 malaria cases in 
Ireland were hospitalised as a result of their illness, 
This represents around 80% of the notifications where 
hospitalisation status was reported. A further seven 
cases were hospital out-patients, two were hospital day-
patients, two were GP patients, with the hospitalisation 
status of the remainder not known or not reported. No 
deaths due to malaria were reported to HPSC in 2008.
The vast majority of infections reported in Ireland 
are due to recent exposure in a country endemic for 
malaria. As has been the case for the last few years, 
the vast majority of cases were exposed in sub-Saharan 
Africa, with a small number of cases associated with 
exposure in Asia and South America (Table 1).  There 
were no cases of airport, congenital, induced or 
introduced malaria reported, although two P. ovale 
cases were reported as relapsed infections. 
The most common species reported was P. falciparum, 
accounting for 83% of all cases notified (n=68). There 
were also two P. vivax, three P. ovale, two P. malariae, 
two mixed infections, and five cases where the species 
was not specified. P. falciparum has been the most 
common species among notifications in Ireland since 
species information was first collected in 2001. This 
reflects the fact that most infections in Ireland were 
acquired in Africa. 
Based on information provided on the cases reason 
for travelling, the largest subgroup identified in 2008 
was people who had travelled to visit family/friends in 
their country of origin –over 70% of those for whom 
the information was available (Table 2). This included 
nine children who were born in Ireland (age range 0-16 
4.2 Malaria 
Summary
Number of cases, 2008: 82
Number of cases, 2007: 71
Crude incidence rate, 2008: 1.9/100,000
International information on malaria is available at 
http://www.who.int/malaria/ 
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Figure. Number of malaria notifications, Ireland 1982-2008
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years). Seven cases were exposed during holiday travel, 
two were Irish citizens living abroad, one was a visitor to 
Ireland from an endemic country, one was a new entrant 
and three reported their reason for travel as ‘other’ 
(Table 2). 
Only five cases reported being fully compliant with 
advice received on prophylaxis. A further seven cases 
took  prophlaxis but failed to complete the course, 
while 41 cases took no prophylaxis. No information was 
available for the remaining cases. 
The epidemiology of malaria in Ireland bears 
many similarities with that in the United Kingdom, 
with the highest burden of illness being borne by 
people of African origin travelling to visit family 
in their country of origin. For more information see 
http://www.hpa.org.uk/hpr/archives/2009/hpr1609.pdf 
Protection from biting mosquitoes and appropriate 
prophylaxis can minimise the risk of malaria during 
travel in malarious regions. 
Table 1: Malaria notifications by country of exposure, Ireland 2008
Country of exposure Number 
notifications
% notifications
Sub-saharan Africa 58 71%
   Nigeria 49 60%
   Other that Nigeria 9 11%
Asia 1 1%
South America 1 1%
Not reported 22 27%
Total 82 100%
Table 2: Malaria notifications by country of birth and reason for  travel, Ireland 2008
Reason for travel
Country of birth
Nigeria
Other 
African 
country
Ireland
Other non-
endemic 
country
Not 
specified
Total
Visiting family/friends in country of origin 25 2 9 5 41
Holiday travel 2 2 1 2 7
Irish citizen living abroad 2 2
New entrant 1 1
Foreign visitor ill while in Ireland 1 1
Business/professional travel 1 1
Other 2 1 3
Unknown/not specified 2 1 23 26
Total 30 5 13 2 32 82
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Thirty cases of leptospirosis were notified in Ireland in 
2008, compared to 22 in 2007 and 20 in 2006. Figure 1 
shows the rise in the reported number of notifications 
in Ireland over the last number of years. The crude 
incidence rate for Ireland now stands at 0.71 per 
100,000 (95% CI 0.45-0.96). The last year for which data 
is available across the EU is 2006. At that time, Ireland 
had the third highest incidence among those countries 
for whom data was available. The incidence in the EU as 
a whole was 0.18 per 100,000 (Figure 2). 
The leptospirosis notification dataset is typically 
dominated by adult males, and this year is no exception. 
Ninety per cent of cases this year was male and the 
age range was 13-85 (mean age =45 years, median 
age=37 years). Figure 3 shows the age-sex distribution 
of notifications in 2008. This is consistent with the 
exposures most commonly associated with leptospirosis 
in temperate regions, e.g. occupational contact with 
farm animals and watersports.
Seventeen cases required hospitalization, two were 
reported as GP patients, and patient type was not 
available for the remaining 11 patients. One elderly 
patient died as a result of their illness. 
Ten cases were believed to have acquired their illness 
occupationally –five of these were farmers. Nine 
cases reported recent watersports activity including 
six canoeists, two swimming outdoors and one 
triathlete. For three of these cases, these activities 
occurred outside of Ireland –two in Asia and one in the 
United Kingdom. For six cases, their infections were 
reported to have been possibly due to engaging in 
more common outdoor activities such as gardening, 
spending time by a river bank, or holidaying in a tropical 
destination. No risk factor information was available for 
the remaining five cases. 
While a number of regional hospital laboratories offer 
a diagnostic service for leptospirosis, annually around 
two thirds of cases are diagnosed by the National Virus 
Reference Laboratory. Positive specimens are generally 
referred to the UK Leptospirosis Reference Unit for 
4.3 Leptospirosis           
Summary
Numbet of cases, 2008: 30
Number of cases, 2007: 22
Crude incidence rate, 2008: 0.71/100,000
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Figure 1 : Annual number of leptospirosis notifications, Ireland 1991-2008
(data source: CIDR)
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Figure 2: Crude incidence rate leptospirosis in EU member states, 2006
(Data source: ECDC - note excludes France which did not provide data to ECDC in 2006)
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confirmation and for typing where possible. Overall, 
species information was available for seven cases 
in 2008 –two cases were infected with Leptospira 
interrogans hardjo, both of which were farming-
related cases. There were five cases reported as 
Leptospira interrogans icterohaemorrhagiae, three of 
whom reported river water contact.  Species was not 
reported for the remaining 23 cases.
Activities that have been associated with leptospirosis 
risk include farming, occupations that involve contact 
with wet rodent-infested environments, recreational 
activities such as water sports, and flooding. In the last 
few years, travel to Asia has emerged as a risk factor 
for leptospirosis in Ireland. In general the incidence 
of leptospirosis is higher in tropical climates than in 
temperate areas like Ireland.
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Blood-borne and 
Sexually Transmitted Infections
Hepatitis B is a vaccine preventable disease which is 
transmitted through percutaneous or mucocutaneous 
contact with the blood or body fluids of an infected 
person. The main routes of transmission are through 
sexual contact, from mother to baby and through 
injecting drug use.
Over 90% of people infected as adults clear the virus 
within a year of infection, but there is a high probability 
of developing chronic infection if hepatitis B is 
acquired in infancy (90%) or early childhood (25-50%). 
A proportion of people with chronic infection develop 
progressive fibrosis which can lead to cirrhosis, liver 
failure and hepatocellular carcinoma (liver cancer).
The prevalence of hepatitis B in the general population 
in Ireland is low (less than 1%) and most cases are in well 
defined risk groups such as people with multiple sexual 
partners, household or sexual partners of known cases, 
babies of positive mothers, injecting drug users and 
people who were born in hepatitis B endemic countries.
The number of hepatitis B cases reported in Ireland 
increased by 10% in 2008, with 949 cases (22.4/100,000 
population) notified compared to 863 in 2007 (figure 
1). Fifty seven percent (n=540) of notifications were 
from the HSE-E, corresponding to a notification rate of 
36/100,000 population.
All cases were laboratory confirmed. Eighty nine percent 
contained information on acute/chronic status. Where 
status was known, 90% of cases were chronic (n=765) 
and 10% were acute (n=82).
Acute cases (recent infections)
Of the 82 acute cases notified in 2008, 84% (n=69) were 
male, 14% (n=12) were female and sex was not known 
for one case. The highest notification rates were in 
young to middle aged adults. Ninety percent (n=74) of 
acute cases were aged between 20 and 54 years (figure 
5.1 Hepatitis B
Summary
Number of cases, 2008: 949
Crude notification rate, 2008: 22.4/100,000 
population
Number of cases, 2007:863
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2). Female cases were younger than males overall, with 
a median age of 29.5 years compared to 33 years for 
males.
Information on risk factor was available for 89% (n=73) 
of acute cases. Of these, 66% (n=48) were likely to have 
been sexually acquired. Twenty nine were men who 
have sex with men, eighteen were heterosexual and 
sexual orientation was not known for one case. A further 
nine cases (12%) were born in a hepatitis B endemic 
country (hepatitis B surface antigen prevalence > 2%). 
No risk factors were identified for eight cases (11%) 
despite follow up being carried out.
Country of birth was known for 85% of acute cases.  
Sixty six percent (n=56) were born in Ireland and 10% 
were born in Eastern or Central European countries. 
Where country of infection was known, 72% (n=38) of 
acute cases were infected in Ireland and 11% (n=6) were 
infected in Thailand. Information on reason for testing 
was available for 73 acute cases. Most were identified 
because they were symptomatic (69%, n=50) or through 
STI services (11%, n=8).
Chronic cases (long-term infections)
Of the 765 chronic cases notified in 2008, 51% (n=389) 
were male, 45% (n=343) were female and sex was not 
known for 4% (n=33). Ninety one percent of chronic 
cases were aged between 20 and 54 years when 
notified (figure 2). The median age for female cases was 
29 years and the median age for males was 32 years. 
Some enhanced data were available for 56% (n=428) 
of chronic cases. Of these, 86% (n=369) were born in 
hepatitis B endemic countries or were identified as 
asylum seekers. Data on country of birth was available 
for 45% (n=345). The most common regions of birth 
were Eastern or Central Europe (30%, n=104), Sub-
Saharan Africa (30%, n=102) and Asia (26%, n=89). 
Thirty seven chronic cases were known to have been 
born in Ireland. 
Reason for testing was known for 60% (n=456) of 
chronic cases. Thirty three percent (n=149) were 
identified through antenatal screening programmes, 
23% (n=103) were identified through asylum seeker 
screening programmes and 11% (n=51) were tested in 
STI settings.
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis B by acute/chronic status, 2008
0
10
20
30
40
50
0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+
Age group (years)
N
o
ti
fic
at
io
n 
ra
te
s 
p
er
 1
00
,0
00
 
p
o
p
ul
at
io
n
Male acute cases Female acute cases Male chronic cases Female chronic cases
-70-HPSC Annual Report 2008 5 Blood-borne and Sexually Transmitted Infections
A further 3% (n=13) of chronic cases were residents of 
intellectual disability institutions. Most were diagnosed 
as a result of routine screening and may have been 
infected for some time. Their ages ranged from 34 to 57 
years and all were born in Ireland.
Notification rates for hepatitis B in Ireland have 
increased dramatically over the past decade. This is 
mostly due to increasing immigration from countries 
with intermediate or high hepatitis B endemicity and 
increases in sexually transmitted hepatitis B in Ireland.
Although the age at notification was similar for acute 
and chronic cases, this reflects age when tested and 
most of those who acquired their infection in endemic 
countries are likely to have been infected as infants 
or in early childhood and have now been infected for 
decades. This has implications for the likely future 
burden of disease due to hepatitis B in Ireland.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 7th August 2009. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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The hepatitis C virus is primarily transmitted through 
sharing contaminated equipment when injecting 
drugs or through receipt of unscreened blood or 
blood products. Sexual, occupational and perinatal 
transmission can also occur but are less common. 
Infection is initially asymptomatic in approximately 90% 
of cases, but between 60 and 85% of those infected 
fail to clear the virus and develop chronic infection. A 
proportion of people with chronic infection develop 
progressive fibrosis which can lead to cirrhosis, liver 
failure and hepatocellular carcinoma (liver cancer).
Hepatitis C became a notifiable disease in Ireland in 
2004. The number of cases reported in 2008 was similar 
to 2007, with 1,537 notifications (36/100,000 population) 
compared to 1,556 in 2007 (figure 1). 
The sex distribution of cases was very similar to previous 
years with a strong predominance of male cases (figure 
1).  In 2008, 63% (n=967) of cases were male, 35% 
(n=542) were female and sex was not known for 28 
cases. The highest notification rates were in young to 
middle aged adults. Seventy two percent (n=1,101) of 
cases were aged between 25 and 44 years (figure 2). The 
median age for females was younger (32 years) than that 
for males (35 years).
The geographic distribution of cases was skewed, with 
the HSE-E reporting 77% of all cases (n=1,183) notified 
in 2008. Their age-standardised notification rate, of 
79/100,000 population, was over 4 times that of the next 
highest area (figure 3).
Some information on most likely risk factor was available 
for 38% of cases (n=581) in 2008. The most likely risk 
factor for 77% (n=447) was injecting drug use.  A further 
3% (n=16) were either prison inmates or homeless. 
Although mode of transmission was not reported for 
these cases, both groups have high prevalences of 
injecting drug use. 
5.2 Hepatitis C
Summary
Number of cases, 2008: 1,537
Crude notification rate, 2008: 36/100,000 population
Number of cases in 2007: 1,556
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Figure 1. Number of hepatitis C notifications, 2004-2008
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Twenty four cases (4%) were reported as infected 
through receipt of blood or blood products. Of these, 
twelve were infected in Ireland. No further information 
was available for one, but the remainder were all 
infected through anti-D or blood transfusions acquired 
many years in the past, but were notified for the first 
time in 2008. Nineteen cases (3%) were known to 
be asylum seekers and the most likely risk factor for 
fourteen cases (2%) was sexual exposure.
The number of cases of hepatitis C notified in 2008 
remained high and, where risk factor data were 
available, injecting drug use remained the predominant 
mode of transmission. Although information on risk 
factor was not available for over 60% of cases, the age 
and sex profile of these cases did not differ significantly 
from those for whom information was available.
The prevalence of hepatitis C in the general population 
in Ireland is thought to be very low. Infection is mostly 
in defined risk groups such as injecting drug users 
and people who received unscreened blood or blood 
products in the past. In a report on blood-borne viral 
infections among injecting drug users in Ireland, the 
Health Research Board found that approximately 70% 
of injecting drug users, who attended drug treatment 
services between 1995 and 2005, had tested positive for 
hepatitis C antibodies (current or past infection).1 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 7th August 2009. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
1.  Long J (2006). Blood-borne viral infections among injecting drug 
users in Ireland, 1995-2005. Overview 4. Dublin: Health Research 
Board
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Figure 3. Notification rates/100,000 population for hepatitis C by HSE area, 2006-2008
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A total of 405 new HIV diagnoses were reported to 
the HPSC during 2008. This compares to 391 in 2007 
and represents a 3.6% increase. The rate of newly 
diagnosed HIV infection in Ireland in 2008 was 95.5 per 
million population. The cumulative total number of HIV 
infections reported in Ireland since surveillance began to 
the end of December 2008 is 5,243. 
The total number of AIDS diagnoses reported to 
the end of 2008 is 999 with reports of 28 new AIDS 
diagnoses during 2008. The total number of deaths 
among AIDS cases reported to the end of 2008 is 411 
with reports of three deaths among AIDS cases in 2008. 
It is important to note that there is both under-reporting 
and late reporting of both AIDS cases and deaths 
among AIDS cases. 
Figure 1 shows the number of HIV and AIDS diagnoses 
annually in Ireland from 1990 to 2008. HIV data from 
2003 to 2007 have been updated and a detailed analysis 
can be found in the HIV and AIDS surveillance tables on 
the HPSC website. 
Table 1 below outlines some key findings from case 
based surveillance during 2008 and compares them 
with the most recent data from the European Centre for 
Disease Prevention and Control (ECDC).  From these 
data, we can conclude that the HIV epidemic in WHO 
Europe, West is characterised mainly by heterosexual 
transmission
Figure 2 shows probable route of transmission for newly 
diagnosed cases among the three major risk groups, 
heterosexual contact, men who have sex with men 
(MSM) and injecting drug users (IDUs) between 2000 
and 2008. 
The 318 reported cases of HIV with information 
available on probable route of transmission indicate that
•  the highest number of new HIV diagnoses (56%), was 
reported as due to heterosexual transmission
5.3 HIV and AIDS
Summary
Number of HIV cases: 405
Crude HIV incidence rate: 9.6 per 100,000 population
Number of AIDS cases: 28
Number of deaths in AIDS cases: 3
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Figure 1: New HIV and AIDS diagnoses by year of diagnosis (1990 to 2008) 
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•  thirty percent (97 cases) of new infections were among 
MSM
•  eleven percent (36 cases) of new cases were among 
IDUs
HIV infection was newly diagnosed in seven children in 
2008. The probable route of transmission was mother to 
child transmission (MCT) for all seven cases.  In addition, 
there were 106 babies born to a HIV infected mother 
in Ireland during 2008: 86 are not infected, 18 remain 
of indeterminate status (i.e. do not meet the criteria for 
HIV infection and are <18 months at time of test) and 
two were infected.
Of the 405 cases, 36% (146 cases) were female and 
64% (258 cases) were male. Gender was unknown for 
one case. Of the 146 female cases newly diagnosed in 
2008, 21 (14.4%) were reported to be pregnant at HIV 
diagnosis.  A breakdown of cases in 2008 by probable 
route of transmission and sex can be seen in Table 2. 
Most of the newly diagnosed cases (67%) were aged 
between 20 and 39 years. The median age at HIV 
diagnosis among the three major risk groups was:
Heterosexual: 32 years (range 16-63 years)
IDUs:  33 years (range 21-61 years)
MSM:  34 years (range 19-67 years)
The 312 reported cases of HIV with information 
available on geographic origin indicate that: 
•  39% (123 cases) were born in Ireland, 39% (121 cases) 
were born in sub-Saharan Africa, 9% (20 cases) were 
born in Western Europe and 5% (17 cases) were born 
in Central Europe. 
•  Of the 178 cases acquired through heterosexual 
contact, 63% (112 cases: 73 female, 38 male, 1 
unknown) were born in sub-Saharan Africa and 21% 
(37 cases: 22 male, 15 female) were born in Ireland.
Information on stage of infection at time of HIV 
diagnosis was available for 305 of the 405 cases. Of 
the 305 cases, 240 were asymptomatic and 21 were 
diagnosed with AIDS at the time of HIV diagnosis.
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Table 1: Newly diagnosed cases of HIV infection reported in the WHO European Region and by geographical region
Indicator
WHO                  Ireland
European Region 2007
European Region 
West 2007
2007 2008
Number of HIV cases 48,892 24,202 391 405
Rate per million 76.4 77.0 92.2 95.5
Percentage of cases    
Age 15-29 years 33% 26% 44% 39%
Female 33% 31% 38% 36%
Probable route of transmission (Unknowns excluded)
Heterosexual 46% 51% 53% 56%
MSM 20% 40% 27% 31%
IDU 32% 8% 17% 11%
Source: ECDC 2007 report http://ecdc.europa.eu/
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Discussion
Since 2002, the annual HIV total has been in excess 
of 320 infections. The data suggest that although the 
numbers are increasing, the epidemic is concentrated 
among a number of risk groups where the numbers may 
fluctuate from year to year. Due to the voluntary nature 
of the reporting system, it is likely that the number of 
case reports is an underestimate. In addition, each year 
10-20% of case reports are incomplete.  
More detailed information on the epidemiology of HIV and 
AIDS in Ireland in 2008 is available at www.hpsc.ie/hpsc/A-Z/
HepatitisHIVAIDSandSTIs/HIVandAIDS/
 
Table 2: HIV diagnoses in Ireland by probable route of transmission 
and sex (2008)
Probable route of transmission Sex Number  
MSM
Male 97
Sub total 97
Heterosexual
Male 72
Female 105
Unknown 1
Sub total 178
IDU
Male 27
Female 9
Sub total 36
MCT
Male 5
Female 2
Sub total 7
Unknown
Male 57
Female 30
Unknown -
Sub total 87
Total  405
-76-HPSC Annual Report 2008 5 Blood-borne and Sexually Transmitted Infections
Clinicians and laboratories notify their respective 
departments of public health of anonymised probable 
and confirmed cases of sexually transmitted infections 
(STIs). These notifications are then reported to HPSC in 
aggregated form on a quarterly basis. Because of delays 
in STI reporting, annual data are not always available 
nationally in a timely manner. Consequently, this report 
focuses on STIs notified to HPSC in 2007. 
In 2007, 11,915 STIs were reported in Ireland, more 
than a 20% increase compared to 2006 when 9,892 
STIs were reported (table 1). This increase is largely 
attributable to a rise in the number of chlamydia and 
genital herpes notifications reported between 2006 and 
2007, particularly in the HSE-E Area where a significant 
new source of reporting emerged. Furthermore, the 
figures would be greater were it not for the fact that 
one STI clinic in the HSE-MW Area was unable to 
provide returns. Three infectious diseases accounted 
for 85.4% of all STI notifications in 2007: ano-genital 
warts, Chlamydia trachomatis and non-specific urethritis. 
Between 2006 and 2007, notifications for non-specific 
urethritis ano-genital warts, and gonorrhoea decreased 
by 13.5%, 6% and 3.2%, respectively. However, 
notifications of herpes simplex (genital), trichomoniasis, 
chlamydia, syphilis, and hepatitis B (acute or chronic) 
and chlamydia increased by 117.1%, 80.8%, 59.8%, 
58.2% and 25%, respectively (table 1).
STIs in males accounted for 54% of all notifications; 
44.9% were in females. Gender data were not reported 
for 1.2% of notifications (table 2). The number of 
notifications among males generally exceeded that of 
5.4  Sexually Transmitted Infections  
 (STIs), 2007
Summary
Total number of STI notifications in 2007: 11,915
Three most common STIs reported in 2007:
1.  Chlamydia trachomatis infection (genital): 5,023 
cases (118.5/100,000)
2.  Ano-genital warts: 3,283 cases (77.4/100,000)
3. Non-specific urethritis: 1,870 cases (44.1/100,000)
Table 1. Notifiable sexually transmitted infections from 1999 to 2007
Sexually Transmitted Infection 1999 2000 2001 2002 2003 2004 2005 2006 2007
Ano-genital warts 3049 3735 3993 3932 3981 4174 3456 3494 3283
Chancroid 1 16 1 1 0 1 0 1 1
Chlamydia trachomatis infection (genital) 869 1343 1649 1922 2258 2803 3353 3144 5023
Gonorrhoea 175 290 349 214 186 270 342 431 417
Granuloma inguinale 1 0 0 0 0 1 0 0 0
Hepatitis B (acute or chronic) 2 15 39 57 112 85 80 20 25
Herpes simplex (genital) 275 269 331 358 375 411 441 455 988
Lymphogranuloma venereum 2 0 0 1 0 0 1 0 2
Non-specific urethritis 1265 1726 1634 2025 2332 2746 2106 2161 1870
Syphilis 6 46 279 303 235 144 282 134 212
Trichomoniasis 47 78 64 73 59 60 83 52 94
Total 5692 7518 8339 8886 9538 10695 10144 9892 11915
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females for all STI diseases with the exception of C. 
trachomatis, herpes simplex (genital) and trichomoniasis 
(table 2). In 2007, the highest number of notifications 
was in the 20-29 year age group, accounting for 60.4% 
of all STIs notified (table 2). This age group also had 
the highest number of notifications for each of the STI 
diseases except syphilis, trichomoniasis and hepatitis B 
(acute or chronic) (table 2).
During 2007, over 51% (n=6,148) of all STI notifications 
were from the HSE-E. Four areas (HSE-E, HSE-SE, HSE-S 
and HSE-W) accounted for over 90% (n=10,793/11,915) 
of the STI notifications in 2007 (table 3). The breakdown 
of STI data by geographical area should, however, 
be interpreted with caution, as figures are largely a 
reflection of the area where cases availed of STI services 
rather than a reflection of the burden of STIs in the 
population in that area. 
Summary Statistics on Selected STIs, 2007
Ano-genital warts
In 2007, 3,283 cases of ano-genital warts were notified 
(77.4/100,000 population) which accounted for 27.6% 
of all STI notifications reported. This number represents 
a decrease of 6% since 2006. More cases were notified 
among males than females (1,811 versus 1,470) and 
in the 20-29 year old age group which had 66.9% 
(n=2,195) of all such cases reported. 
Chlamydia trachomatis infection (genital)
The crude incidence rate in 2007 for C. trachomatis 
infection was 118.5/100,000 (5,023 notifications). 
Chlamydia notifications constituted 42.2% of all STI 
notifications reported in 2007 and represent an increase 
of 59.8% since 2006. More cases were notified among 
females than males (2,877 versus 2,042) and 60% 
(n=3,015) of cases were reported in the 20-29 year old 
age group.
Non-specific urethritis
In 2007, 1,870 cases of non-specific urethritis were 
notified (44.1/100,000), a decrease of 13.5% since 
2006. These notifications constituted 15.7% of all STI 
notifications reported. Considerably more cases were 
notified among males than females (1,698 versus 172). 
Sixty-three percent of cases (n=1,179) were reported in 
the 20-29 year old age group. 
Table 2. Notified sexually transmitted infections by gender and age group, 2007
Sexually Transmitted Infection Male Female
Gender 
Unknown 0-19 20-29 30-39 40+
Age
Unknown Total
Ano-genital warts 1811 1470 2 338 2195 561 184 5 3283
Chancroid 0 1 0 0 1 0 0 0 1
Chlamydia trachomatis infection (genital) 2042 2877 104 589 3015 650 148 621 5023
Gonorrhoea 355 56 6 28 225 86 52 26 417
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Hepatitis B (acute or chronic) 21 4 0 1 9 11 4 0 25
Herpes simplex (genital) 356 619 13 124 478 215 140 31 988
Lymphogranuloma venereum 2 0 0 0 0 0 2 0 2
Non-specific urethritis 1698 172 0 108 1179 426 155 2 1870
Syphilis 145 60 7 3 67 81 42 19 212
Trichomoniasis 1 87 6 2 28 32 22 10 94
Total 6431 5346 138 1193 7197 2062 749 714 11915
(% of Total) 54.0% 44.9% 1.2% 10.0% 60.4% 17.3% 6.3% 6.0% 100
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Herpes simplex (genital)
The crude incidence rate for genital herpes in 2007 
was 23.3/100,000 (988 notifications). The notifications 
constituted 8.3% of all STI notifications reported in 2007 
and represent an increase of 117.1% since 2006. More 
cases were notified among females than males (619 
versus 356) and in the 20-29 year old age group (48.3% 
of all such cases notified; n=478).
Gonorrhoea
In 2007, 417 cases of gonorrhoea were notified 
(9.8/100,000), a decrease of 3.2% since 2006. These 
notifications constituted 3.5% of all STI notifications 
reported in 2007. More cases were notified among 
males than females (355 versus 56) and most frequently 
in the 20-29 year old age group (54% of all such cases 
reported; n=225). 
Hepatitis B
The data presented here reflect only those cases 
notified through STI services. Further information on the 
epidemiology can be found in the hepatitis B chapter of 
this report.
Note: Crude incidence rates calculated for the year 2007 based on 
census 2006 denominator data.
Table 3. Notified sexually transmitted infections by HSE Area, 2007
Sexually Transmitted Infection HSE-E HSE-M HSE-MW* HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
Ano-genital warts 1255 1 0 3 296 464 577 687 3283
Chancroid 0 0 0 0 0 0 1 0 1
Chlamydia trachomatis infection (genital) 2741 142 215 86 80 955 413 391 5023
Gonorrhoea 273 6 11 7 4 45 29 42 417
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Hepatitis B (acute or chronic) 0 0 0 0 0 4 17 4 25
Herpes simplex (genital) 761 3 0 1 2 58 71 92 988
Lymphogranuloma venereum 0 0 0 0 0 0 0 2 2
Non-specific urethritis 945 0 0 0 241 197 303 184 1870
Syphilis 122 9 0 2 4 27 24 24 212
Trichomoniasis 51 7 2 0 0 17 12 5 94
Total 6148 168 228 99 627 1767 1447 1431 11915
(% of Total) 51.6% 1.4% 1.9% 0.8% 5.3% 14.8% 12.1% 12.0% 90
* Data not available from STI Clinic in HSE-MW. Above data based on lab-confirmed reports provided by the laboratory to public health
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Since 2000, case-based records are available nationally 
on syphilis cases. An enhanced surveillance system is 
in place whereby enhanced forms are completed by 
Departments of Public Health in conjunction with the 
clinician and are then forwarded to HPSC. The data 
presented in this chapter are on the case-based reports 
received on syphilis (some with enhanced details) which 
are held on a national database at HPSC. The syphilis 
figures presented here are not comparable with the 
aggregate counts of syphilis notifications provided by 
HSE areas as part of the routine quarterly reporting 
of sexually transmitted infections (See STI chapter for 
more details). This difference arises because case-based 
reports are not received for all syphilis cases notified.
The first section of this report focuses on 2007 data and 
the second part on the main syphilis trends between 
2000 and 2007.
Syphilis 2007
In 2007, case-based reports with enhanced surveillance 
data were received on 146 syphilis notifications. Eighty-
three (2.0/100,000 population) cases were diagnosed 
with early, infectious syphilis (i.e. primary, secondary and 
early latent stages) and the remaining 63 cases were 
either latent, late, tertiary, other or unknown. 
The 83 cases of early syphilis were analysed in more 
detail since the disease is infectious at this stage and 
therefore has the greatest public health implications. 
Cases ranged in age from 18 to 60 years of age (median 
31 years). The majority of cases were diagnosed in 
the HSE-E (89%, n=74) and the majority of the cases 
were also resident in HSE-E (76%, n=63). Most cases 
were acquired by those who were born in Ireland (66%, 
n=55).
Seventy-one percent of early syphilis cases (n=59/83) 
were men who had sex with men (MSM). These cases 
ranged in age between 18 and 60 years (median 33 
years), with the 25-34 years age group having the 
highest number of cases (n=23). Primary and secondary 
syphilis accounted for 47% (n=28) and 41% (n=24) of 
these 59 MSM cases, respectively. Early latent syphilis 
accounted for 12% (n=7/59). 
5.5 Syphilis, 2007
Summary
Number of case-based syphilis reports with   
enhanced surveillance data, 2007: 146
Number of early syphilis cases, 2007: 83
Crude incidence rate of early syphilis, 2007: 
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Figure 1. Quarterly number of early syphilis cases diagnosed in 
Ireland by sexual orientation, 2000-2007, based on completed 
enhanced forms (excluding nine cases without quarterly year details)
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‘Oral sex only’ was the type of sexual behaviour 
reported by 32.2% (n=19/59) of these early syphilis 
MSM cases. The annual number of male sexual contacts 
among early syphilis MSM cases ranged between 0 and 
300. The most common range was 1-9 partners in 66% 
(n=39/59) of cases overall.
Syphilis trends 2000-2007
Between 2000 and 2007, a total of 1,774 case-based 
reports were received on syphilis. Most syphilis cases 
were among males (72%; n=1,280) while females 
accounted for 27% of cases (n=483). Cases ranged in 
age from 0 to 95 years, with a median age of 33 years. 
The majority of cases occurred in the 25-34 year old 
age group (40%; n=709). Forty-nine percent (n=866) 
were classified as early, infectious syphilis. The other 
stages reported were: congenital (0.2%; n=4), latent 
(6%; n=99), late (20%; n=357) and other/unknown (25%; 
n=448). 
Enhanced surveillance forms were completed for 61% 
(n=1,091/1,774) of individual case-based reports and 
768 (70%) of these 1,091 cases were reported as early 
syphilis. The majority of these 768 cases were male 
(89%; n=690) and most male cases occurred in the 25-
44 years age group (41%; n=280/690). Of the 768 early 
syphilis cases with enhanced data, 119 (15%) were HIV 
positive.
Early syphilis is far more common in the MSM 
population in Ireland compared to the non-MSM 
population (figure 1, table 1). There were 669 MSM 
cases reported with enhanced data between 2000 and 
2007, 87% (n=582) of which were early syphilis cases. 
‘Oral sex only’ was the type of sexual behaviour 
reported by 31% (n=183) of these 582 early syphilis 
MSM cases. The annual number of male sexual contacts 
ranged between 0 and 300. Overall, the most common 
range was 1-9 partners in 58% (n=340/582) of cases.
Nine percent (n=55/582) of early syphilis MSM cases 
reported were the result of re-infections. The most 
frequent reason for attendance for STI services was self-
referral (37%; n=218/582), followed by contact referral 
(13%; n=73), Gay Men’s Health Clinic (12%; n=70) 
general practice (10%; n=60) and routine visit (10%; 
n=58) attendance. 
A total of 103 early syphilis MSM cases (18%) were 
reported to be HIV positive between 2000 and 2007. 
Concurrent STIs were relatively common with 21% of 
MSM with early syphilis (n=121/582) having an STI other 
than HIV. Past STIs were also quite common with 42% 
(n=244/582) of MSM with early syphilis reporting a 
previous history. In addition, 51 of these 244 cases with 
a past history of STIs were HIV positive, ten of which 
were reported being infected more than once with 
syphilis.
Table 1. A breakdown of early syphilis cases by sexual orientation in Ireland, 2000-2007, based on completed enhanced forms
Diagnosis
Heterosexual Heterosexual Heterosexual 
MSM** Unknown Total
Male Female* Unknown
Primary 40 12 0 224 5 281
Secondary 29 27 1 217 0 274
Early Latent 28 35 0 132 5 200
Other 0 2 0 9 2 13
Total 97 76 1 582 12 768
*includes one female bisexual, primary case
** includes 48 male, bisexual cases
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Other infections
Not all viral infections are notifiable, but some can and 
do cause encephalitis. In this chapter, the focus is on 
those viral pathogens that cause encephalitis, but are 
not notifable in their own right. 
In 2008, five cases of viral encephalitis (caused by 
non-notifiable organisms) were notified in Ireland, 
which is a crude incidence rate of 0.12 per 100,000 
total population. The number of viral encephalitis 
notifications in 2008 is just over half that which was 
reported in 2007, and a third of cases notified in 2006. 
The decrease in viral encephalitis in 2007, compared to 
2006 was particularly related to a decrease in varicella 
zoster virus associated encephalitis notifications.
Of the five cases notified in 2008, three cases occurred 
in males and two in females giving a ratio of 1.5:1.0.
Cases ranged in age from two weeks to 61 years. Three 
of the five cases occurred in children <=5 years of age 
and the remainder occurred in adults >=15 years of age 
(table 1). The highest incidence rates were in infants 
aged <1 years (3.27.100,000) and also in children aged 
5-9 years (0.35/100,000) (table 1).
The causative agent was identified in all five cases of 
viral encephalitis notified; herpes simplex virus (n=3) 
and enterovirus (n=2). Three of the cases due to herpes 
simplex occurred in children <10 months of age and in 
two adults aged >=15 years. Another two cases were 
caused by enterovirus and occurred in children <=5 
years of age. No deaths from viral encephalitis were 
notified between 1997 and 2008.
6.1 Viral Encephalitis  
Summary
  
Number of cases, 2008: 5
Number of cases, 2007: 8
Number of cases, 2006: 16
Crude incidence rate, 2008:  0.12/100,000
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Figure 1. Number of invasive meningococcal disease (IMD) 
notifications in Ireland by serogroup, 1999-2008
Herpes simplex virus
Enterovirus
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Not all viral infections are notifiable, but many can and 
do cause meningitis. In this chapter, the focus is on 
those viral pathogens that cause meningitis, but are not 
notifable in their own right.
In 2008, 97 cases (2.3/100,000 total population) of viral 
meningitis were notified in Ireland. Most of the cases 
were classified as confirmed (89%, n=86), 10 (10%) as 
probable and one (1%) where the case classification was 
not specified. The numbers of cases in both sexes were 
similar with 49 cases in males and 47 in females, giving a 
ratio of 1.04:1.0. Gender was not reported for one case. 
Cases ranged in age from two weeks to 79 years with a 
median age of 12 years. Two cases in 2008 had no age 
details. Eighty one percent (n=79) of all cases were <35 
years of age. Children <1 year of age had the highest 
incidence rate: 44.2 per 100,000, followed by those in 
the 1-4, year group, 3.3/100,000 (table 1). 
In 2008 the overall incidence of viral meningitis in 
Ireland was highest in the HSE-NE area (4.1/100,000) 
followed by the HSE-E area (3.2/100,000) (table 2).
Of the 97 cases notified in 2008 the causative agent 
was reported as enterovirus (n=60; 62%), herpes 
simplex virus (n=8; 8%), varicella zoster virus (n=7; 7%), 
echovirus (n=1; 1%), and unknown (n=21; 21%) (table 1).
In Ireland, viral meningitis activity tends to be highest 
in the second half of the year. In 2008 the numbers of 
cases peaked in July (n=24), August (n=14), October 
(n=15) and November (n=12), with an average of 
12 cases per month (total n=75) between July and 
December. In contrast, viral meningitis was low d uring 
the first six months of the year with a monthly average 
of four cases (total n=22).                     
Although the number of viral meningitis cases fluctuates 
from year to year, the number of cases notified in 2008 
(n=97) exceeded the yearly average (n=66) between 
1997 and 2008 (range 23-161) (figure 1). 
High numbers of cases occurred in 2000 (n=98), 
2001 (n=161) and 2006 (n=148). These upsurges in 
notifications coincided with an increase in reports by 
the National Virus Reference Laboratory (NVRL) of 
6.2 Viral Meningitis 
Summary
Number of cases, 2008: 97
Number of cases, 2007: 45
Number of cases, 2006: 148
Crude incidence rate, 2008:  2.3/100,000
Table 1. Number and age specific incidence rates of viral meningitis notifications by causative organism, 2008 
Age Group Entero-virus
Herpes 
simplex virus
Varicella 
zoster virus
Echo-virus Unknown Total ASIR
<1 21 1 0 1 4 27 44.2
1-4 5 0 0 0 3 8 3.3
5-9 6 0 0 0 1 7 2.4
10-14 5 0 1 0 1 7 2.6
15-19 3 2 1 0 1 7 2.4
20-24 5 1 1 0 4 11 3.2
25-34 8 2 0 0 2 12 1.7
35-44 4 0 1 0 0 5 0.8
45-54 0 1 1 0 1 3 0.6
55-64 1 0 1 0 0 2 0.5
65+ 2 1 0 0 3 6 1.3
Total 60 8 7 1 21 97 2.3
ASIR, age specific incidence rate
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laboratory confirmed non-polio enterovirus isolates. 
Towards the end of 2005 NVRL introduced PCR testing 
of CSF samples for enteroviral nucleic acid. This was in 
addition to the routine method of viral isolation from 
stool samples. 
Based on data obtained from NVRL, it is evident that 
there was some under-reporting of viral meningitis cases 
in 2008, when 157 cases were diagnosed (excluding 
three cases caused by the mumps virus): 78 (49.7%) 
were attributable to enterovirus, 46 (29.3%) to herpes 
simplex virus, 28 (17.8%) to varicella zoster virus, 
four (2.5%) to Epstein-Barr virus and one (0.6%) to 
cytomegalovirus.
No deaths due to viral meningitis were reported in 
2008. Only one death from viral meningitis ( a probable 
case) has ever been notified since 1997, the causative 
organism of which was not reported.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 6th July 2009. 
Figure 1. Annual number of viral meningitis notifications, 1997-2008
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Table 2. Age specific incidence rates of viral meningitis notifications by HSE area, 2008
HSE Area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
E 107.6 6.0 2.1 2.3 1.0 1.4 1.2 3.2
M 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.4
MW 0.0 0.0 0.0 4.2 7.8 3.5 0.0 1.1
NE 31.5 11.8 6.7 3.7 3.7 7.1 1.6 4.1
NW 29.7 0.0 5.8 0.0 0.0 0.0 0.7 1.3
SE 14.8 0.0 3.0 3.1 0.0 3.1 1.7 2.0
S 0.0 0.0 0.0 5.0 2.4 4.2 0.7 1.3
W 0.0 0.0 3.6 0.0 6.8 6.2 1.1 1.9
Ireland 44.2 3.3 2.4 2.6 2.4 3.2 1.0 2.3
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Two cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2008 compared to three cases in 2007.  Both 
cases in 2008 were aged greater than 64 years and were 
sporadic CJD cases.
In total, 43 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December 1996.  
Figure 1 shows the 43 CJD notifications by age group.  
Over 80% (n=36) of the cases were aged greater than 
54 years.  Of the 43 cases, 23 were male and 20 were 
female.  Forty cases were sporadic CJD, two were 
familial CJD and one was iatrogenic CJD.
Variant CJD (vCJD) is specified as a separate notifiable 
disease.  No cases of vCJD were notified in 2008.  
Four cases of vCJD were notified since vCJD became 
notifiable in December 1996.  A summary of these four 
cases was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on 
notifications from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.  The figures 
were extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on the 17th August 
2009 and may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.  Annual figures published here are based 
on the year the notification was entered on CIDR and 
consequently may differ from annual figures published 
by the Irish National Creutzfeldt-Jakob Disease 
Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2008: 2
Number of cases, 2007: 3
Figure 1.  Number of CJD notifications (n=43) from December 1996 to 2008 
by age group
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Infectious Disease Outbreaks
During 2008 there was a significant increase in outbreak 
activity throughout the country. Outbreaks of infectious 
disease are notifiable under the Infectious Diseases 
Regulations (amended 2003). These regulations define 
an outbreak as two or more linked cases of the same 
illness or the situation where the observed number of 
cases exceeds the expected number, or a single case 
of disease caused by a significant pathogen. Outbreaks 
are classified as infectious intestinal disease (IID) or non-
infectious intestinal disease (non-IID). 
Table 1 summarises national outbreak data reported 
via CIDR for the year. A total of 380 outbreaks meeting 
the outbreak definition were notified in 2008. This 
represents a 47% increase on the number of outbreak 
notifications in 2007. These outbreaks were responsible 
4517 cases of illness, a 4% decrease on the previous 
year’s rate of outbreak associated illness. General 
outbreaks had 4282 associated cases of illness. Family 
outbreaks had 235 associated cases of illness.
Table 2 presents outbreaks by outbreak type and 
pathogen type. In 2008 there were 99 non-IID outbreaks 
reported, representing a three-fold increase in non-IID 
outbreak notifications since 2007 and accounting for the 
overall increase in outbreak notifications observed.
The increase in non-IID outbreaks is reflected in 
the national outbreak crude incidence rate (CIR) of 
9.0/100,000 in 2008 (compared to a CIR of 6.1/100,000 
in 2007). Seven of the eight health regions experienced 
a rise in CIR. The north-west region experienced not 
only the highest regional CIR rate for the year but also 
the largest increase in CIR from 9.3/100,000 in 2007 to 
23.6/100,000 in 2008 (figure 1). 
Norovirus and mumps were responsible for the two 
largest outbreaks where numbers ill exceeded 100 
persons. In 2007 there were seven outbreaks that 
caused this level of infection, 86% of which were caused 
by norovirus. The largest mumps outbreak started in 
October 2008 in a university/college with 143 cases of 
mumps cases reported. The largest norovirus outbreak 
7. Outbreaks
Summary
Number of outbreaks, 2008: 380
Number of IID outbreaks: 281
Number of non-IID outbreaks: 99
Table 1: All outbreaks of Infectious Disease, number of IID and non-IID outbreaks, and total numbers ill in all outbreaks reported by health 
region (2008)
HSE Region
No of 
Outbreaks
Outbreak 
Rate
Total number 
ill
No of IID 
Outbreaks
Total number 
ill IID 
Outbreak
No of non-IID 
outbreaks
Total number 
ill non-IID 
Outbreak
East 107 7.2 1384 66 1044 41 340
Midland 20 7.9 144 18 125 2 19
Midwest 20 5.5 153 18 102 2 51
HPSC 6 ~ 55 6 55 0 0
Northeast 32 8.1 516 27 417 5 99
NWHB 56 23.6 865 41 672 15 193
SEHB 38 8.2 393 32 370 6 23
SHB 57 9.2 765 53 721 4 44
WHB 44 10.6 242 20 163 24 79
Total 380 9.0 4517 281 3669 99 848
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Table 2: Number of outbreaks and persons ill by pathogen type and outbreak type, 2008. 
 General Family  
Outbreak Pathogen Type No. of Outbreaks Number  ill No. of Outbreaks
Number 
ill
Total ill
IID 215 3502 66 167 3669
Non IID 74 780 25 68 848
Total 289 4282 91 235 4517
Figure 1: Outbreak CIR by region, 2007 and 2008. 
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occurred in May in a factory location. There were 291 
cases of illness in this outbreak.
Private homes, hospitals and community hospitals/
long stay units were locations where most outbreaks 
occured in 2008 (Table 3). While private homes 
experienced the greatest number of outbreaks, they 
only account for 5% of outbreak cases. Healthcare 
facilities such as hospitals, long-stay units/community 
hospitals and residential institutions all had high 
numbers of outbreaks and high levels of illness 
associated.
During 2008 universities/colleges experienced a 
significant upsurge in outbreaks mainly due to mumps. 
There were 19 outbreaks nationally of mumps in 
these institutions (including one university/community 
outbreak) with 429 reported cases. There was one 
reported outbreak of norovirus in a university/college 
with 43 cases.
Significantly the number of outbreaks occurring within 
crèches (n=28) doubled compared to 2007. When 
examined by causative pathogen the largest outbreaks 
were caused by acute infectious gasteroenteritis 
(AIG) (n=7 and 107 cases of illness), norovirus (n=3 
and 47 cases of illness) and EHEC (n=5 and 22 cases 
of illness).  Shigellosis, cryptosporidiosis, mumps 
individually caused one outbreak each. Varicella/
chickenpox (confirmed and suspected), hand foot and 
mouth (confirmed and suspected) and tinea/ringworm, 
cumulatively caused ten outbreaks and 86 cases of 
illness in crèches. Varicella (n=5) was the most common 
cause of these ten outbreaks, accounted for 71% of 
cases.
IID-Outbreaks
There were 281 IID outbreaks (table 4). Norovirus 
(including suspected Norovirus and mixed outbreaks 
with Norovirus listed as an agent) remained the largest 
cause of IID outbreaks in Ireland. In 2008 164 of these 
outbreaks caused 2873 cases of illness (compared to 
1644 cases of illness associated with all other outbreaks 
during the year). 
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Table 3: Location of All Outbreaks, 2008
Outbreak Location % of Outbreaks % ill
Private house 23.2% (n=88) 5% (n=227)
Hospital 19.5% (n=74) 25.9% (n=1168)
Comm. Hosp/Long-
stay unit
13.4% (n=51) 17.2% (n=775)
Residential institution 12.1% (n=46) 15.1% (n=681)
Other 8.7% (n=33) 14.6% (n=658)
Creche 7.4% (n=28) 6.5% (n=294)
University/College 5% (n=19) 9.6% (n=431)
Community outbreak 3.7% (n=14) 1.8% (n=79)
School 2.9% (n=11) 1.5% (n=68)
Hotel 1.6% (n=6) 2.1% (n=96)
Travel related 1.6% (n=5) 0.4% (n=20)
Unknown 1% (n=3) 0.1% (n=6)
Not Specified 0% (n=1) 0.0% (n=2)
Restaurant / Cafe 0% (n=1) 0.0% (n=2)
After norovirus (n=164), the next most commonly 
reported IID outbreak pathogens were EHEC (n=42), 
salmonellosis (n=22), AIG (n=14), rotavirus (n=8), 
cryptosporidiosis (n=8) and campylobacter (n=7) (table 
5). The number of outbreaks due to EHEC reported in 
2008 (n=42) was double the number reported in 2007 
(n=21) and resulted in a 14% increase in numbers ill. 
Person to person contact was reported as the most 
frequent mode of transmission for IID outbreaks, 
foodborne was the second most common. Mixed 
person to person and waterborne mode of transmission 
(which was not documented in 2007) was specified in 
six outbreaks (EHEC n=5, cryptosporidiosis n=1). All 
six outbreaks were family outbreaks in private homes. 
In four of the five EHEC outbreaks, the households’ 
private wells tested positive for EHEC. In the fifth case, 
a private well was the suspected source. No further 
information was available on the cryptosporidium 
outbreak.  
There was a 73% increase on the number of outbreaks 
where the mode of transmission was listed as mixed 
person to person and airborne. These were caused 
primarily by norovirus (92%, including one mixed 
norovirus and C. difficile outbreak). All but three of 
these outbreaks were general outbreaks and occurred 
mainly in the healthcare facilities.
Hospitals (n=70), private homes (n=62), community 
hospitals/long stay units (n=48) and residential 
institutions (n=42) were the commonest place of 
occurrence of IID outbreaks. In hospitals 86% of 
outbreaks were attributable to norovirus, 6% to C. 
difficile and 3% due to salmonellosis.
There were 22 outbreaks of Salmonella during the 
year (four travel related) resulting in 79 persons ill 
(hospitalisation rate of 25%). This is an increase of 120% 
on the number of salmonellosis outbreaks reported in 
the previous year. Ten outbreaks were family outbreaks 
in private houses. In eight of the 12 general outbreaks 
the suspected mode of transmission was foodborne 
(three being related travel related). 
Eight outbreaks of cryptosporidiosis were reported in 
2008: four general outbreaks and four family outbreaks. 
All were small outbreaks, and between them accounted 
for 29 cases. Two small outbreaks occurred in crèches 
and were believed to be due to person-to-person 
spread, as was one of the family outbreaks.
Forty-two VTEC outbreaks were reported in 2008. Nine 
outbreaks were described as general outbreaks and 33 
as family outbreaks. Twenty-nine outbreaks were due 
to VTEC O157, seven due to VTEC O26, and six were 
caused by a mixture of VTEC strains. Person-to-person 
spread was suspected to have played a role in 21 VTEC 
outbreaks. The second most common transmission 
route reported for EHEC outbreaks in 2008 was 
waterborne (n=8).
In July 2008 the National Surveillance Reference 
Laboratory (NSRL) alerted colleagues in the HPSC of a 
cluster of five S. Agona cases.  Following contact with 
UK colleagues, a much larger cluster involving the UK 
was identified. A joint outbreak investigation involving 
HPSC, NSRL, the HSE, the Food Safety of Authority of 
Ireland, the Department of Agriculture and Food and 
sister agencies in the UK was conducted. Alerts were 
sent using the Food and Waterborne Diseases (FWD) 
network, the European Union’s Early Warning and 
Response System (EWRS) and the European Unions’ 
Rapid Alert System for Food and Feed (RASFF). These 
ultimately resulted in the identification of 11 Irish cases 
and 152 cases throughout England, Scotland, Wales 
and five other European countries. The outbreak strain 
was associated with two deaths. Epidemiological 
investigations, supported by microbiological evidence, 
identified meat product produced at an Irish food plant 
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Table 4: Pathogens associated with IID outbreaks notified on CIDR in 2008
Disease
No. Family 
Outbreaks
No. 
General 
Outbreaks
Total No. 
Outbreaks 
2008
No ill 
2008
AIG-Unknown 0 14 14 297
Adenovirus 2  0 2 5
Campylobacter 7 0 7 14
Clostridium difficile  0 5 5 84
Clostridium difficile and 
Norovirus
0 1 1 12
Cryptosporidiosis 4 4 8 29
EHEC 33 9 42 119
Giardiasis 3  0 3 6
Norovirus/Suspected 
Norovirus infection
2 161 163 2861
Rotavirus 3 5 8 97
Salmonellosis 10 12 22 79
Shigellosis 2 2 4 36
Suspected Rotavirus  0 2 2 30
Total 66 215 281 3669
Table 5:  Non–IID outbreaks notified on CIDR in 2008
Disease
Total No 
Outbreaks
No ill
Botulism 1 5
ESBL E. coli 2 6
Group A strep 1 10
Hand Foot & Mouth Disease  
(including suspected)
5 24
Hepatitis A (acute) 4 9
Hepatitis B (acute and chronic) 1 2
Influenza 4 62
Legionellosis 1 3
Measles 2 6
Meningococcal disease 1 2
MRSA 1 5
Mumps 57 580
Mycobacterium tuberculosis 1 1
Pertussis 2 6
Scabies 1 7
Tinea/Ringworm 2 17
Tuberculosis 1 6
Unknown 2 12
Varicella (including suspected) 9 83
Viral meningitis 1 2
Total 99 848
as the source of the outbreak. The company voluntarily 
closed the implicated section of the plant temporarily 
and recalled affected product.
During 2008 there were seven family outbreaks of 
Campylobacter notified on CIDR with 14 associated 
cases of illness. These were all small clusters of illness 
with no more than two people ill in any outbreak. 
There were eight outbreaks of rotavirus notified in 
2008 accounting for 97 cases of illness. Four of the 
seven outbreaks occurred in crèches, two were private 
family outbreaks, an outbreak occurred in a long 
stay community hospital with 45 cases of illness. The 
location of the final outbreak is unknown.
Non-IID Outbreaks
Non-IID outbreaks occurred mostly in educational and 
childcare settings (n=40), and, private houses (n=26). 
Table 5 presents all outbreaks occurring during 2008 
due to non-IID agents. 
In 2008, there were five outbreaks of hand, foot 
and mouth disease notified, only one of which was 
laboratory confirmed. Four occured in crechés and one 
within a school. In total there were 24 ill. These are the 
first outbreaks of (suspected) hand, foot and mouth 
disease outbreaks notified since 2006.
In 2008, mumps emerged as the leading cause of 
non-IID outbreaks (table 5). As mentioned previously 
the number of reported non-IID outbreaks in Ireland 
increased three fold during 2008. The number of 
mumps outbreaks increased from only three in 2007 
(with ten cases of illness) to a total of 57 in 2008 causing 
580 cases of illness. Of the mumps outbreaks, 49% 
(n=28) occurred in educational institutions (including 
schools, summer schools and university/colleges), 
30% (n=17) in private houses and 11% (n=6) in the 
community. Of the 580 cases of illness due to mumps, 
480 were linked to educational settings. The second 
largest reported outbreak in 2008 was due to mumps 
in a university/college with 143 cases of mumps illness. 
One mumps outbreak involved a mixed location, 
occurring within a university and a community, causing 
41 cases of illness.  As some of the mumps outbreaks 
continued into 2009 the final number of cases 
associated with these outbreaks may change.
In 2008 an outbreak of wound botulism due Clostridium 
botulinum type b occurred in intravenous drug users in 
the Dublin area. There were six cases of illness, five of 
which were hospitalised and one patient died. Three 
cases were laboratory confirmed. Patients were aged 
between 23-42 years of age and presented to four 
different hospitals across the city. A contaminated batch 
of heroin was thought to be the most likely source of 
the outbreak but this was not confirmed. Botulism in 
Ireland (both foodborne and wound) is extremely rare 
in Ireland and had not been seen in injecting drug users 
since 2002.
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Immunisation Uptake
In 2008, each HSE Area provided HPSC with quarterly 
immunisation uptake data for their Area and for 
each of the Local Health Offices (LHOs) in their Area.  
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website.  
The annual immunisation uptake rates presented 
here represent the collation of the 2008 quarterly 
data.  The proportion of children who completed the 
recommended childhood immunisation schedule by 12 
months (born between 01/01/2007 and 31/12/2007) or 
24 months (born between 01/01/2006 & 31/12/2006) of 
age in 2008 are reported.
The Irish childhood immunisation schedule 
recommended that babies born during 2006 and 
2007 should receive one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month 
of age and three doses of vaccines against diphtheria 
(D3), tetanus (T3), pertussis (P3), Haemophilus influenzae 
type b (Hib3), polio (Polio3) and meningococcal group 
C (MenC3) with one dose of each given at two, four 
and six months of age.  Between 12 and 15 months 
of age these children were recommended to receive 
the first dose of the measles-mumps-rubella vaccine 
(MMR1).  From September 18
th 2006 a Hib booster 
(Hibb) was recommended at the same time as MMR1, this 
followed the national Hib campaign from November 
2005 to May 2006 among children less than four years 
of age.  Children born between September 2nd 2006 
and June 30th 2008 were recommended pneumococcal 
conjugate vaccine (PCV) as part of a catchup campaign 
introduced in September 2008, however, PCV catch-
up data are not reported here.Further vaccinations 
are recommended for older children, please see            
www.immunisation.ie for complete information on the 
Irish childhood immunisation schedule and changes to 
the schedule introduced in September 2008.
The immunisation uptake rates are reported here by 
HSE Area and LHO.  While there are 32 LHOs the 
immunisation uptake rates for the LHOs of North Lee 
and South Lee are reported as a combined figure.
Immunisation uptake rates at 12 months
In 2008, national immunisation uptake rates, in children 
12 months of age, were 88% for D3, T3, P3, Hib3, Polio3 
8. Immunisation Uptake
Summary
At 12 months uptake of:
D3, T3, P3, Hib3, Polio3 and MenC3 was 88%
At 24 months uptake of:
D3, T3, P3, Hib3 and Polio3 was 93%
MenC3 was 92% 
Hibb was 82%
MMR1 was 89% 
Table 1.  Annual immunisation uptake rates by HSE Area for children 12 and 24 months of age in 2008
HSE Area
% Uptake at 12 months
Cohort born 01/01/2007 - 31/12/2007
% Uptake at 24 months
Cohort born 01/01/2006 - 31/12/2006
D3 P3 Hib3 Polio3 MenC3 BCG D3 P3 Hib3 Hibb Polio3 MenC3 MMR1
HSE-E 87 87 87 87 87* na 92 92 92 76 92 91* 87
HSE-M 93 93 93 93 93 93 96 96 96 90 96 96 94
HSE-MW 90 90 90 90 90* 96 93 93 93 82§ 93 93* 90
HSE-NE 90 90 90 90 88 na 94 94 94 89 94 94 90
HSE-NW 92 92 92 92 91 94 96 96 95 94 96 93 92
HSE-SE 88 88 88 88 88 93 91 91 91 87§ 91 90 87
HSE-S 85 85 85 85 85 90† 93 93 93 83 93 93 89
HSE-W 88 88 88 88 88 na 93 93 93 82 93 94 88
Ireland 88 88 88 88 88* 94‡ 93 93 93 82§ 93 92* 89
na=not available
Since T3 uptake identical to D3 uptake only D3 uptake figures presented
*The HSE-E and HSE-MW MenC3 data for Quarter 3 2008 were not available
†HSE-S part coverage of neonatal BCG (i.e. Kerry only)
‡ Based on data from five of the eight HSE Areas, these five areas represent approximately a third of the national birth cohort
§The HSE-MW data for Quarter 3 2008 and the HSE-SE data for Quarter 2 2008 were not available
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and MenC3.  (The national MenC3 figure is incomplete as 
the HSE-E and HSE-MW MenC3 data were not available 
in Quarter 3 2008.)  Compared to 2007, these uptake 
rates increased by one percent in 2008.
Uptake rates for D3, T3, P3, Hib3, Polio3 and MenC3 
ranged from 85% in the HSE-S to 93% in the HSE-M 
(table 1).  Four HSE Areas had uptake rates of ≥90% for 
D3, T3, P3, Hib3 and Polio3 while three had uptake rates 
of ≥90% for MenC3 (table 1).
Among the LHOs, uptake rates for D3, T3, P3, Hib3 and 
Polio3 ranged from 81% to 96% and uptake rates for 
MenC3 ranged from 80% to 96% (appendix 2.1).  Twelve 
of the LHOs had uptake rates of ≥90% for D3, T3, P3, 
Hib3 and Polio3 with the target uptake of 95% reached 
or exceeded in three of these LHOs (appendix 2.1).  
Eleven of the LHOs had uptake rates of ≥90% for MenC3 
with uptake of ≥95% in three of these LHOs (appendix 
2.1).
BCG uptake data were available from five of the 
eight HSE Areas (table 1).  These five areas represent 
approximately a third of the national birth cohort.  
Where data were available national BCG uptake was 
94% in 2008, an increase of one percent compared to 
2007.  Among the 12 LHOs that reported BCG data, 
uptake rates ranged from 90% to 98% (appendix 2.1).  
The target uptake of 95% was reached or exceeded in 
four of the 12 LHOs (appendix 2.1).
Immunisation uptake rates at 24 months
National immunisation uptake rates, in children 24 
months of age in 2008, were 93% for D3, T3, P3, Hib3 and 
Polio3 and 92% for MenC3.  (The national MenC3 figure 
is incomplete as the HSE-E and HSE-MW MenC3 data 
were not available in Quarter 3 2008).  Compared with 
2007, the uptake rates for these vaccines increased by 
one percent in 2008 (figure 1).  
Uptake rates for D3, T3, P3, Hib3, Polio3 and MenC3 
ranged from 90-91% in the HSE-SE to 96% in the HSE-M 
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Figure 1.  National annual immunisation uptake rates at 24 months, 1999-2008
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
The 2005 MMR1 uptake figure is incomplete as the HSE-E was unable to provide MMR data for Quarter-4 2005, due to technical problems with extraction of MMR1 
data from the HSE-E database.  The 2006 MMR1 figure includes the Quarter-1 2006 HSE-E figure, which is an estimate only due to technical problems 
with extraction of MMR1 data from the HSE-E database.  The 2007 national Hibb figure is incomplete, as the HSE-W data for Quarter 1 2007 and the 
HSE-NW data for Quarter 3 2007 were not available.  The 2007 national Hibb figure also includes the HSE-SE data which are an underestimate due to data extraction 
methods.  The 2008 Hibb figure is incomplete as the HSE-SE data for Q2 2008 and the HSE-MW data for Quarter 3 2008 were not available.  The 2008 national MenC3 
figure is incomplete as the HSE-E and HSE-MW MenC3 data for Quarter 3 2008 were not available.
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 (table 1).  The target uptake of 95% was reached or 
exceeded for D3, T3, P3, Hib3, Polio3 and MenC3 in the 
HSE-M and for D3, T3, P3, Hib3 and Polio3 in the HSE-NW 
during 2008 (table 1).
Uptake rates for D3, T3, P3, Hib3, Polio3 and MenC3 
ranged from 86% to 97-98% among the LHOs, with 29 
LHOs reporting uptake rates of ≥90% (appendix 2.2).  
The target uptake of 95% was reached or exceeded for 
D3 (figure 2a), P3, T3 and Polio3 in nine LHOs, for Hib3 in 
eight LHOs and for MenC3 in six LHOs (appendix 2.2). 
During 2008 MMR1 uptake was 89% nationally; an 
increase of two percent when compared to 2007 (figure 
1).  In 2008, uptake rates for MMR1 ranged from 87% in 
the HSE-E and HSE-SE to 94% in the HSE-M, with four 
HSE Areas reporting uptake of ≥90% (table 1).  Uptake 
rates for MMR1 ranged from 81% to 94% among the 
LHOs, with 14 LHOs reporting uptake of ≥90% (figure 
2b, appendix 2.2).  
Hibb figures relate to children who received a dose of 
Hib after 12 months of age.  National uptake of Hibb in 
2008, in those 24 months of age, was 82% (table 1 and 
figure 1).  However, the Hibb figure is incomplete, as the 
HSE-SE data for Quarter 2 2008 and the HSE-MW data 
for Quarter 3 2008 were not available.  
Hibb national uptake statistics were reported for the 
first time in 2007, when uptake of Hibb was 74% (figure 
1).  However, the 2007 Hibb figure is incomplete, as 
the HSE-W data for Quarter 1 2007 and the HSE-NW 
data for Quarter 3 2007 were not available.  The 2007 
figure also includes the HSE-SE data which were an 
underestimate due to data extraction methods.
In 2008, uptake of Hibb ranged from 76% in the HSE-E 
to 94% in the HSE-NW (table 1).  Two HSE Areas had 
uptake rates of ≥90% (table 1).  Among the LHOs, 
uptake of Hibb ranged from 68% to 95%, with seven of 
the LHOs reporting uptake of ≥90% and one reporting 
uptake of ≥95% (appendix 2.2).
National immunisation uptake rates have continually 
increased since 2003 (figure 1); however, further 
improvements in uptake are necessary so that the 95% 
target rate is achieved nationally for all vaccines.  In 
2008, national uptake rates at 24 months for D3, T3, P3, 
Hib3, Polio3 and MenC3 were two to three percent below 
the target rate, MMR1 was six percent below the target 
rate and Hibb was 13% below the target rate.
A new routine childhood immunisation programme is 
effective since September 1st 2008 for children born on 
or after July 1st 2008.  Changes include the addition of 
pneumococcal vaccine and hepatitis B vaccine and a 
change in the recommended age of Hib booster and 
MenC vaccine.  
The 2008 immunisation uptake rates for each LHO are 
presented in appendix 2.  The immunisation reports for 
Quarters 1 to 4 2008 are available on the HPSC website 
in Topics A-Z under the heading vaccination.
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Figure 2.  D3 (A) and MMR1 (B) immunisation uptake rates (%) in those 24 months of age in 2008 by Local Health Office (LHO) 
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Antimicrobial Consumption 
and  Resistance 
Ireland participates in the European Surveillance of 
Antimicrobial Consumption (ESAC) which aims to collect 
systemic antibiotic usage data from the outpatient 
(ambulatory, community or primary care) setting and 
from the hospital (inpatient) setting. Consumption is 
measured in Defined Daily Dose (DDD), which is the 
assumed average maintenance dose per day for a 
drug used for its main indication in adults. Rates are 
calculated in DDD per 1000 inhabitants per day (DID) 
for outpatients and DDD per 1000 bed-days used (DBD) 
for inpatients.
Outpatient Antibiotic Consumption
The overall outpatient antibiotic consumption for Ireland 
in 2008 was 21.5 DID, a fall from the previous year’s 
rate of 22.4 DID, the first time this trend has decreased 
since 2000. In an ESAC report of outpatient antibiotic 
consumption from 29 EU countries with reliable data 
for 2005, the range of outpatient antibiotic usage was 
9.2 DID (Russian Federation) to 34.7 DID (Greece). 
The median for all countries was 18.1 DID. Outpatient 
antibiotic usage in Ireland has been around 19 - 23 DID 
over the last five years. Thus the overall rate in Ireland is 
mid-to-high in Europe. 
In Ireland in 2008, outpatient consumption of penicillins 
accounted for the largest class used (51% of total at 
10.9 DID), followed by macrolides (18%, 3.9 DID), 
tetracyclines (14%, 3.1 DID), cephalosporins (7%, 1.5 
DID), quinolones (5%, 1.0 DID) and sulphonamides (4%, 
1.0 DID). Other antibiotic classes accounted for about 
1% of total use.
Penicillin in combination with beta-lactamase inhibitor 
(such as co-amoxiclav) accounted for the largest 
proportion of penicillins and continues to show a 
dramatic rise over the last eight years (3.2 DID in 2000 
to 5.6 DID in 2008). Broad-spectrum penicillin (such as 
ampicillin and amoxicillin) usage was stable but high (3.4 
DID).
9.1 Antimicrobial Consumption 
 
Summary
Outpatient antibiotic consumption, 2008: 21.5 DID
Outpatient antibiotic consumption, 2007: 22.4 DID
Median hospital antibiotic consumption, 2008: 76.4 DBD
Median hospital antibiotic consumption, 2007: 80.1 DBD
EU Network: ESAC  www.esac.ua.ac.be 
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Figure 1. Outpatient antibiotic consumption in Ireland by month, 2000-2008. 
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Seasonal fluctuation (26% rise in DID from summer to 
winter, figure 1) has been seen every year in outpatient 
antibiotic consumption and is probably related to over-
prescribing of antibiotics for respiratory tract infections 
in winter months. In August and November of 2008, 
there was significantly less usage than the predicted 
values.
There was considerable variability in the overall 
outpatient antibiotic usage at county level (17.4 to 27.9 
DID) as shown in figure 2. 
The first-ever European Antibiotic Awareness Day 
took place across Europe on Tuesday 18 November 
2008. To mark the day, a seminar was held in Dublin to 
highlight initiatives being taken to combat over-use of 
antibiotics in Ireland, which included a media campaign, 
an educational programme for General Practitioners, 
development of antibiotic prescribing guidelines and 
distribution of educational material through health 
centres, community pharmacies and elsewhere. 
It is likely that these initiatives accounted for the 
significant decrease in the expected level of antibiotic 
consumption seen in November 2008. 
Hospital Antibiotic Consumption
Forty-two public acute hospitals provided valid 
antibiotic usage data for 2008. The median rate of 
antibiotic consumption usage was 76.4 DBD (range 22.2 
– 117.4 DBD). This was a drop from the previous year’s 
revised rate of 80.1 DBD. These levels are again mid-to-
high in Europe.
Hospital function was the main driver for the differences 
in the rates of antibiotic consumption between 
hospitals. The rates for regional/tertiary and general 
hospitals (medians 79.0 and 78.5 DBD) centred just 
above the median for Ireland, while the rate for single 
specialist facilities (maternity, orthopaedic or paediatric) 
was much lower (median 45.0 DBD). The lower median 
consumption in single speciality hospitals probably 
reflects differences in case mix, compared to other 
hospitals, but may also reflect the fact that DDDs are 
based on adult dosing and may therefore underestimate 
antibiotic consumption in paediatric settings. 
There was also a small reduction in the proportionate 
use of intravenously administered specific antibiotics 
(those with good oral bioavailability) over total use, 
17.4 - 19.1
19.1 - 21.8
21.8 - 23.7
23.7 - 25.8
25.8 - 27.9
Figure 2. Outpatient antibiotic consumption in Ireland by county, in DDD per 
100 inhabitants per day for 2008. 
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from a median of 10.3% in 2007 to 9.4% in 2008. This 
measure reflects patient acuity and also the category of 
hospital.
As shown in table 1,  there was an increase in the usage 
of penicillins with beta-lactamase inhibitors of 4% (0.88 
DBD), and a corresponding decrease in consumption of 
other penicillins of about 5% (0.84 DBD). There were, 
however, significant reductions in other key antibiotic 
groups, particularly fluoroquinolones (2.37 DBD, 23%). 
These reductions in hospital antibiotic consumption 
are probably related to antibiotic stewardship iniatives, 
which have been put in place by medical microbiologists 
and antimicrobial pharmacists in many hospitals. 
Table 1. Key antibiotics and antibiotic groups, and the average consumption rate among all hospitals in DDD per 100 bed-days used for 2008 
compared with the revised figures for 2007. Also shown is the percentage change in consumption.
Antibiotic 2007 2008 Change
Penicillin with beta-lactamase inhibitor 20.11 20.99 4%
Other Penicillins 17.13 16.29 -5%
First-generation cephalosporins 0.33 0.24 -27%
Second-generation cephalosporins 2.53 2.50 -1%
Third-generation cephalosporins 1.82 1.59 -13%
Macrolides 10.46 10.24 -2%
Fluoroquinolones 10.30 7.93 -23%
Injectable Vancomycin & Teicoplanin 2.86 2.58 -10%
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More detailed analyses of antibiotic usage 
data can be found at www.hpsc.ie/hpsc/A-Z/
MicrobiologyAntimicrobialResistance/European 
SurveillanceofAntimicrobialConsumptionESAC/
Detailed breakdown of antibiotic consumption for 2007 
and 2008 by individual hospital may be found at
 www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
EuropeanSurveillanceofAntimicrobialConsumptionESAC/
SurveillanceReports/. The figures presented in this report 
may vary from previously published levels owing to 
methodological changes
9.2	Antimicrobial	Resistance
Summary
•   There were 1,289 reports of S. aureus bacteraemia 
submitted to the European Antimicrobial Resistance 
Surveillance System (EARSS), of which 435 (33.7%) 
were meticillin-resistant S. aureus (MRSA).  This  
represents a significant decrease from 38.5%  
reported in 2007.  Overall, the number of MRSA 
reports was down by 18.8% from 536 in 2007  
       
For acute public hospitals only, the rate (and   
corresponding proportion) of MRSA bacteraemia 
was 0.11 per 1,000 patient bed days used (33.8%),  
a decrease from 0.14 per 1,000 patient bed days 
used (39.3%) in 2007
•   There were 447 reports of invasive S. pneumoniae 
infection compared to 438 in 2007.  The national 
rate of invasive infection was 10.8 per 100,000  
population compared to 10.5 in 2007   
       
The proportion of penicillin-non-susceptible  
S. pneumoniae (PNSP) has increased significantly 
over the past 4 years from 10.3% in 2004 to 23.1%  
in 2008; the proportion of isolates with high-level 
resistance to penicillin increased marginally from 
5.7% in 2007 to 6.1% in 2008 while intermediate 
level resistance increased significantly from 11.0% to 
16.7%      
    
Serotype data were available on 371 of 447 isolates 
(83%) and results indicate good coverage for both 
the 23-valent polysaccharide (PPV23) and 7-valent 
conjugate (PCV7) vaccines in their target popula-
tions: 83% (adults ≥65 years) and 60% (children <2 
years), respectively
•   There were 406 reports of E. faecium bacteraemia, 
an increase of 22% from 332 in 2007.  The pro-
portion that was vancomycin-resistant E. faecium 
(VREfm) increased marginally from 33.5% in 2007 
to 35.7% in 2008, however, the number of VREfm 
isolates increased by over 30% from 111 to 145 over 
the same period. Multi-drug resistant (MDR)   
E. faecium decreased from 22.3% to 16.2%  
•   There were 1,923 reports of invasive E. coli infec-
tion, an increase of almost 8% from 1,783 reports in 
2007.  Resistance to third-generation cephalosporins 
(3GCs) and extended-spectrum beta-lactamase 
(ESBL)-production increased from 6.7% and 4.1%  
in 2007 to 7.5% and 5.0%, respectively, in 2008.  
Ciprofloxacin resistance increased marginally from 
22.1% to 23.4% and the overall trend is still upwards. 
MDR E. coli increased marginally from 11.4% in 2007 
to 12.1% in 2008
•   There were 311 and 199 reports of invasive  
K. pneumoniae and P. aeruginosa infections,  
respectively.  Of note, resistance to 3GCs and ESBL-
production in K. pneumoniae increased from 9.9% 
and 3.7% in 2007 to 11.3% and 7.7%, respectively, in 
2008 while ciprofloxacin resistance decreased from 
18.1% to 12.7%. Resistance to all “indicator” classes 
of antibiotics in P. aeruginosa decreased. MDR  
isolates accounted for  9.9% and 11.1%, respectively, 
of the total for both pathogens
•   See http://www.hpsc.ie for further details of EARSS 
and antimicrobial resistance in Ireland
•   European data are available at http://www.rivm.nl/
earss/database/
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Introduction
The European Antimicrobial Resistance Surveillance 
System (EARSS) in Ireland collects routinely-generated 
antimicrobial susceptibility testing data on seven 
important bacterial pathogens using the EARSS case 
definition. Participating laboratories submit data on the 
“primary” or first isolate from blood or CSF per patient 
per quarter.  EARSS does not distinguish clinically 
significant isolates from contaminants and primarily 
serves as a surveillance system to measure national 
levels of antimicrobial resistance (AMR).  By the end 
of 2008, two of the 44 microbiology laboratories in 
Ireland had suspended their participation in EARSS, thus 
resulting in the reduction of the estimated coverage of 
the Irish population by EARSS from 100% in 2007 to 
98% in 2008.
Staphylococcus aureus
There were 1,289 reports of S. aureus bacteraemia from 
1,242 patients, of which 435 (33.7%) were meticillin-
resistant S. aureus (MRSA) (table 1).  This represents the 
lowest annual proportion since surveillance began in 
1999.  In 2007, the proportion was 38.5%.  The decrease 
observed in 2008 was significant (Chi2=6.7, P=0.01).  
This is the second successive year in which a decrease 
has been observed and this downward trend is highly 
significant (Chi2trend=19.0, P<0.0001) (figure 1).  Overall, 
there was an 18.8% decrease in the number of MRSA 
bacteraemia reports compared with 2007 (435 vs. 536), 
or 15.7% for the 42 laboratories that submitted data for 
both years (515 in 2007 vs. 434 in 2008). Overall, the 
total overall number of meticillin-susceptible S. aureus 
(MSSA) bacteraemia reports remained at the same level 
(857 in 2007 vs. 854 in 2008, although there was an 
increase from 828 to 847 when only the 42 laboratories 
that submitted data for both years are included) 
highlighting that different factors are at play beyond 
those required for the control of MRSA.  Despite the 
decrease in numbers and proportion of MRSA, Ireland 
still had one of the highest proportions of MRSA in 
Europe in 2008 (see http://www.rivm.nl/earss/database/ 
for European data, including EARSS maps).  
One MRSA isolate with reduced susceptibility to 
vancomycin was detected at the National MRSA 
Reference Laboratory by the Etest® macromethod with 
a value of 16mg/L.  This isolate also had a vancomycin 
minimum inhibitory concentration (MIC) of 2mg/L, 
by which it was classified as vancomycin-susceptible 
S. aureus according to the latest CLSI guidelines.  The 
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Figure 1. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage MRSA with 95% 
confidence intervals.
The numbers of participating laboratories by year-end are indicated above the bars
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Table 1. Summary of EARSS data by pathogen and year 
Pathogen Year
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Number laboratories by year-end 12 19 20 23 28 41 42 42 44 42
S. aureus
Number of isolates 510 639 815 1042 1140 1323 1424 1412 1393 1289
Number Meticillin-R (or MRSA) 198 249 337 445 480 553 592 592 536 435
Meticillin-R (or MRSA) 38.8% 39.0% 41.3% 42.7% 42.1% 41.8% 41.6% 41.9% 38.5% 33.7%
Number VISA 0 0 0 0 0 0 0 2 1 0
VISA* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0%
S. pneumoniae
Number of isolates 157 201 245 278 364 400 401 407 438 447
Penicillin-NS* 19.1% 13.4% 12.2% 11.5% 11.8% 10.3% 11.7% 15.7% 17.4% 23.1%
of which:  HLR 0.0% 3.5% 1.6% 1.4% 2.2% 1.8% 3.0% 2.9% 5.7% 6.1%
                 Int 16.6% 8.5% 10.6% 9.7% 8.8% 7.0% 8.7% 12.5% 11.0% 16.9%
Erythromycin-R* 14.0% 12.0% 12.5% 12.7% 11.6% 14.4% 12.1% 16.1% 16.4% 16.7%
Number laboratories by year-end 21 27 40 41 42 44 42
E. faecalis
Number of isolates No data No data No data 168 218 242 290 294 281 301
Ampicillin-R* 8.1% 5.1% 0.8% 3.5% 4.5% 2.2% 0.7%
Vancomycin-R 2.4% 1.4% 1.3% 2.5% 3.7% 2.8% 3.7%
HLG-R* 38.5% 33.9% 41.3% 43.1% 42.4% 37.2% 30.5%
E. faecium
Number of isolates No data No data No data 85 135 187 224 265 332 406
Ampicillin-R* 88.9% 91.0% 95.7% 92.3% 93.9% 93.1% 95.1%
Vancomycin-R 11.1% 19.4% 23.2% 31.7% 37.1% 33.5% 35.7%
HLG-R* 16.7% 53.8% 58.0% 51.4% 44.3% 34.9% 28.1%
MDR* 3.7% 11.4% 18.5% 25.6% 25.6% 22.3% 16.2%
E. coli
Number of isolates No data No data No data 741 991 1256 1445 1656 1784 1923
Ampicillin-R* 62.2% 61.9% 65.0% 67.6% 70.7% 68.3% 70.3%
3GC-R* 3.0% 2.4% 2.4% 4.1% 4.1% 6.7% 7.5%
Ciprofloxacin-R* 5.4% 9.5% 12.6% 17.3% 21.5% 22.1% 23.4%
Gentamicin-R* 2.7% 3.9% 5.7% 8.5% 7.7% 9.9% 10.2%
ESBL-producers* 1.2% 1.3% 1.1% 2.4% 2.5% 4.1% 5.0%
MDR* 2.4% 3.8% 5.6% 7.7% 9.0% 11.4% 12.1%
Number laboratories by year-end 36 39 41
K. pneumoniae
Number of isolates No data No data No data No data No data No data No data 217 244 311
Ampicillin-R* 97.7% 99.2% 99.7%
3GC-R* 10.2% 9.9% 11.3%
Ciprofloxacin-R* 15.3% 18.1% 12.7%
Gentamicin-R* 7.8% 9.9% 10.6%
Imipenem/meropenem-R* 0.0% 0.6% 0.0%
ESBL-producers* 8.6% 3.7% 7.7%
MDR* 11.2% 11.9% 9.9%
P. aeruginosa
Number of isolates No data No data No data No data No data No data No data 128 177 199
Pipericillin/tazobactam-R* 10.2% 13.2% 10.8%
Ceftazidime-R* 10.6% 11.8% 8.7%
Imipenem/meropenem-R* 11.8% 12.2% 9.3%
Ciprofloxacin-R* 18.0% 22.9% 21.8%
Gentamicin-R* 10.2% 13.3% 9.0%
MDR* 9.5% 12.5% 11.1%
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VISA, Vancomycin-Intermediate S. aureus
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime 
and cefpodoxime); ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
* Not all isolates tested
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isolate was shown to be hetero-VISA by Population 
Analysis Profiling.
The MRSA rate for acute public hospitals only was 
0.11 per 1,000 patient bed days used (calculated using 
acute public hospital activity data from the National 
Hospitals Office at the Health Services Executive).  The 
corresponding MRSA proportion was 33.8% (419 of 
1,239 isolates).  Both the MRSA rate and proportion for 
acute public hospitals decreased from 0.14 per 1,000 
patient days and 39.3% observed in 2007.
In patients with laboratory-confirmed S. aureus 
bacteraemia, the probability that the infecting organism 
was MRSA as compared to MSSA was over 2-times 
greater in patients aged ≥65years than in those aged 
<65 years (RR=2.12, Chi2=85.9, P<0.0001).
Males were approximately 1.6-times more likely to get 
an invasive S. aureus infection (1.5-times for MRSA, 
z=4.2, P<0.0001; 1.7-times for MSSA, z=7.7, P<0.0001) 
than females (z=8.7, P<0.0001).  The frequency of 
invasive S. aureus infection increased with age, with 
the majority of infections (n=742; 58%) occurring in 
adults over 60 years.  The median age for patients with 
an MRSA infection was 72 years (95%CI, 70-74) while 
the median age for patients with MSSA was 59 years 
(95%CI, 57-61).  This was considered to be a significant 
difference as the confidence intervals did not overlap.
Streptococcus pneumoniae
There were 447 reports of invasive S. pneumoniae 
infection (426 from blood and 21 from CSF) from 
443 patients.  See table 1 for the annual proportions 
of S. pneumoniae isolates non-susceptible/resistant 
to penicillin and erythromycin by year since 1999 
when surveillance began.  Penicillin-non-susceptible 
S. pneumoniae (PNSP) accounted for 23.1% (n=103) 
of all isolates tested against penicillin (n=445) in 2008 
(table 1).  The proportion of PNSP in Ireland has 
increased significantly over the past four years from 
10.3% in 2004 (Chi2trend=31.5, P<0.0001) (figure 2).  The 
proportion of isolates with high-level resistance (HLR) 
to penicillin increased marginally from 5.7% in 2007 
to 6.1% in 2008, which was not significant (Chi2=0.82, 
P=0.05).  Sixty-nine (16.7%) of 343 isolates were 
resistant to erythromycin, which compares with 16.4% 
in 2007.  In 2008, moderately high levels of PNSP and 
erythromycin resistance were seen in Ireland, similar to 
the situation observed in much of Southern and Central 
Europe.  More notably, Ireland had one of the highest 
proportions of HLR to penicillin (6.1%) in Europe, after 
Hungary (7.8%), Spain (7.1%) and France (6.6%).
Of the 103 PNSP isolates, 75 were intermediately-
resistant (Int; MIC=0.1-1.0mg/L) and 27 were HLR (MIC 
>1.0mg/L) to penicillin.  No penicillin MICs was available 
for one non-susceptible (NS) isolate.
Of isolates tested against both penicillin and 
erythromycin (n=411), 42 (10.2%) were simultaneously 
PNSP (35 Int, 7 HLR) and erythromycin-resistant in 2008 
compared with 7.9% in 2007.
Prior to the introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) into the childhood 
immunisation schedule in September 2008, a national 
pilot project was established early in 2007 as a result 
of a collaborative initiative between RCSI/Beaumont 
Hospital, Children’s University Hospital, Temple St and 
HPSC with the aim of providing baseline serotyping 
data on invasive S. pneumoniae isolates.  Serotype 
data were available on 371 pneumococcal isolates from 
31 laboratories (of 35 that reported pneumococcal 
isolates to EARSS in 2008) representing 83% of all 
pneumococcal isolates reported in 2008.  Overall, 314 
(85%) and 179 (48%) isolates belonged to serotypes 
covered by the pneumococcal polysaccharide (PPV23; 
target population: adults ≥65 years and at risk groups) 
and conjugate (PCV7; target population: children <2 
years) vaccines, respectively.  From adults ≥65 years, 
125 of 151 (83%) isolates were covered by PPV23, while 
from children <2 years, 34 of 48 (60%) isolates were 
covered by PCV7.  Of the 88 PNSP isolates for which 
serotyping data were available, 30 of 38 (79%) from 
adults ≥65 years were covered by PPV23 while 11 of 
13 (85%) were from children <2 years were covered by 
PCV7.
Total S.pneumoniae PNSP %PNSP %Pen-HLR %Pen-I
Figure 2. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and percentage PNSP 
with 95% confidence intervals.
HLR, High-level resistant; I, Intermediately resistant
The numbers of participating laboratories by year-end are indicated above the bars
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The rate of invasive pneumococcal disease (IPD) in 
Ireland in 2008 was estimated to be 10.8 per 100,000 
population compared with 10.5 in 2007 (note: both 
calculated using the 2006 census data and adjusted 
for the estimated population coverage by EARSS for 
that year).  The highest rates of IPD were observed in 
children <1 year (57.3 per 100,000) and adults aged 75-
79 years (45.4), 80-84 years (47.8) and ≥85 years (75.0).
Males were approximately 1.5-times more likely to 
have an invasive S. pneumoniae infection [1.2-times for 
PNSP, z=1.1, P=0.28; 1.5-times for penicillin-susceptible 
S. pneumoniae (PSP), z=3.9, P<0.0001] than females 
(z=4.0, P<0.0001). Although these findings were 
significant for PSP and S. pneumoniae overall, they 
were not significant for PNSP.  The frequency of invasive 
S. pneumoniae infection was highest in children aged 
<1 year (n=35; 8% of all reported isolates) and 1-4 years 
(n=40; 9%) and in adults aged ≥65 years (n=214; 49%).   
The median age was 58 years (95%CI, 53-61).
Enterococcus faecalis
There were 301 reports of E. faecalis bacteraemia 
from 295 patients, an increase of 7% from 281 reports 
in 2007.  See table 1 for the annual proportions of 
E. faecalis isolates resistant to the three “indicator” 
antibiotics (ampicillin, vancomycin and high-level 
gentamicin) by year since 2002 when surveillance began. 
Vancomycin-resistant E. faecalis (VREfa) accounted for 
3.7% of isolates.  Although this proportion was low, 
Ireland still had one of the highest proportions of VREfa 
in Europe in 2008.  
Two isolates were ampicillin-resistant, which suggests 
that these isolates were either misidentified as 
E. faecalis or misclassified as ampicillin-resistant, as 
resistance to ampicillin is rare in E. faecalis.
Males were approximately 1.6-times more likely to 
have an invasive E. faecalis infection than females 
(z=4.3, P<0.0001).  The frequency of invasive E. faecalis 
infection increased with age with the majority of 
infections (n=210; 70%) occurring in adults over 55 
years.  The median age was 65 years (95%CI, 62-70).
Enterococcus faecium
There were 406 reports of E. faecium bacteraemia from 
390 patients, an increase of 22.2% from 332 reports 
in 2007. See table 1 for the annual proportions of 
E. faecium isolates resistant to the three “indicator” 
antibiotics (as for E. faecalis above) by year since 2002.  
Vancomycin-resistant E. faecium (VREfm) accounted 
for 35.7% of isolates.  This represents an increase 
from 33.5% in 2007, however, the number of VREfm 
isolates increased by over 30% from 111 to 145 over the 
same period. Between 2002 and 2006, the proportion 
of isolates that was VREfm increased significantly 
(Chi2trend=30.0; P<0.0001) (figure 3).  In 2008, Ireland had 
the highest proportion of VREfm in Europe, followed by 
Greece (30.7%) and the UK (29.5%). 
Resistance to high-level gentamicin decreased from 
34.9% in 2007 to 28.1% in 2008, which was only 
bordering on significance (Chi2=3.70; P=0.054). 
However, the downward trend since 2004 is highly 
significant (Chi2trend=62.1; P<0.0001) (figure 3).
Of 377 isolates tested against all three “indicator” 
antibiotics, 61 (16.2%) were resistant to all three and 
therefore classed as multi-drug resistant (MDR).  This 
represents a borderline significant decrease from 22.3% 
in 2007 (Chi2=4.04; P=0.044). 
Males were approximately 1.3-times more likely to have 
an invasive E. faecium infection than females (z=2.6, 
P=0.009).  The frequency of invasive E. faecium infection 
increased with age with the majority of infections 
(n=331; 82%) occurring in adults over 45 years.  The 
median age was 64 years (95%CI, 62-65).
Escherichia coli
There were 1,923 reports of invasive E. coli infection 
(1,919 from blood and four from CSF) from 1,875 
patients, an increase of 7.8% from 1,784 reports in 2007. 
See table 1 for the proportion of E. coli isolates resistant 
to the four “indicator” antibiotics/antibiotic classes 
[ampicillin, third-generation cephalosporins (3GCs; 
cefotaxime, ceftriaxone, ceftazidime or cefpodoxime), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
Total E. faecium %AMP-R %HLG R %VAN R
Figure 3. Trends for E. faecium – total numbers of E. faecium and percentage resistance to high-level 
gentamicin (HLG) and vancomycin (VAN) with 95% confidence intervals.
The numbers of participating laboratories by year-end are indicated above the bars
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aminoglycosides (gentamicin or tobramycin)] by 
year since 2002.  Ciprofloxacin resistance increased 
marginally from 22.1% in 2007 to 23.4% in 2008 (non-
significant; Chi2=0.92, P=0.34).  Looking at the overall 
trend, the proportion of ciprofloxacin resistant isolates 
has increased significantly since 2002 (Chi2trend=209.5, 
P<0.0001) (figure 4), although the rate of increase has 
slowed down since 2006.  The proportions of isolates 
with resistance to 3GCs and gentamicin increased from 
6.7% and 9.9% in 2007 to 7.5% and 10.2%, respectively, 
in 2008 but these findings were not significant 
(Chi2=0.87, P=0.35 and Chi2=0.08, P=0.78, respectively). 
Looking at the recent trends, the proportions of isolates 
with resistance to 3GCs increased from 4.2% in 2006 
to 7.5% in 2008 (highly significant; Chi2trend=15.8, 
P<0.0001), while resistance to gentamicin increased 
from 7.7% to 10.2% over the same period (significant; 
Chi2trend=6.2, P=0.01). Resistance to 3GCs, ciprofloxacin 
and gentamicin in E. coli isolates have been increasing 
throughout most of Europe in recent years.  In 2008, 
ciprofloxacin resistance was at moderately high levels 
in Ireland compared to other European countries 
while resistance to 3GCs and gentamicin were both 
moderately low.
Extended spectrum beta-lactamases (ESBLs) were 
detected in 91 (5.0%) of 1,815 isolates tested.  There 
was a significant increase in ESBLs from 2.5% in 2007 
and 4.1% in 2007 (Chi2=5.7, P=0.02), however the 
increase observed in 2008 was not significant (Chi2=1.8, 
P=0.18).  ESBLs are enzymes that confer resistance to 
most penicillins and cephalosporins (including 3GCs).  
ESBL-producing bacteria (including K. pneumoniae and, 
increasingly, E. coli) are often resistant to other classes 
of antibiotics and have emerged as important causes of 
infections in hospitals.
Of 1,877 isolates tested against all four “indicator” 
antibiotics, 227 (12.1%) were identified as MDR (defined 
as resistance to three or more of these), including 53 
with resistance to all four.  The proportion of isolates 
that are MDR has increased significantly (Chi2trend=125.3, 
P<0.0001) from 2.4% in 2002 when surveillance began.
Females were approximately 1.2-times more likely to 
have an invasive E. coli infection than males (z=3.6, 
P<0.0001), however males were 1.3-times more likely 
to get an infection with ciprofloxacin-resistant E. coli 
(z=2.5, P=0.013) and 1.6-times more likely to get an 
infection with MDR E. coli (z=3.7, P=0.0002).  The 
frequency of invasive E. coli infection increased with age 
with the majority of infections (n=1,485; 77%) occurring 
in adults over 55 years.  The median age was 72 years 
(95%CI, 70-75).
Klebsiella pneumoniae
There were 311 reports of invasive K. pneumoniae 
infection (all from blood) from 307 patients (with 41 
of 44 laboratories participating in the surveillance 
of this pathogen).  See table 1 for the proportion of 
K. pneumoniae isolates resistant to the four “indicator” 
antibiotics (as for E. coli above), plus imipenem/
meropenems, since 2006.  Ciprofloxacin resistance 
decreased from 18.1% in 2007 to 12.7% in 2008, while 
resistance to both 3GCs and gentamicin both increased 
from 9.9% to 11.3% and 10.6%, respectively, however 
none of the differences was found to be significant.
One isolate was ampicillin-susceptible, which either 
represents an isolate that was misidentified as 
K. pneumoniae or misclassified as ampicillin-susceptible, 
as all klebsiellae are inherently resistant to this 
antibiotic.
ESBLs were detected in 22 (7.7%) of 286 isolates tested. 
This represents an increase from 3.7% (8 of 214 isolates) 
in 2007 (borderline approaching significance; Chi2=3.39, 
P=0.065). 
Thirty, or 9.9%, of 302 isolates tested against all four 
“indicator” antibiotics were identified as MDR, including 
14 with resistance to all four.  This compares with 11.9% 
in 2007.
Males were approximately 1.4-times more likely 
to have an invasive K. pneumoniae infection than 
females (z=3.3, P=0.001).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
         
Figure 4. Trends for E. coli – total numbers of E. coli and percentage resistance to 3GCs, 
ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin (GEN) with 95% confidence intervals.
The numbers of participating laboratories by year-end are indicated above the bars
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majority of infections (n=215; 69%) occurring in adults 
over 55 years.  The median age was 65 years (95%CI, 
62-67).
Pseudomonas aeruginosa
There were 199 reports of invasive P. aeruginosa 
infection (197 from blood and two from CSF) from 191 
patients (with 41 of 44 laboratories participating in 
the surveillance of this pathogen).  See table 1 for the 
proportion of P. aeruginosa isolates resistant to the five 
“indicator” antibiotics/antibiotic classes [piperacillin-
tazobactam, ceftazidime, carbapenems (meropenem or 
imipenem), fluoroquinolones (ciprofloxacin or ofloxacin) 
and gentamicin] since 2006.  The resistance proportions 
observed in 2008 were all lower compared with the 
data for 2007, however, none of the differences was 
significant. 
Twenty (11.1%) of 180 isolates tested against all five 
“indicator” antibiotics were MDR, including two 
(from two laboratories) with resistance to all five.  This 
compares with 12.5% in 2007.
Males were approximately 1.7-times more likely to have 
an invasive P. aeruginosa infection than females (z=3.7, 
P=0.0002).  The frequency of invasive P. aeruginosa 
infection increased with age with the majority of 
infections (n=159; 80%) occurring in adults over 50 
years.  The median age was 65 years (95%CI, 64-66).
Conclusion
The reduction in the numbers and proportion of MRSA 
first observed in 2007 has continued into 2008. Since 
2006, there has been a 26.5% reduction in the numbers 
of MRSA bacteraemia reports. The proportion of MRSA 
has decreased from 41.2% to 33.5% over the same 
period, while the MRSA rate has decreased from 0.16 
per 1,000 bed days used to 0.11.  It is important to note 
that the total overall numbers of MSSA bacteraemia 
reports have remained at approximately the same level 
over the last couple of years. This may be related to 
infection prevention and control interventions selectively 
targeted at MRSA. Greater participation of laboratories 
in enhanced bacteraemia surveillance would go some 
way to elucidate the key risk factors for acquisition and 
infection by MSSA strains, thereby allowing appropriate 
measures to be implemented to help reduce the burden 
of infection associated with these organisms. One key 
factor at play is that MRSA is clonal (i.e. one or two 
strains may be responsible for the majority of infections 
in a healthcare setting) while MSSA is much more 
heterogeneous in nature (i.e. many different strains are 
present) and often acquisition is from the patient’s own 
normal bacterial flora. 
Despite the continuing downward trend in MRSA, AMR 
remains a major problem in other EARSS pathogens in 
this country. PNSP has been increasing for the past four 
years and in 2008 the proportion of isolates with HLR to 
penicillin increased again to over 6% with the result that 
Ireland now has one of the highest proportions of HLR 
to penicillin in S. pneumoniae in countries reporting to 
EARSS.  The introduction of the 7-valent pneumococcal 
conjugate vaccine, PCV7, into the childhood 
immunisation program in September 2008 may go some 
way to reduce the burden of invasive pneumococcal 
disease in children less than two years and also the 
general population as a whole as children are known to 
act as reservoirs for pneumococci.  However, on-going 
surveillance of the predominant serotypes is required 
as strains with serotypes other than those in the vaccine 
have been reported to increase in prevalence following 
introduction of PCV7 in other countries, hence the need 
for a fully resourced reference facility.  
E. faecium is another important Gram-positive pathogen 
that is increasingly a cause of bloodstream infections in 
this country. The number of E. faecium isolates reported 
to EARSS rose by 22% between 2007 and 2008.  Over 
this period the proportion of isolates that were VREfm 
increased slightly from 33.5% to 35.7%, however in 
contrast to this the total number of VREfm isolates 
actually increased by over 30% from 111 to 145.
Resistance in E. coli and other Gram-negative 
pathogens is also problematic. Although the data for 
2008 indicate that the rate of increase in ciprofloxacin 
resistance slowed down since 2006, the overall trend 
was still upwards.  Gentamicin and 3GC resistance plus 
ESBL-production also increased and consequently the 
proportion of MDR isolates now stands at 12.1% (up 
from 2.4% in 2002).  Resistance to 3GCs and ESBL-
production also increased in K. pneumoniae. 
On a more positive note, resistance to ciprofloxacin 
in K. pneumoniae decreased from 18.1% to 12.7%, 
resistance to all of the “indicator” antibiotics decreased 
in P. aeruginosa; and the proportion of MDR isolates for 
both of these pathogens decreased slightly compared 
to the previous year.
Recent improvements in infection prevention and 
control structures may have contributed to reducing 
the burden of MRSA bacteraemia in Ireland in 2007 and 
2008.  However, the data for the other pathogens again 
highlight the on-going commitment and resources that 
are necessary to reduce the burden of AMR and HCAI in 
this country, as outlined in the Strategy for the control 
of Antimicrobial Resistance in Ireland (SARI) in 2001, 
and in particular measures to promote more prudent 
antibiotic use in both hospital and community settings.
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARSS 
project.
The data presented in this report were taken from the 
EARSS database on 1st September 2009.
-106-HPSC Annual Report 2008 9. Antimicrobial Consumption and  Resistance 
For further details of EARSS and antimicrobial 
resistance in Ireland see www.hpsc.ie/hpsc/
A-Z/MicrobiologyAntimicrobialResistance/
EuropeanAntimicrobialResistanceSurveillance 
SystemEARSS/
European data are available at http://www.rivm.nl/earss/
database/
The European Antimicrobial Resistance Surveillance 
System (EARSS) in Ireland has been enhanced to 
collect demographic, risk factor and clinical data since 
2004. The enhanced programme involves voluntary 
participation by hospitals that provide data on invasive 
pathogens causing bloodstream infections (BSI).
There were 1618 individual records (cases or isolates 
under the EARSS definition) submitted from 13 
laboratories. This figure is up from the 2007 finalised 
figure of 1395 due to an increase in participation. The 
total number of records thus far for 2008 represents 
33% of the total core EARSS dataset.
Demographic and other basic data for the major 
resistance profiles of EARSS pathogens are shown 
in table 1. These and clinical features of the BSI 
are detailed in the rest of this chapter. Note that 
each patient may have more than one risk factor 
reported. Malignancies were noted in 27% and 
immunosuppression in 13% of all BSI, and these two risk 
factors are not mentioned again in relation to specific 
pathogens here. 
Staphylococcus aureus 
There were 409 records for Staphylococcus aureus, 
160 (39%) of which were meticillin-resistance S. aureus 
(MRSA) and 249 were meticillin-sensitive S. aureus 
(MSSA). The majority of MRSA isolates (72%) were in 
those aged 65 or older. Common sources of MRSA 
BSI were central venous catheter (CVC, 24%), skin/soft 
tissue (13%) and respiratory tract infections (8%). Recent 
surgery (13%) and stay in intensive care unit (ICU stay, 
9%) were risk factors specific to MRSA. The common 
origins of MSSA BSI were CVC (19%), and skin/soft 
tissue infections (15%). The most common risk factor 
specific to MSSA was recent surgery (8%).
Results for S. aureus and MRSA BSI for hospitals with 
consistent data 
Four of the participating hospitals provided good 
quality consistent data for every quarter since 2006. This 
section is an analysis of the Enhanced EARSS data from 
these hospitals to determine the possible reasons for 
changes in MRSA and MSSA BSI rates taking place over 
time.
The rate of MRSA infections acquired in the reporting 
hospital decreased from 0.145 in 2006 to 0.097 per 
1000 bed-days used in 2008 (33% reduction), with a 
smaller reduction in the corresponding rate for MSSA 
(7% reduction). This implies a greater impact from 
control measures targeted towards MRSA specifically 
(e.g. improvements in laboratory methods, screening 
and isolation), compared to more general control 
measures (e.g. hand and environmental hygiene).
There was a decrease in patients with MRSA BSI who 
had no known risk factors. This decrease was not seen 
in those patients with one or more known risk factors to 
the same extent. This implies that strategies targeted 
at MRSA BSI rate reduction, had a particular benefit 
9.3 Enhanced EARSS Surveillance
Table 1. Age and gender breakdown by organisms with their major resistance profiles. Proportion of isolates detected <48 hours and >5 days 
post-admission is also shown. See text for abbreviations.
 Total for  2008 Percent female Mean age in 
years
Percent <5 
years
Percent 65 
years or older
Detected <48 
hours after 
admission
Detected >5 
days after 
admission
MRSA 160 45% 68.3 4% 72% 34% 47%
MSSA 249 37% 55.6 8% 43% 51% 27%
PNSP 30 40% 47.1 27% 33% 83% 7%
PSSP 114 39% 51.6 13% 38% 89% 4%
FQREC 144 44% 68.7 0% 58% 49% 42%
FQSEC 490 57% 64.1 3% 58% 63% 23%
VRE 61 51% 64.8 0% 56% 8% 77%
VSE 199 41% 63.5 1% 51% 28% 56%
KPN 103 40% 63.3 0% 51% 40% 46%
PAE 68 31% 70.7 0% 71% 41% 46%
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for low-risk patients. Reduction in hospital antibiotic 
usage, particularly fluoroquinolones, which is known to 
have occurred, is also likely to have had an effect on the 
reduction of MRSA infections. 
Reductions in MRSA in patients with risk factors such 
as stay in ICU and recent surgery, as well more general 
targeted reduction of CVC use, took effect in the 
final year of this dataset, 2008, implying that different 
approaches were effective during the three years.
Other organisms
Of the 144 records for Streptococcus pneumoniae BSI, 
88% were isolated <48 hours after admission showing 
that these infections were mainly community-acquired. 
They tended to occur in younger patients (mean age 
51 years, compared to a mean age of 63 years for all of 
the pathogens), reflecting the bimodal age distribution 
of S. pneumoniae BSI (see table 1). The majority (72%) 
originated from respiratory tract infections. Thirty 
records (21%) were for penicillin non-susceptible 
S. pneumoniae (PNSP) BSI as compared to 114 for 
penicillin susceptible S. pneumoniae (PSSP).
There were 634 records for Escherichia coli, 144 (23%) 
of which were fluoroquinolone-resistant E. coli (FQREC) 
and 490 were fluoroquinolone-sensitive E. coli (FQSEC). 
Over half of the patients (58%) were 65 years or over. 
Urinary tract infections (31% FQREC and 39% FQSEC) 
and gastrointestinal tract infections (19% FQREC and 
20% FQSEC) were common sources for these BSI. 
Urinary catheter was also a common source for FQREC 
BSI (11%), but only in 5% of FQSEC BSI. 
There were 260 enterococcal BSI records, 111 
Enterococcus faecalis and 149 E. faecium. Of the 
enterococci BSI, 61 (23%) were vancomycin-resistant 
enterococci (VRE) and 199 vancomycin-sensitive 
enterococci (VSE). VRE BSI were associated with longer 
stay in hospital (77% detected >5 days after admission). 
CVC were a common source for these BSI (23% VRE and 
15% VSE), as well as gastro-intestinal tract (28% VRE 
and 27% VSE). Common pathogen-specific risk factors 
were ICU stay (15% VRE and 19% VSE) and recent 
surgery (21% VRE and 18% VSE).
There were 103 records for Klebsiella pneumoniae 
(KPN) BSI, originating mainly from gastro-intestinal 
tract sources (29%), CVC (14%), respiratory tract (10%) 
and urinary tract infections (15%). Common risk factors 
specific for KPN BSI were recent surgery (16%) and ICU 
stay (5%). 
There were 68 records for Pseudomonas aeruginosa 
(PNE) BSI, originating mainly from respiratory tract 
(15%) urinary tract catheter (22%), CVC (7%) and gastro-
intestinal (13%). Common risk factors specific for PNE 
BSI were recent surgery (15%) and ICU stay (16%). 
Conclusion
Analysis of enhanced data for MRSA and MSSA BSI from 
consistent sources has helped to explain changes seen 
in the epidemiology of S. aureus BSI in recent years. 
Increased hospital participation in enhanced EARSS 
surveillance would help to improve our understanding 
of these changes. Improvements to the reporting and 
analysis of enhanced EARSS data are planned, which 
should allow participating hospitals to analyse and act 
on their own data in a timely fashion.
CVCs remain a common, and potentially preventable, 
source of BSI for many of the EARSS pathogens. This 
underlines the importance of the national guidelines 
on prevention of intravascular catheter-associated 
infections, which have been developed by the Strategy 
for the Control of Antimicrobial Resistance in Ireland 
(SARI). 
Further analyses of other organisms, particularly for 
FQREC and FQSEC, are planned.
 
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
R
at
e 
p
er
 1
00
0 
b
ed
-d
ay
s 
us
ed
Rate/1000BDU** 0.112 0.115 0.120 0.064 0.057 0.049 0.094 0.084 0.088 0.145 0.116 0.097
2006 2007 2008 2006 2007 2008 2006 2007 2008 2006 2007 2008
ASRMASSMASRMASSM
latipsoh gnitroper ni deriuqcA*latipsoh gnitroper ni deriuqca toN  
Figure 1 shows rates of MRSA and MSSA BSI most likely to have acquired compared with rates not likely to have acquired in the reporting hospital. * Based on
length of stay <48hrs, although infections may be healthcare-associated. ** These are true rates and thus only appropriate for infections acquired in the 
reporting hospital.
-108-HPSC Annual Report 2008 9. Antimicrobial Consumption and  Resistance 
More information can be found at www.hpsc.ie/hpsc/
A-Z/Microbiology AntimicrobialResistance/European 
Antimicrobial ResistanceSurveillanceSystemEARSS/Enhanced 
BacteraemiaSurveillance/MainBody,1889,en.html
Healthcare-associated infection (HCAI) is increasingly 
recognised as an important cause of patient morbidity 
and mortality and contributes significantly to healthcare 
costs. The establishment of HCAI surveillance programs 
reduces HCAI, however, for surveillance to be effective, 
it needs to be standardised, timely and relevant to the 
institution providing the data.
Surgical site infection surveillance
The 2006 UK and Ireland HCAI prevalence survey 
revealed that in the Republic of Ireland, surgical site 
infection and urinary tract infection were the most 
common HCAI at the time of the survey. The HPSC 
established a multidisciplinary expert group in 2007 
under the auspices of the Strategy for the Control 
of Antimicrobial Resistance in Ireland (SARI) to 
evaluate and recommend standardised internationally 
comparable methods for surgical site infection 
surveillance. Following the publications of national 
recommendations for surveillance infrastructure and 
a national surveillance protocol for general surgery 
in 2007, the group produced a national protocol 
for surveillance of SSI in Caesarean section in 2008. 
These protocols are available at: http://www.hpsc.
ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
SurgicalSiteInfectionSurveillance/SurgicalSiteInfectionSu
rveillance-Protocols/ 
MRSA in ICU prevalence
The meticillin-resistant Staphylococcus aureus (MRSA) in 
intensive care unit (ICU) prevalence study commenced 
in April 2008 following a nine month pilot study. The 
project is overseen by a multidisciplinary steering 
committee. The primary objective of the study is to 
provide a weekly snapshot of MRSA in the critical care 
setting that requires minimal if any additional resources.  
Data is fedback to participants on a quarterly basis to 
enable ICUs to monitor trends over time. 
The 2008 report represents weekly prevalence data 
collected from 1st April to 31st December 2008 
inclusive. ICUs were stratified by ICU type;  
Level 2/3 ICU: An ICU containing a combination of •	
true ICU patients and coronary care unit (CCU) or 
high dependency unit (HDU) patients or a variable 
combination of these groups. 
Level 3 ICU: An ICU containing patients classified as •	
ICU patients only.
32 Irish ICUs participated in 2008, 18 level 2/3 ICUs and 
14 level 3 ICUs. ICU bed occupancy and isolation room 
occupancy rates were high in both level 2/3 (88% and 
75%, respectively) and level 3 ICU groups (90% and 
90%, respectively).  However, this is an underestimate of 
the true occupancy of ICUs as this project only accounts 
for patients within the ICU and not those receiving 
9.4  Healthcare-associated infection 
surveillance 
Table 1: Number of isolation rooms by ICU type and hospital bed 
capacity 
ICU type
Number of 
Isolation 
Rooms
Hospital Bed Capacity
<150 151-300 301-450 >450
Level 2/3 
(n=23)
0 3 1
1 4 5
2 1 1 1
4 1 1
Level 3 
(n=38)
1 4 1 1
2 2
3 1
4 1 1
5 1
6 2
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intensive care ‘off-site’, e.g., in a theatre recovery or 
hospital ward area, the level of which is substantial.
Large differences in isolation room resources were 
identified, with four of the 32 participating ICUs having 
no isolation room facilities (table 1). Of the remaining 
28 ICUs, there are a total of 61 isolation rooms ranging 
from 1 to 6 per ICU. The majority (62%, n=38) of 
isolation rooms are found within level 3 ICUs (table 1). 
Seventy-one percent of ICUs with isolation rooms have 
one to two isolation rooms. All ICUs with five or more 
isolation rooms are level 3 ICUs. 
The majority of isolation rooms were found to be 
equipped with hand sinks (98%) but only 20% were 
found to have anterooms, (table 2). Only two of the 
ICUs could successfully isolate all of their MRSA patients 
when surveyed. There are several reasons for this 
including lack of isolation rooms availability, isolation 
room occupancy for other reasons, e.g., security,  a risk 
assessment prioritises other patients with infectious 
disease for a room, (e.g., ‘open’ tuberculosis) or 
insufficient staff available to care for a patient in an 
isolation room. The data showed that on average 21.9% 
of all ICU patients were isolated; another 3.8% required 
isolation but could not be isolated due to a lack of 
facilities.
As recommended in national MRSA guidelines, all ICUs 
screen for MRSA colonisation on admission to ICU.  
However, there are differences in screening protocols 
between hospitals. The problem of tackling MRSA 
in ICUs is multifaceted. It is difficult to control MRSA 
acquisition within a unit when the population of patients 
admitted have a high prevalence of MRSA on admission. 
While all patients are being screened upon admission, 
there is still a large delay in the diagnosis of MRSA 
using culture alone, which can take up to 48 hours or 
longer. Once the results are available there are often 
no isolation rooms available to accommodate MRSA 
patients therefore making the problem of containing 
MRSA a difficult one. An improvement in the time to 
diagnose patients along with an improvement in
isolation room resources would enhance efforts to 
minimise ICU acquisition of MRSA.
The mean MRSA prevalence ranged from 2.9% to 
21.2%, with a median of 7.8%. This reflects mostly 
patients colonised with MRSA upon admission to the 
ICU. No direct information on MRSA infection was 
collected. MRSA prevalence varies widely depending on 
the type of ICU. The level 2/3 ICU group had a median 
MRSA prevalence of 5.9% with the level 3 group having 
a significantly higher median prevalence of 13%, (p 
<0.001). The weekly proportion of ICU-acquired MRSA 
varied nationally from 0 to 3.3% with 84% of ICUs 
showing a proportion of <1.5%. Level 2/3 ICUs had an 
average proportion of 0.5% compared to level 3 units 
with 0.9% (p=0.3). 
The aim of this point prevalence surveillance project 
is to provide some estimate of MRSA prevalence and 
acquisition in Irish ICUs within the limited resources 
available for surveillance. Since the prevalence and 
transmission of MRSA increases in high-risk patient 
groups, ICU data should ideally be stratified by ICU 
acuity (i.e., APACHE score) to allow robust comparison 
and avoid misinterpretation of the parameters 
Table 2: Number of isolation rooms and their available facilities 
Facilities available # of rooms % of total
Presence of a hand sink 55 98
Anteroom 11 20
Negative pressure 21 38
Positive pressure 15 27
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measured. The association between intensity of care 
and risk for MRSA acquisition is well described. ICUs 
with more ‘at-risk’ patient populations are more prone 
to higher rates of MRSA acquisition for a number of 
reasons including more staff to patient contact, higher 
use of medical devices compared to units with less 
acute patients and more selective pressures induced by 
antibiotic therapy. This type of risk stratification is not 
possible with the current protocol as it was designed 
so that the burden of data collection was kept to a 
minimum.  It is therefore important to emphasise, the 
limitations of using a simple surveillance tool such 
as this point prevalence survey. A point prevalence 
survey only captures ICU data at a particular point in 
time on a single day each week. This is in contrast to 
a period prevalence which captures data every day in 
the ICU over a particular period of time, (e.g., a year) or 
incidence data, the collection of which would be even 
more time consuming. Therefore, the purpose of this 
tool is for ICUs to compare their own rates over time at 
a local level. It is unsuitable to compare individual ICUs. 
HPSC plan to continue to improve this project to allow 
more robust stratification of ICUs by level of acuity and 
to allow hospitals capture other aspects of infection 
prevention and control such as the staff to patient 
ratio as a predictor of cross-infection, and the ability to 
staff isolation rooms. Such improvements will enhance 
the ability of this tool to more accurately identify the 
underlying issues surrounding differences in MRSA 
prevalence and acquisition within the ICU setting.
Alcohol-based hand rub surveillance
Alcohol-based hand rubs have been shown to be 
an effective and rapid method of hand hygiene in 
healthcare settings, and are recommended as the 
primary means of hand hygiene in Irish national 
guidelines. Measurement of hospital-level consumption 
of alcohol-based hand rub, expressed as volume used 
per 1,000 bed-days, has been shown to correlate 
with overall hand hygiene activity in hospitals. It is a 
recommended process measure of hand hygiene activity 
by both the World Health Organisation (WHO) and the 
US Centers for Disease Control (CDC). 
HPSC have collated data on alcohol hand rub 
consumption in acute public hospitals in Ireland since 
2006. The data collected represents the total volume 
of alcohol-based hand rub delivered or dispensed to 
wards, clinics and other hospital areas per quarter, 
excluding that used for pre-operative surgical ‘scrub’. 
The rate of usage per hospital was calculated as the 
total volume of hand rub consumed (in litres) per 1,000 
bed-days used (table 3).
In 2008 the median rate of alcohol hand rub 
consumption increased to 19.5 litres per 1,000 bed-days 
used, from 10.5 and 15.0 in 2006 and 2007, respectively. 
This represents a 30% increase in national consumption 
since 2007. This increase between 2006 and 2008 
could be explained in part by the increased importance 
placed on hand hygiene since the publication of the 
national guidelines by the SARI Infection Control 
Subcommittee in 2005 and local hospital initiatives. The 
overall level of alcohol-based hand rub consumption 
is comparable to other successful hand hygiene 
campaigns internationally. The wide variation in levels of 
alcohol-based hand rub consumption between hospitals 
Table 3: National data on alcohol hand rub consumption in acute public 
hospitals in Ireland, 2006 – 2008.
2006* 2007** 2008
Minimum Value 0.5 5.2 5.9
National Median 10.5 15 19.5
Maximum Value 29 47.1 52.5
*No data received from one hospital
**No data received from two hospitals
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(table 3) may be largely explained by differences in 
methodologies for collecting and reporting the data, 
and differences in the types and range of hand hygiene 
agents used.
The main limitations to be noted when examining the 
data in table 3 is that the data only refers to the use of 
alcohol-based hand rub, and does not take account of 
other hand hygiene agents (e.g. medicated liquid soap) 
that may also be in use in hospitals. In addition, the data 
does not give an indication of the frequency with which 
hand decontamination is carried out at a given hospital 
nor distinguish between who has used the hand rub 
(visitor, patient and healthcare worker). There is clearly 
a need for better standardisation of data collection and 
reporting. However, even with better standardisation, 
the volume of alcohol-based hand rub consumed 
remains a crude measure of hand hygiene activity and 
additional outcome measures are required. In 2009, 
the HPSC are planning to develop a standardized audit 
tool for measuring healthcare worker hand hygiene 
compliance in healthcare settings.
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New cases of Clostridium difficile-associated disease 
(CDAD) have been notifiable in Ireland since the 
4th May 2008 under the category ‘acute infectious 
gastroenteritis’ (AIG).  A new CDAD case is defined as a 
patient two years or older, to whom one or more of the 
following criteria applies:
•  Diarrhoeal stools or toxic megacolon, with either a 
positive laboratory assay for C. difficile toxin A (TcdA) 
and/or toxin B (TcdB) in stools or a toxin-producing C. 
difficile  organism detected in stool via culture or other 
means.
•  Pseudomembranous colitis (PMC) revealed by lower 
gastrointestinal endoscopy.
•  Colonic histopathology characteristic of C. difficile 
infection (with or without diarrhoea) on a specimen 
obtained during endoscopy, colectomy or autopsy)
Recurrent CDAD cases are not notifiable.  
There were 2829 notifications of AIG in 2008 of which 
1607 (57%) were CDAD cases, giving a national 
crude incidence rate (CIR) of 37.9 cases per 100,000 
population (table 1). 
CDAD data from 2008 represents notifications made 
from the 04th May 2008 (week 19) until the 03rd January 
2009 (week 53). The estimated CIR over a 52 week 
period is also shown in table 1. All cases were laboratory 
confirmed. Additional information as specified in the 
CDAD definitions are not currently captured on CIDR.
CDAD predominated in older patients and in females 
(61%) (figure 1). The over 65 age category has the 
highest calculated age specific incidence rate (ASIR) of 
245 per 100,000. 
Patients classified as ‘hospital inpatient’ had the highest 
occurrence of cases, accounting for 52.7% of all cases 
notified. Of the remaining cases, 6% were classified as 
GP patients, 2.7% hospital outpatient, 1.2% ‘other’, 
0.3% hospital day patient and 27% as either “not 
specified” or “unknown”.
The seasonal trend is indistinguishable at present as the 
data does not represent a complete annual data set. In 
addition, identification of seasonal patterns is hindered 
by late and batch notifications from institutions.
9.5  Clostridium difficile-associated 
disease in Ireland
Table 1.  CDAD in Ireland by HSE area 2008
HSE Region No. Cases CIR* incl. 95% CI Estimated No. Cases** Estimated CIR incl. 95% CI**
East 758 50.5 [46.9 - 54.1] 1126 75.1 [70.7-79.5]
Midlands 37 14.7 [10.0 - 19.4] 55 21.9 [16.1-27.6]
Mid West 80 22.2 [17.3 - 27.0] 119 33.0 [27.0-39.0]
North east 36 9.1 [6.2 - 12.1] 53 13.5 [9.8-17.1]
North West 95 40.1 [32.0 - 48.1] 141 59.5 [50.0-69.3]
South East 122 26.5 [21.8 - 31.2] 181 39.3 [33.6-45.0]
South 256 41.2 [36.2 - 46.3] 380 61.2 [55.0-67.3]
West 223 53.8 [46.8 - 60.9] 331 80.0 [71.3-88.5]
Total 1607 37.9 [36.0 - 39.8] 2388 56.32 [54.1-58.6]
*Rates calculated using 2006 census data 
**Using the number of notifications over this 35 week period, the estimated CIR for a 52 week period has been calculated
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Five Clostridium difficile outbreaks and one mixed C. 
difficile and Norovirus outbreak were notified in 2008. 
(table 2)
Conclusion
•  There were 1607 notifications of CDAD in 2008 
(35 weeks data). Regional CIR for this period varies 
greatly in range. This may be due to differences in 
testing criteria and/or available testing facilities. 
•  The incidence of CDAD in Ireland is prominent 
in older age groups. In the over 65 age category 
(n=1147) ages range from 65 (n=15) to 103 (n=1).  
Cases aged 82 had the highest number of cases 
(n=69). 
•  Healthcare institutions reported the most cases of 
CDAD (53%). This figure represents the location 
of patient at diagnosis only. Enhanced information 
is required to determine the onset and origin of 
infection.   
•  All notified CDAD outbreaks were health-care 
associated. 
•  The seasonal trend is indistinguishable at present. 
National guidelines for the surveillance, diagnosis, 
management, and prevention and control of CDAD in 
Ireland are available for download (http://www.hpsc.
ie/hpsc/A-Z/Gastroenteric/Clostridiumdifficile/). All 
healthcare professionals must promote practices known 
to reduce the incidence of CDAD including antibiotic 
stewardship and compliance with infection prevention 
and control measures.  These measures are outlined in 
the National guidelines. 
Table 2: C. difficile associated outbreaks, Weeks 01 – 53, 2008
HSE Region Organism/Pathogen Type Transmission mode Location Number ill
East C difficile General P-P Hospital 42
South C difficile General Not Specified Comm. Hosp/Long-stay 8
South C difficile General P-P Hospital 5
South C difficile General Unknown Hospital 11
South C difficile and Norovirus General P-P and Airborne Residential institution 12
West C difficile General Unknown Hospital 18
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Figure 1: Age-specific incidence rate of CDAD in Ireland, Weeks 19-53 2008, per 100,000 populations
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Computerised Infectious Disease 
Reporting System (CIDR)
2008 represented a significant milestone in the 
development of CIDR with the deployment of new 
hardware and updated operating system (Windows 
2000 Server to Windows 2003 Server), database 
software (SQL Server 2000 to SQL Server 2005) and 
reporting software (Business Objects version 5 to 
Business Objects XI r2, effectively version 11). This 
replaced the system originally built in 2003/4. The 
deployment of CIDR2 was preceded by extensive 
testing to ensure that the CIDR application continued 
to work as required and that the large number of CIDR 
reports were migrated from the previous version of the 
reporting software.
The biggest change was in the version of the reporting 
software used in CIDR. This means that CIDR users 
now access CIDR reporting entirely through their 
web browser, both to run existing reports but also to 
edit and create new reports. This latter functionality 
previously required Business Objects software to be 
installed on a user’s PC which was difficult to manage 
with a widely dispersed user base and also represented 
a possible security risk to local networks because it 
required users to have administrative privileges over 
their PC. Another major change associated with the use 
of the new reporting software was that local reports that 
had previously been stored on users’ local networks (in 
the regions and separately in HPSC) were now stored on 
the CIDR reporting server.
To ensure that CIDR2, and particularly the new 
reporting software, were capable of delivering the 
service required by large number (now greater than 
200) of CIDR users utilising the system, the system was 
extensively tested by a specialist third party software 
10. Computerised Infectious Disease 
 Reporting (CIDR)
Summary
•  New CIDR hardware and updated software 
deployed after rigorous application and 
performance testing
•  Additional clinical microbiology laboratories 
implemented
•  Updated version of CIDR National Business 
approved
•  Clostridium difficile notifications and reporting 
supported by CIDR
•  Pilot implementation of disaggregate STI 
notifications initiated using CIDR
Figure 1. The numbers of laboratories using CIDR.
Implemented (19) Implementation underway (7)
To be implemented (12)
Lab Notifications (72.5%)
Clinical Notifications excluding those created from lab sources
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testing company. The results of this testing provided 
reassurance that the core CIDR system was more than 
capable of meeting the anticipated load. 
Although implementation of CIDR in the two remaining 
Public Health regions remained constrained through 
2008, CIDR was implemented in three new microbiology 
laboratories. The laboratory in the Mater Hospital 
went live in February whilst the two laboratories 
in HSE Northwest – Sligo General Hospital and 
Letterkenny General Hospital – went live in May and 
August respectively. This brought the total number of 
laboratories utilising CIDR for online infectious disease 
notifications up to 19. 
Infectious disease notifications from laboratories 
represent the majority of notifications through CIDR 
Figure 2) and this is expected to increase further as 
CIDR is implemented in the remaining laboratories.
The operation and use of CIDR over the past four 
years continued to be underpinned through 2008 
by the CIDR Business Rules initially developed from 
the pilot implementation in 2004. It had become 
increasingly clear in the light of operation and further 
implementations since that time that these rules needed 
to be updated. Consequently a new national CIDR 
Business Rules Committee was formed in 2007 to review 
the existing document. This committee met three times 
through 2008 to continue to update and clarify these 
rules, including roles and responsibilities, to ensure that 
CIDR continued to be used appropriately and that the 
security of the system was maximised. A new version 
(version 2) of the CIDR Business Rules was finalised 
by the CIDR National Business Rules Committee and 
approved by the CIDR National Steering Group in 
November. 
Clostridium difficile became notifiable in May under 
the heading ‘acute infectious gastroenteritis (AIG)’ 
and CIDR was updated to reflect this. The fact that 
C. difficile was not explicitly notifiable in its own right 
meant that valuable additional information cannot yet 
be captured in CIDR – we will be able to capture this 
enhanced surveillance information once C. difficile is 
explicitly notifiablein its own right. In the meantime a 
series of reports were developed to identify the number 
of C.difficile notifications under the ‘AIG’ category.
Historically notifications of sexually transmitted 
infections (STI’s) have been made quarterly on an 
aggregate basis. This limits the degree of analysis that 
can be carried out. Disaggregate timelier reporting of 
STI’s using CIDR was initiated as a pilot programme 
Figure 2. Proportion of notifications originating from laboratories in 2008.
Implemented (19) Implementation underway (7)
To be implemented (12)
Lab Notifications (72.5%)
Clinical Notifications excluding those created from lab sources
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involving St James’s Hospital, Dublin and the 
Department of Public Health in HSE – East in January. 
They were joined by Waterford Regional Hospital and 
the Department of Public Health in HSE – South East 
in April. This appears to be operating satisfactorily 
although a formal evaluation is still awaited.
The CIDR helpdesk provided ongoing support to CIDR 
users in relation to business and technical support calls 
with the number of calls similar to those received in 
2007 (795 in 2008 compared with 769 in 2007).
CIDR training for CIDR users was delivered through 
2008 with 5 courses delivered to 26 trainees. The 
courses delivered included introductory courses for 
public health and for laboratory users, and an advanced 
course for public health users. Unfortunately training 
had to postponed in the latter half of the year because  
of the effort involved in ensuring that CIDR2 was fully 
tested prior to deployment.
The CIDR User Group met four times in 2008 and 
as in previous years remained a valuable channel of 
communication with the CIDR team. It also allowed 
CIDR users to continue to share expertise and best 
practice amongst themselves. A subject that that 
extensively discussed was the notification of C. difficile 
infections in CIDR and how best to do this on an 
ongoing interim basis under the heading of acute 
infectious gastroenteritis.
The CIDR National Steering Group continued to provide 
overall governance of the CIDR system and met on 
3 occasions in 2008. Dr Suzanne Cotter stood down 
during the year as CIDR team leader and John Brazil 
took over this responsibility. 
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Appendix 1
Notifiable Infectious Diseases in Ireland
Notes:
Figures presented in this appendix were extracted from the Computerised Infectious Disease Reporting 
(CIDR) system on the 14th August 2009. These figures may differ from those published previously due to 
ongoing updating of notification data on CIDR.
Figures on EARSS pathogens, tuberculosis and sexually transmitted infections are not presented here. 
Separate databases are used to collate data on these diseases. Details on the epidemiology of these diseases 
can be found in separate chapters in this document.
Table  A1.1. List of notifiable infectious diseases and their respective causative pathogens under Infectious Diseases (Amendment) (No. 3) 
Regulations 2003 (S.I. No. 707 of 2003)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Acute infectious gastroenteritis
Ano-genital warts
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)
Botulism Clostridium botulinum
Brucellosis Brucella species
Campylobacter infection Campylobacter species
Chancroid Haemophilus ducreyi
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease
Creutzfeldt Jakob disease (new variant)
Cryptosporidiosis Cryptosporidium parvum
Diphtheria Corynebacterium diphtheriae
Echinococcosis Echinococcus species
Enterococcal bacteraemia Enterococcus species (blood)
Enterohaemorrhagic Escherichia coli Escherichia coli of serogroup known to be toxin-producing
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) Hepatitis A virus
Hepatitis B (acute and chronic) Hepatitis B virus
Hepatitis C Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Influenza Influenza A and B virus
Legionellosis Legionella species
Leptospirosis Leptospira species
Listeriosis Listeria monocytogenes
Lymphogranuloma venereum
Malaria Plasmodium falciparum, P. vivax, P. ovale, P. malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis
Noroviral infection Norovirus
Paratyphoid Salmonella paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Q fever Coxiella burnetii
Rabies Rabies virus
Rubella Rubella virus
Salmonellosis Salmonella enterica
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella species
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Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus  pneumoniae (blood, CSF or other normally sterile 
site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella species
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella typhi
Typhus Rickettsia prowazekii
Viral encephalitis
Viral haemorrhagic fevers Lassa virus, Marburg virus, Ebola virus, Crimean-Congo 
haemorrhagic fever virus
Viral meningitis
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
 
Table A1.2 Number of notifiable infectious diseases, 2006-2008 and crude incidence rates of diseases, 2008
Infectious Disease 2006 2007 2008 CIR* 2008
Acute anterior poliomyelitis 0 0 0 0.00
Acute infectious gastroenteritis 2306 2521 4203 99.13
Anthrax 0 0 0 0.00
Bacillus cereus food-borne infection or intoxication 0 0 0 0.00
Bacterial meningitis (not otherwise specified) 46 33 40 0.94
Botulism 1 0 7 0.17
Brucellosis 29 28 3 0.07
Campylobacter infection 1812 1890 1757 41.44
Cholera 0 0 0 0.00
Clostridium perfringens (type A) food-borne disease 0 0 1 0.02
Creutzfeldt Jakob disease 6 3 2 0.05
Creutzfeldt Jakob disease (new variant) 1 0 0 0.00
Cryptosporidiosis 369 609 416 9.81
Diphtheria 0 0 0 0.00
Echinococcosis 0 0 2 0.05
Enterohaemorrhagic Escherichia coli 174 192 238 5.61
Giardiasis 64 62 71 1.67
Haemophilus influenzae disease (invasive) 38 31 22 0.52
Hepatitis A (acute) 39 32 42 0.99
Hepatitis B (acute and chronic) 810 863 949 22.38
Hepatitis C 1219 1556 1537 36.25
Influenza 275 280 475 11.20
Legionellosis 13 16 12 0.28
Leptospirosis 20 22 30 0.71
Listeriosis 7 21 13 0.31
Malaria 96 71 82 1.93
Measles 83 53 55 1.30
Meningococcal disease 209 179 168 3.96
Infectious Disease Causative Pathogen(s)
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Mumps 427 142 1385 32.66
Noroviral infection 1636 1316 1777 41.91
Paratyphoid 1 4 8 0.19
Pertussis 62 77 104 2.45
Plague 0 0 0 0.00
Q fever 12 17 13 0.31
Rabies 0 0 0 0.00
Rubella 14 19 40 0.94
Salmonellosis 422 456 449 10.59
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0.00
Shigellosis 54 43 76 1.79
Smallpox 0 0 0 0.00
Staphylococcal food poisoning 0 0 1 0.02
Streptococcus group A infection (invasive) 61 57 68 1.60
Streptococcus pneumoniae infection (invasive) 293 361 465 10.97
Tetanus 0 1 2 0.05
Toxoplasmosis 44 49 49 1.16
Trichinosis 0 2 0 0.00
Tularemia 0 0 0 0.00
Typhoid 9 9 5 0.12
Typhus 0 0 0 0.00
Viral encephalitis 16 8 5 0.12
Viral haemorrhagic fevers 0 0 0 0.00
Viral meningitis 148 45 97 2.29
Yellow fever 0 0 0 0.00
Yersiniosis 1 6 3 0.07
Total 10817 11074 14672 346.05
 See explanatory note on first page of Appendix 1.
*Crude incidence rate per 100,000 total population.
Table A1.3 Number of notifiable infectious diseases by HSE area, 2008
Infectious Disease HSE- E
HSE- 
M
HSE-
MW
HSE-
NE
HSE-
NW
HSE-
SE
HSE-  
S
HSE-      
W Total
Acute infectious gastroenteritis 1455 352 192 202 293 478 633 598 4203
Bacterial meningitis (not 
otherwise specified) 7 1 2 2 5 3 8 12 40
Botulism 6 0 0 0 0 0 1 0 7
Brucellosis * * * * * * * * 3
Campylobacter infection 565 151 176 134 98 180 268 185 1757
Clostridium perfringens (type 
A) food-borne disease * * * * * * * * 1
Creutzfeldt Jakob disease * * * * * * * * 2
Cryptosporidiosis 12 32 70 33 41 66 74 88 416
Echinococcosis * * * * * * * * 2
Enterohaemorrhagic 
Escherichia coli 47 41 28 17 19 23 38 25 238
Giardiasis 37 1 2 2 3 9 9 8 71
Haemophilus influenzae 
disease (invasive) 8 2 3 0 0 3 4 2 22
Hepatitis A (acute) 15 1 2 3 1 7 10 3 42
Hepatitis B (acute and chronic) 540 28 74 66 26 55 90 70 949
Hepatitis C 1183 36 47 63 22 49 66 71 1537
Influenza 198 24 113 42 19 30 30 19 475
Legionellosis 6 2 0 1 0 0 2 1 12
Infectious Disease 2006 2007 2008 CIR* 2008
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Leptospirosis 11 1 3 0 2 2 7 4 30
Listeriosis 4 0 4 1 1 0 3 0 13
Malaria 32 4 7 13 3 10 8 5 82
Measles 27 2 1 3 2 7 5 8 55
Meningococcal disease 41 13 12 24 7 27 33 11 168
Mumps 422 58 105 53 181 88 183 295 1385
Noroviral infection 641 122 146 217 174 76 252 149 1777
Paratyphoid 5 0 0 0 0 0 1 2 8
Pertussis 43 3 10 12 3 4 12 17 104
Q fever 1 0 3 0 0 0 9 0 13
Rubella 23 1 0 6 0 6 4 0 40
Salmonellosis 149 44 35 60 19 43 55 44 449
Shigellosis 24 21 10 4 3 4 7 3 76
Staphylococcal food poisoning * * * * * * * * 1
Streptococcus group A 
infection (invasive) 31 0 1 10 3 8 5 10 68
Streptococcus pneumoniae 
infection (invasive) 162 14 40 27 28 94 51 49 465
Tetanus * * * * * * * * 2
Toxoplasmosis 18 3 4 1 2 4 13 4 49
Typhoid 1 0 0 2 0 1 0 1 5
Viral encephalitis 3 0 0 1 0 0 0 1 5
Viral meningitis 48 1 4 16 3 9 8 8 97
Yersiniosis * * * * * * * * 3
Total 5770 959 1097 1016 959 1287 1890 1694 14672
See explanatory note on first page of Appendix 1.
*Data not reported to HSE area level when total number in Ireland <5 cases
Table A1.4 Number of notifiable infectious diseases by age group (years), 2008
Infectious Disease
0-
4
5-
9
10-
14
15-
19
20-
24
25-
34
35-
44
45-
54
55-
64
65+
Un-
known
Total
Acute infectious gastroenteritis 2348 86 21 22 41 67 79 111 201 1202 25 4203
Bacterial meningitis (not 
otherwise specified)
24 0 0 3 1 5 1 0 3 3 0 40
Botulism 0 0 0 0 1 4 2 0 0 0 0 7
Brucellosis 0 0 0 0 0 0 1 1 1 0 0 3
Campylobacter infection 429 118 58 76 150 309 199 134 104 173 7 1757
Clostridium perfringens (type A) 
food-borne disease
0 0 1 0 0 0 0 0 0 0 0 1
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 0 0 2 0 2
Cryptosporidiosis 270 74 24 8 11 11 6 1 4 6 1 416
Echinococcosis 0 0 0 0 0 0 1 1 0 0 0 2
Enterohaemorrhagic Escherichia 
coli
101 39 5 2 7 15 32 12 6 18 1 238
Giardiasis 9 7 0 0 5 16 9 13 8 4 0 71
Haemophilus influenzae disease 
(invasive)
7 2 0 0 1 0 0 2 2 8 0 22
Hepatitis A (acute) 3 5 2 5 4 11 4 2 3 3 0 42
Hepatitis B (acute and chronic) 3 3 6 41 161 406 214 83 21 11 0 949
Hepatitis C 4 3 1 18 126 665 436 173 80 23 8 1537
Influenza 54 14 13 19 29 96 107 60 42 36 5 475
Legionellosis 0 0 0 0 0 0 0 3 4 5 0 12
Leptospirosis 0 0 1 0 5 5 6 1 8 4 0 30
Listeriosis 2 0 0 0 1 2 1 1 1 5 0 13
Malaria 6 9 1 5 3 24 28 5 1 0 0 82
Infectious Disease HSE- E
HSE- 
M
HSE-
MW
HSE-
NE
HSE-
NW
HSE-
SE
HSE-  
S
HSE-      
W Total
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Measles 39 9 2 0 1 2 2 0 0 0 0 55
Meningococcal disease 100 12 9 17 13 5 2 2 6 2 0 168
Mumps 47 39 99 402 455 213 65 24 16 8 17 1385
Noroviral infection 276 15 10 24 26 68 66 69 148 1052 23 1777
Paratyphoid 0 0 0 0 0 4 2 1 1 0 0 8
Pertussis 71 13 9 3 1 2 3 1 0 0 1 104
Q fever 1 0 0 0 1 0 3 2 4 2 0 13
Rubella 32 5 0 0 0 2 1 0 0 0 0 40
Salmonellosis 102 30 17 17 54 87 30 38 30 42 2 449
Shigellosis 21 3 3 2 4 16 9 13 4 0 1 76
Staphylococcal food poisoning 1 0 0 0 0 0 0 0 0 0 0 1
Streptococcus group A infection 
(invasive)
5 7 3 1 1 8 7 6 11 18 1 68
Streptococcus pneumoniae 
infection (invasive)
73 2 5 7 7 25 57 36 58 195 0 465
Tetanus 0 0 0 0 1 0 0 0 0 1 0 2
Toxoplasmosis 3 1 1 10 4 12 10 6 1 1 0 49
Typhoid 0 1 1 0 1 1 0 1 0 0 0 5
Viral encephalitis 2 1 0 1 0 0 0 0 1 0 0 5
Viral meningitis 35 7 7 7 11 12 5 3 2 6 2 97
Yersiniosis 0 0 0 0 0 0 1 1 1 0 0 3
Total 4068 505 299 690 1126 2093 1389 806 772 2830 94 14672
See explanatory note on first page of Appendix 1.
Table A1.5 Number of notifiable infectious diseases by gender, 2008
Infectious Disease Male Female Unknown Total
Acute infectious gastroenteritis 1947 2226 30 4203
Bacterial meningitis (not otherwise specified) 22 17 1 40
Botulism 4 3 0 7
Brucellosis 3 0 0 3
Campylobacter infection 911 838 8 1757
Clostridium perfringens (type A) food-borne disease 1 0 0 1
Creutzfeldt Jakob disease 1 1 0 2
Cryptosporidiosis 239 176 1 416
Echinococcosis 1 1 0 2
Enterohaemorrhagic Escherichia coli 96 142 0 238
Giardiasis 39 32 0 71
Haemophilus influenzae disease (invasive) 14 8 0 22
Hepatitis A (acute) 18 24 0 42
Hepatitis B (acute and chronic) 514 386 49 949
Hepatitis C 967 542 28 1537
Influenza 236 232 7 475
Legionellosis 7 5 0 12
Leptospirosis 27 3 0 30
Listeriosis 6 7 0 13
Malaria 48 34 0 82
Measles 25 30 0 55
Meningococcal disease 100 68 0 168
Mumps 785 596 4 1385
Noroviral infection 741 1030 6 1777
Paratyphoid 7 1 0 8
Pertussis 36 65 3 104
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Q fever 9 4 0 13
Rubella 26 14 0 40
Salmonellosis 226 221 2 449
Shigellosis 27 47 2 76
Staphylococcal food poisoning 0 1 0 1
Streptococcus group A infection (invasive) 32 36 0 68
Streptococcus pneumoniae infection (invasive) 265 200 0 465
Tetanus 2 0 0 2
Toxoplasmosis 15 34 0 49
Typhoid 4 1 0 5
Viral encephalitis 3 2 0 5
Viral meningitis 47 49 1 97
Yersiniosis 1 2 0 3
Total 7452 7078 142 14672
See explanatory note on first page of Appendix 1.
Table A1.6 Number of notifiable infectious diseases by case classification, 2008
Infectious Disease Confirmed Probable Possible Not Specified Total
Acute infectious gastroenteritis 3966 231 0 6 4203
Bacterial meningitis (not otherwise specified) 22 12 6 0 40
Botulism 5 2 0 0 7
Brucellosis 2 1 0 0 3
Campylobacter infection 1754 0 0 3 1757
Clostridium perfringens (type A) food-borne disease 1 0 0 0 1
Creutzfeldt Jakob disease 2 0 0 0 2
Cryptosporidiosis 414 0 0 2 416
Echinococcosis 2 0 0 0 2
Enterohaemorrhagic Escherichia coli 226 12 0 0 238
Giardiasis 71 0 0 0 71
Haemophilus influenzae disease (invasive) 22 0 0 0 22
Hepatitis A (acute) 41 1 0 0 42
Hepatitis B (acute and chronic) 949 0 0 0 949
Hepatitis C 1537 0 0 0 1537
Influenza 369 0 106 0 475
Legionellosis 11 1 0 0 12
Leptospirosis 30 0 0 0 30
Listeriosis 13 0 0 0 13
Malaria 82 0 0 0 82
Measles 13 0 42 0 55
Meningococcal disease 157 0 11 0 168
Mumps 705 231 446 3 1385
Noroviral infection 1676 101 0 0 1777
Paratyphoid 8 0 0 0 8
Pertussis 71 2 31 0 104
Q fever 10 3 0 0 13
Rubella 2 1 37 0 40
Salmonellosis 448 1 0 0 449
Shigellosis 63 13 0 0 76
Staphylococcal food poisoning 1 0 0 0 1
Streptococcus group A infection (invasive) 66 1 0 1 68
Streptococcus pneumoniae infection (invasive) 405 59 1 0 465
Infectious Disease Male Female Unknown Total
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Tetanus 2 0 0 0 2
Toxoplasmosis 49 0 0 0 49
Typhoid 5 0 0 0 5
Viral encephalitis 5 0 0 0 5
Viral meningitis 86 10 0 1 97
Yersiniosis 3 0 0 0 3
Total 13294 682 680 16 14672
See explanatory note on first page of Appendix 1.
Case classifications are assigned to notifications as per the Case Definitions for Notifiable Diseases booklet, available at http://www.hpsc.ie
*As per the case definitions, meningococcal disease notifications are classified as definite, presumed and possible. For convenience they are 
reported in this table as confirmed, probable and possible, respectively.                
Infectious Disease Confirmed Probable Possible Not Specified Total
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Appendix 2
Immunisation Uptake in Ireland
Table A2.1 Immunisation uptake (%) at 12 months of age in 2008 (i.e. cohort born 01/01/2007-31/12/2007)
HSE Area Local Health Office/HSE Area
Number in 
cohort for 
BCG
Number 
in cohort 
for other 
vaccines*
Immunisation Uptake (%)
BCG† D3 P3 T3 Hib3 Polio3 MenC3
‡
HSE-E
Dublin South na 1596 na 92 92 92 92 92 91
Dublin South East na 1439 na 96 96 96 96 96 96
Dublin South City na 1694 na 81 81 81 81 81 80
Dublin South West na 2508 na 91 91 91 91 91 90
Dublin West na 2795 na 88 88 88 88 88 86
Dublin North West na 3740 na 85 85 85 85 85 86
Dublin North Central na 1695 na 86 86 86 86 86 83
Dublin North na 4223 na 89 89 89 89 89 89
Kildare/West Wicklow na 4312 na 83 83 83 83 83 82
Wicklow na 2052 na 88 88 88 88 88 88
HSE-E Total na 26054* na 87 87 87 87 87 87‡
HSE-M
Laois/Offaly 2726 2726 92 91 91 91 91 91 91
Longford/Westmeath 2031 2031 93 95 95 95 95 95 95
HSE-M Total 4757 4757 93 93 93 93 93 93 93
HSE-MW
Clare 1798 1873 98 90 90 90 90 90 90
Limerick 2061 2020 97 89 89 89 89 89 88
Tipperary NR/East Limerick 1934 2045 95 91 91 91 91 91 91
HSE-MW Total 5793 5938* 96 90 90 90 90 90 90‡
HSE-NE
Cavan/Monaghan na 2082 na 91 91 91 91 91 90
Louth na 2107 na 88 88 88 88 88 86
Meath na 3600 na 90 90 90 90 90 89
HSE-NE Total na 7789 na 90 90 90 90 90 88
HSE-NW
Donegal 2344 2344 93 91 91 91 91 91 91
Sligo/Leitrim 1443 1443 96 93 93 93 93 93 91
HSE-NW Total 3787 3787 94 92 92 92 92 92 91
HSE-SE
Carlow/Kilkenny 2020 2020 93 87 87 87 87 87 86
South Tipperary 1423 1423 94 89 89 89 89 89 89
Waterford 2082 2082 92 87 87 87 87 87 86
Wexford 2333 2333 92 89 89 89 89 89 89
HSE-SE Total 7858 7858 93 88 88 88 88 88 88
HSE-S
North Cork na 1254 na 84 84 84 84 84 84
North South Lee na 5846 na 86 86 86 86 86 86
West Cork na 997 na 83 83 83 83 83 83
Kerry 2129 2126 90 84 84 84 84 84 85
HSE-S Total 2129 10223 90§ 85 85 85 85 85 85
HSE-W
Galway na 3924 na 87 87 87 87 87 86
Mayo na 1892 na 88 88 88 88 88 88
Roscommon na 885 na 95 95 95 95 95 95
HSE-W Total na 6701 na 88 88 88 88 88 88
  Ireland 24324 73107* 94† 88 88 88 88 88 88‡
na=not available          
* As the denominator/number in cohort may vary slightly according to vaccine, most commonly used number is presented here.  The HSE-E and 
HSE-MW MenC3 data were not available for Quarter 3 2008.  Number in HSE-E MenC3 cohort is 19,032.  Number in HSE-MW MenC3 cohort is 
4,332.  Number in national MenC3 cohort is 64,455.
† BCG uptake data were available for five of the eight HSE-Areas only (data from HSE-Southern Area relates to Kerry only)
‡ The HSE-E and HSE-MW MenC3 data were not available for Quarter 3 2008 
§ HSE-Southern Area - part coverage of neonatal BCG (i.e. Kerry only)      
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here  
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Table A2.2 Immunisation uptake (%) at 24 months of age in 2008 (i.e. cohort born 01/01/2006-31/12/2006)
HSE Area Local Health Office/HSE Area
Number 
in cohort 
for Hibb
Number 
in cohort 
for other 
vaccines*
Immunisation Uptake (%)
D3 P3 T3 Hib3 Hibb
† Polio3 MenC3
‡ MMR1
HSE-E
Dublin South 1473 1473 95 95 95 95 80 95 94 93
Dublin South East 1260 1259 97 97 97 97 77 97 97 93
Dublin South City 1469 1471 86 86 86 86 68 86 86 81
Dublin South West 2339 2338 96 96 96 95 81 96 93 93
Dublin West 2552 2552 93 93 93 92 76 92 92 87
Dublin North West 3302 3303 91 91 91 91 77 91 91 84
Dublin North Central 1402 1402 90 90 90 90 71 90 89 85
Dublin North 3745 3744 93 93 93 93 78 93 92 89
Kildare/West Wicklow 3953 3953 90 90 90 89 75 90 89 84
Wicklow 1923 1924 92 92 92 92 72 92 92 86
HSE-E Total 23418 23419* 92 92 92 92 76 92 91‡ 87
HSE-M
Laois/Offaly 2450 2463 96 96 96 96 90 96 96 93
Longford/Westmeath 1967 2003 97 97 97 97 91 97 97 94
HSE-M Total 4417 4466 96 96 96 96 90 96 96 94
HSE-MW
Clare 1292 1786 94 94 94 94 83 94 94 92
Limerick 1405 1936 92 92 92 92 79 92 92 88
Tipperary NR/East Limerick 1350 1784 94 94 94 94 83 94 93 92
HSE-MW Total 4047 5506* 93 93 93 93 82† 93 93‡ 90
HSE-NE
Cavan/Monaghan 1925 1925 94 94 94 94 88 94 94 91
Louth 2053 2053 94 94 94 94 87 94 94 90
Meath 3138 3138 93 93 93 93 90 93 93 90
HSE-NE Total 7116 7116 94 94 94 94 89 94 94 90
HSE-NW
Donegal 2199 2199 97 97 97 96 94 97 95 91
Sligo/Leitrim 1313 1313 96 96 96 94 95 96 91 94
HSE-NW Total 3512 3512 96 96 96 95 94 96 93 92
HSE-SE
Carlow/Kilkenny 1467 1940 91 91 91 91 91 91 90 89
South Tipperary 1003 1335 92 92 92 91 84 92 90 88
Waterford 1555 2073 89 89 89 89 82 89 88 84
Wexford 1724 2267 92 92 92 92 88 92 91 88
HSE-SE Total 5749 7615 91 91 91 91 87† 91 90 87
HSE-S
North Cork 1122 1079 92 92 92 92 83 92 92 87
North South Lee 5332 5369 95 95 95 95 85 95 95 91
West Cork 953 941 91 91 91 91 81 91 91 85
Kerry 1900 1879 90 90 90 90 78 90 90 84
HSE-S Total 9307 9268 93 93 93 93 83 93 93 89
HSE-W
Galway 3525 3522 93 93 93 93 84 93 93 89
Mayo 1728 1728 92 92 92 92 72 92 92 82
Roscommon 869 869 97 97 97 97 94 97 98 93
HSE-W Total 6122 6119 93 93 93 93 82 93 94 88
   Ireland 63688 67021* 93 93 93 93 82† 93 92‡ 89
*As the denominator/number in cohort may vary slightly according to vaccine, most commonly used number is presented here.  The HSE-E and 
HSE-MW MenC3 data were not available for Quarter 3 2008.  Number in HSE-E MenC3 cohort is 17,233.  Number in HSE-MW MenC3 cohort is 
4,047.  Number in national MenC3 cohort is 59,334.
†The HSE-SE Hibb data for Quarter 2 2008 and the HSE-MW Hibb data for Quarter 3 2008 were not available  
‡ The HSE-E and HSE-MW MenC3 data for Quarter 3 2008 were not available   
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
 
-129-HPSC Annual Report 2008 Appendix 2 - Immunisation Uptake in Ireland
Table A2.3 Local Health Office (LHO) abbreviations used in the immunisation uptake chapter of this 
document
Local Health Office Abbreviations Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs their combined immunisation 
uptake data are reported
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Explanatory Notes
Glossary of Terms
Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases 
(see Appendix 1), data were collated using the 
Computerised Infectious Disease Reporting (CIDR) 
system.  Notification data were inputted directly by 
areas using the system.  For areas not yet on CIDR, 
data were forwarded weekly to HPSC for input to 
CIDR.  Enhanced surveillance was undertaken for certain 
diseases and these data collated on CIDR.   Outbreak 
data were also collated on CIDR using the same process 
outlined above.  Since 4th May 2008, new cases of 
Clostridium difficile-associated disease (CDAD) were 
notified on CIDR under the category ‘acute infectious 
gastroenteritis’ (AIG). Weekly Reports on infectious 
disease notifications (including a separate report for 
AIG with the emphasis on C. difficile) and outbreaks 
were produced by HPSC.  Throughout the year data 
were cleaned and validated on an ongoing basis 
and final data checks and cleaning were undertaken 
following year end by HPSC and the Departments 
of Public Health.  Data analysis was performed using 
Business Objects Reporting and MS Excel.  Figures for 
the relevant chapters within this report were extracted 
from CIDR between July and September 2009.  These 
figures may differ from those previously published due 
to ongoing updating of data on CIDR.
Data on the notifiable infectious diseases not yet on 
CIDR were collated as follows:
National Tuberculosis Surveillance System (NTBSS)
TB notification data (including enhanced information) 
for 2007 were collated in the regional Departments of 
Public Health, where data were entered on the Epi2000 
NTBSS database.  Each HSE Area provided finalised 
2007 data with outcome information to HPSC in mid 
2009.  Data were validated and cleaned with each area 
and the national data were collated.  Provisional 2008 
data were obtained from each area in August 2009.
European Antimicrobial Resistance Surveillance 
System
Data were collected by participating EARSS laboratories 
in 2008 on the first invasive isolate per patient per 
quarter on Staphylococcus aureus and Enterococcus 
faecalis from blood only and on Streptococcus 
pneumoniae, Escherichia coli, Klebsiella pneumoniae 
and Pseudomonas aeruginosa from blood and 
cerebrospinal fluid (CSF).  Data were reported quarterly 
to HPSC and collated in the WHONET database.  
Quarterly and annual reports were produced.  
Note:  In general, invasive infections due to K. 
pneumoniae and P. aeruginosa are not notifiable but 
these pathogens are now included for surveillance 
under the EARSS project.
Sexually Transmitted Infections (STIs)
Clinicians and laboratories notified their respective 
Departments of Public Health of probable and 
confirmed cases of STIs in 2007.  Notifications were 
anonymised prior to notification.  Data were collated 
and analysed by Departments of Public Health and 
aggregated data were reported quarterly to HPSC.  
National data were collated on an MS Access database, 
analysis preformed and reports produced by HPSC.
An enhanced surveillance system is in place for syphilis 
since 2000.  Enhanced forms were completed by 
clinicians and forwarded to the appropriate Department 
of Public Health from where they were sent to HPSC.  
An MS Access database was used at HPSC for collation 
and analysis of the national syphilis case-based data.
Other Surveillance Systems
Influenza Surveillance
A sentinel surveillance system is used in Ireland for the 
surveillance of influenza activity.  For the 2008/2009 
influenza season (October to May), 54 geographically 
distributed general practices participated (representing 
4.9% of the population) in collaboration with the ICGP, 
NVRL, DoHC and HPSC.  Each week the participating 
GPs reported electronically to the ICGP the number 
of patients who consulted with influenza-like illness 
(ILI).  The NVRL reported to HPSC on a weekly 
basis the number of influenza positive specimens 
tested (from sentinel and non-sentinel sources).  The 
Departments of Public Health notified HPSC weekly 
of all cases of influenza and all influenza/ILI outbreaks.  
Other indicators of influenza activity reported by 
the Departments of Public Health to HPSC included 
a regional influenza activity index, sentinel hospital 
admission levels, sentinel school absenteeism and 
enhanced surveillance data on hospitalised cases of 
influenza in 0-14 year olds.  HPSC was notified of all 
registered deaths on a weekly basis from the General 
Register Office. At HPSC data were collated from the 
various sources and weekly influenza reports were 
produced. Clinical and virological data were reported 
weekly to EISS. Following the end of the influenza 
season, annual data were analysed and reports 
Explanatory Notes
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produced.  During the summer of 2008 the surveillance 
of influenza activity continued involving the ICGP, NVRL 
and HPSC.  Data were reported to EISS biweekly and 
monthly influenza reports were produced by HPSC.
HIV
HIV and AIDS surveillance in Ireland is voluntary 
and anonymised and operates in co-operation with 
laboratories, clinicians and Departments of Public 
Health.  In 2008, clinicians completed surveillance forms 
on newly diagnosed HIV cases, AIDS cases and AIDS 
related deaths and forwarded these to the appropriate 
Department of Public Health who in turn forwarded 
them to HPSC where national data were collated on an 
MS Access database.  Bi annual analysis of these data 
were performed at HPSC and reports produced.  
Immunisation Uptake
Each HSE Area maintains a childhood immunisation 
database.  In 2008, each HSE Area provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis.  National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC website.  
For further details on methods used, please see the 
immunisation uptake chapter within this report.
Antimicrobial consumption
Community (outpatient) consumption data were 
obtained from IMS Health and represent wholesaler 
to retail pharmacy sales figures for Ireland. Hospital 
(inpatient) consumption data were obtained directly 
from clinical pharmacies and validated with the support 
of the Irish Antimicrobial Pharmacists Association. 
Quarterly and annual consumption trends by named 
public acute hospitals are published on the HPSC 
website. All data were stored at the HSPC in an MS 
Access database, and interpreted using the WHO 
Anatomical Therapeutic Chemicals index (www.whocc.
no/atcddd/) in line with European Surveillance of 
Antimicrobial Consumption (ESAC) methodology. See 
relevant section for notes on the denominator data.
Healthcare associated infections
In 2008 data were collected by participating general 
ICUs on MRSA colonisation/infection in the critical care 
setting. Data were reported monthly to the HPSC and 
stored in an MS Access database. Quarterly and annual 
reports were produced.  Data were also collected 
on the total volume of alcohol-based hand rub used 
per hospital per year/quarter, excluding that used for 
pre-operative surgical “scrub”. Hospital activity data, 
bed days used, obtained from the HSE Performance 
Monitoring Unit (PMU), was used to calculate the rate of 
alcohol-based hand rub usage per hospital. See relevant 
section for notes on the denominator data. The rate of 
usage per hospital was calculated as the total volume of 
hand rub consumed (in litres) per 1000 bed days used. 
Data were reported quarterly to the HPSC and stored 
in an MS Access database. Quarterly and annual reports 
were produced.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office, http://www.
cso.ie).  Population figures were applied as follows: 
Census 2006 for analysis of 2004-2008 data, Census 
2002 for 2000-2003 data and Census 1996 for 1999 
data. 
Monthly population changes were estimated between 
1993 and 2008 using a curve interpolation method for 
the calculation of outpatient antibiotic consumption 
rates. These are based on April 2009 update of the 
mid-year population estimates published by the CSO.  
Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring 
Unit of the HSE and used to calculate rates of MRSA 
and hospital antibiotic consumption.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
geographical area (equating to the eight former health 
board regions/areas).  This is because operationally 
the surveillance, prevention and control of infectious 
diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
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Glossary of Terms 
CIDR  Computerised Infectious Diseases Reporting
DoHC  Department of Health and Children
EARSS  European Antimicrobial Surveillance System
EISS  European Influenza Surveillance System
FSAI  Food Safety Authority of Ireland
FSPB  Food Safety Promotion Board
ICGP  Irish College of General Practitioners
IDU  Injecting Drug User
IMMRL  Irish Meningococcal and Meningitis Reference Laboratory
HPSC  Health Protection Surveillance Centre
HSE  Health Services Executive
HSE-E  HSE Eastern Region
HSE-M  HSE Midland Area
HSE-MW HSE Mid-Western Area
HSE-NE HSE North Eastern Area
HSE-NW HSE North Western Area
HSE-SE  HSE South Eastern Area
HSE-S  HSE Southern Area
HSE-W  HSE Western Area
MRSA  Methicillin Resistant Staphylococcus aureus
MSM  Men who have Sex with Men
NSRL  National Salmonella Reference Laboratory
NVRL  National Virus Reference Laboratory
STIs  Sexually Transmitted Infections
TB  Tuberculosis
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